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ABSTRACT OF THESIS  
Background  
The prevalence, aetiology and optimal management of the behavioural and cognitive 
difficulties, and circadian rhythm disturbances in children with midline brain 
abnormalities including isolated growth hormone deficiency (IGHD), isolated optic 
nerve hypoplasia (ONH) and septo-optic dysplasia (SOD) have to date not been 
adequately addressed. 
Aims and Methods 
This thesis aims to assess the prevalence of cognitive/behavioural problems and 
circadian rhythm abnormalities in children with midline brain abnormalities, and to 
further investigate any problems identified using high resolution MRI brain, actigraphy 
and melatonin profiling. 
Results 
Children with IGHD have significant impairments in motor skills and lower cognitive 
function scores, and children with ONH have significantly higher scores on the child 
behavioural checklist than controls. Children with SOD have significant sleep 
abnormalities.  
 
In IGHD corticospinal tract and corpus callosum fractional anisotropy (FA) and specific 
neural volumes are significantly lower than in controls, with neural abnormalities 
correlating significantly with IQ and motor skills scores. In ONH ventral cingulum, 
corpus callosum and optic radiation FA are significantly reduced, with right ventral 
13 
 
cingulum FA correlating significantly with behavioural assessment scores. In SOD 
melatonin production was absent in one child in association with a fragmented sleep 
pattern. Three children had normal melatonin profiles, one with an arrhythmic and two 
with fragmented sleep patterns. The remaining child had fragmented sleep and a modest 
increase in daytime melatonin concentrations. 
Conclusions 
These studies suggest that the GH-IGF-1 axis plays a role in brain and cognitive 
development. They also show that children with ONH require behavioural assessment, 
not previously part of routine clinical care, and that the behavioural abnormalities 
identified in children with ONH may be related to underlying whiter matter 
abnormalities. We have also demonstrated that the aetiology of the sleep disturbances 
found in SOD is complex, and not solely due to abnormal nocturnal melatonin 
production. 
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1.  INTRODUCTION 
Congenital growth hormone deficiency (GHD) may occur in isolation, or in association 
with other hormone deficiencies, with or without other brain abnormalities such as 
underdevelopment of the nerves to the eye and midline forebrain defects (Figure 1). 
Septo-optic dysplasia (SOD) is a rare congenital anomaly in which children have one or 
more of the following; underdevelopment of the fore-brain, the nerves to the eyes and 
the pituitary gland. The pituitary gland produces several different hormones including 
growth hormone which is necessary for normal growth (Figure 2). We have observed 
that there is a high incidence of neuro-developmental delay in patients with septo-optic 
dysplasia with aberrant behaviors that lie within the autistic continuum. Anecdotally, we 
have also found that children with isolated GHD have developmental delay and 
behavioural problems. It is unclear whether these difficulties are related to the 
underlying lack of growth hormone or whether they are related to underlying subtle 
abnormalities of brain development. That the former may be the case is suggested by 
parental reports of marked improvement in; strength, behaviour, concentration, energy 
levels, appetite and school performance in children once they have started on GH 
treatment. Many of the parents are surprised by the apparent benefits of GH treatment in 
those areas of functioning that are not normally believed to dependent on GH. 
 
Parents of children with hypopituitarism manage well with the day-to-day medical 
management and the regular hospital visits that their children require. However, they 
frequently complain during clinic visits of associated problems which present alongside 
the underlying medical condition. These include behavioural and cognitive difficulties 
and circadian rhythm disturbances. The prevalence of these problems, which impact 
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significantly on the well-being of the child and their family has not clearly been defined 
and their aetiology is not well understood. 
 
Aristotle first suggested that there may be an association between ‘dwarfism’ and 
impaired cognition. Subsequently, many studies, including in vitro and in vivo animal 
and human studies, have attempted to clarify the exact nature of the cognitive deficit 
found in individuals with an abnormal growth hormone (GH) axis. Whilst some studies 
have drawn similar conclusions, there remains no consensus as to whether the GH-Insulin 
like growth factor-1 (IGF-1) axis plays a significant role in neural development. The 
advent of high resolution magnetic resonance imaging (MRI) scanning, and the 
development of computer programmes which enable us to statistically analyse these 
images in detail, allows us an opportunity to revisit and potentially draw some 
conclusions in this much disputed area.  
 
In children with septo-optic dysplasia (SOD) there is a high incidence of neuro-
developmental delay and behavioural difficulties. The neural basis for these behavioural 
problems is unknown. Whilst conventional methods of neuroimaging have been unable to 
detect neural abnormalities, other than optic nerve hypoplasia (ONH) in individuals with 
isolated ONH, using diffusion tensor imaging (DTI) may offer us further insights into the 
pathophysiology of the behavioural problems found in children with isolated ONH.  
 
A significant proportion of children with SOD have disordered sleep patterns. This 
circadian rhythm disturbance impacts significantly both the child’s overall health and 
cognitive function and on the family’s ability to manage their child’s complex condition. 
Although melatonin is routinely administered to normalise sleep patterns in children with 
27 
 
SOD, the pathophysiological basis for the underlying sleep disorder in these children, and 
consequently the optimum medical management of their problem, remains largely 
unknown. Using new equipment such as actigraphy, designed to assess circadian rhythms 
in infants and children, in conjunction with assaying melatonin concentrations, may lead 
to improved understanding of the mechanisms underlying the disordered sleep patterns in 
children with SOD.  
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Figure 1  Midline brain MR Images demonstrating the differing effects of isolated 
growth hormone deficiency (IGHD), optic nerve hypoplasia (ONH) and 
septo-optic dysplasia (SOD) on brain structure 
 
 
 
Key Figure 1 CC: corpus callosum, ON: optic nerves, PP: posterior pituitary, AP: 
anterior pituitary, Brain regions highlighted in red structurally abnormal in 
condition specified in title.  
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Figure 2 Schematic representation of the growth hormone Insulin-like growth factor axis 
(Isolated growth hormone deficiency and septo-optic dysplasia disrupt GHRH and GH 
production, leading to GH and IGF-1 deficiency. Optic nerve hypoplasia has no effect on 
the GH-IGF-1 axis) 
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1.1  The role of the growth hormone and Insulin-like growth 
factor axis in neural development and cognitive function 
A.  The growth hormone and insulin-like growth factor axis 
Growth hormone is an anabolic peptide secreted by the somatotroph cells of the anterior 
pituitary gland in a pulsatile fashion (1). The main isoform of human GH (75% 
circulating GH) is a 191 amino acid protein with two disulphide bridges and a molecular 
weight of 22 kiloDaltons (2). The other major isoform present in the circulation is 20kDa 
GH (10%), which lacks amino acids 32-46 and is generated by alternative splicing of 
exon 3 (3). GH has a relatively short half-life of approximately 5 minutes; however, the 
majority of GH circulates in the plasma bound to a specific high-affinity GH-binding 
protein (GHBP) (1;4). Bound GH has a slightly longer half-life of around 20 minutes (5). 
GH mediates its effects by binding to a specific cell surface receptor, the GH receptor 
(GHR), a 620 amino acid, 70kDa protein (6), forming a complex with two dimerized 
GHR components; this activates JAK2 tyrosine kinase and leads to the phosphorylation 
of intracellular signalling molecules (7). 
 
Concentrations of GH are highest approximately 1 hour after sleep begins, with 
concentrations generally being undetectable during the day (8). In addition to being 
released during sleep, GH is secreted in response to stimuli including exercise, 
hypoglycaemia and physical stress, with levels being reduced in the context of 
psychosocial or emotional deprivation and obesity (9;10). Pulsatility is regulated by the 
interaction between two main hypothalamic hormones: growth hormone releasing 
hormone (GHRH), a 44 amino acid protein that stimulates GH secretion, and 
somatostatin, an inhibitory hormone containing 14 amino acids (4;11). The secretion of 
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these hypothalamic hormones is further influenced by neurotransmitters and 
neuropeptides such as dopamine, catecholamines, histamine, serotonin, gamma amino 
butyric acid (GABA), ghrelin and opiates. GH secretion is also under negative feedback 
control by itself and by IGF-1, which is generated in response to GH (12). Both GH and 
growth factors such as IGF-I and IGF-II also negatively feedback on the hypothalamic 
regulators of GH secretion, whereas sex steroids such as testosterone and oestrogen 
increase GH synthesis and secretion.  
 
Whilst GH has both anabolic and metabolic actions of its own which include increasing 
linear growth, fat mobilisation and an increase in muscle mass, most of its effects are 
mediated through the generation of IGF-1. IGF-1 is a 70 amino acid peptide produced 
ubiquitously, with the majority of circulating IGF-1 being derived from the liver (4). IGF-
1 circulates in the blood either as a free molecule, or bound to specific high affinity 
binding proteins (BPs) that prolong its half-life and regulate the availability of IGF-1 to 
specific tissues, modulating IGF-1 effects as well as having actions independent of IGF-1 
(13;14). There is little circadian variation in the concentration of plasma IGF-1 (half-life 
of bound IGF-1: 12-15hrs) and it is therefore a convenient surrogate measure of the 
overall 24-hr secretion of GH (1;15). IGF-1 mediates many of the growth-promoting 
effects of GH acting throughout the body to promote somatic growth and to regulate 
metabolism (16).  
 
B.  Growth hormone deficiency 
The reported incidence of congenital growth hormone deficiency (GHD) is 1 in 4,000 to 
1 in 10,000 live births (17-20). GHD occurs more frequently in males with a 2:1 ratio and 
cases can be sporadic or familial. Familial cases account for 5-30% of cases (21), 
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suggesting a genetic aetiology for the condition. GHD can occur in isolation (isolated 
growth hormone deficiency [IGHD]), in association with other anterior and posterior 
pituitary hormone deficiencies (multiple pituitary hormone deficiency [MPHD]), and 
with or without extra-pituitary features such as optic nerve hypoplasia and midline 
forebrain defects (SOD).  
 
C.  Phenotypic variability in growth hormone deficiency 
There is significant phenotypic variability both in the severity of GHD, the age at 
presentation, and in the association with other hormonal and brain abnormalities (22).  
 
IGHD is the commonest pituitary endocrinopathy, with children classically presenting 
with a reduced height velocity and delayed bone age, frequently in association with a past 
medical history of neonatal hypoglycaemia, jaundice and micropenis (23). Well-
established phenotypic features of IGHD include frontal bossing, midfacial hypoplasia, 
immature facies, truncal adiposity, fat dimpling, male hypogenitalism, a high-pitched 
voice and/or other malformations. There is not yet consensus regarding whether there is 
also a characteristic cognitive and behavioural phenotype in individuals with GHD, the 
evidence for this association will be discussed in detail later in the introduction. 
 
When designing prospective studies to assess the impact of GH treatment in GHD the 
considerable degree of controversy regarding the diagnosis of GHD needs to be taken 
into account. The debate is partly secondary to the continuum which exists between 
deficiency and normal GH secretion, and also due to the significant difficulties 
surrounding the interpretation of GH stimulation tests (24). Prior to the introduction of 
the radioimmunoassay in the mid-1960s the diagnosis was relatively straightforward 
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being made on a clinical basis only in individuals with severe growth failure and other 
clinical features supporting a diagnosis of GHD. Subsequently, both clinical criteria 
(growth velocity, body composition, facial appearance), and biochemical serum GH 
responses to a variety of provocation tests have been used to define the condition. At 
present the “gold standard” for the diagnosis of GHD in the UK is defined by the 
National Institute for Clinical Excellence (NICE) guidelines as a subnormal response to 
two pharmacological stimulation tests. The majority of the debate pertains to the peak 
serum GH concentration that should be used to define GHD, as the peak changes 
according to the assay and stimulation test performed. Severe GHD remains easier to 
diagnose with the majority of studies concluding that individuals with severe GHD have a 
more consistent response to provocative testing (24). In addition, when reduced GH 
production in response to stimulation is associated with either other pituitary hormone 
abnormalities, clinical signs of GHD such as hypoglycaemia or microphallus, genetic 
mutations known to cause GHD, or MRI evidence of structural abnormalities of the 
hypothalamo-pituitary axis, the diagnosis can be made with a greater degree of certainty 
(24). 
 
D.  Short Stature  
Children with GHD frequently present to the endocrine clinic with short stature, with the 
investigations outlined above being used to differentiate between individuals with and 
endocrine abnormality and those with non-GHD short stature. Children with short stature 
(secondary to GHD and non-GHD causes) have been found to have reduced IQ when 
compared to normal stature controls(25), with short stature in childhood being associated 
with emotional immaturity, behavioural problems, underachievement at school and poor 
learning skills (26;27). It has previously been postulated that adults and other children 
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relate to children according to their size rather that their chronological age and short 
stature can lead to a child being infantilized with consequent impacts on development 
(28;29). Studies including select groups of children with short stature, such as individuals 
with GHD therefore need to control for any possible effects of stature on development 
which may occur independent of the disease process being studied. 
 
E.  Evidence for actions of growth hormone and insulin-like growth factor-1 in 
the central nervous system  
Factors including thyroid hormone, cortisol and nutrition (30) have been found to 
impact significantly on cognition during infancy and childhood, whilst the role of GH 
on neural development and cognition remains unclear with many incongruous reports.  
 
A large body of evidence suggests that IGF and IGF receptors, and GH and GHR’s, are 
expressed in the parts of the brain responsible for learning and memory. GH is produced 
both in the pituitary and to a lesser degree by other tissues in the central nervous system 
(CNS), for example the hippocampus (31;32). There is also evidence to support the 
transport of GH into the CNS across the blood brain barrier. There is a high density of 
GHRs in the choroid plexus (33) (34), and several studies report an increase in cerebro-
spinal fluid (CSF) IGF-1 and GH after peripheral recombinant human GH (rhGH) 
administration (35) (36). Peripheral rhGH administration also increases levels of CSF 
neurotransmitters including vasoactive intestinal peptide, noradrenaline, homovanillic 
acid (dopamine metabolite) and aspartate (an excitatory amino acid which acts as a ligand 
for the N- methyl-D-aspartic acid receptor which in turn is involved in memory formation 
in the hippocampus) (37). 
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GH binding sites are found on various cell types in the brain including neurons, 
astrocytes, oligodendrocytes and microglia. In the rodent, GH has been identified in the 
amygdala, cortex, hippocampus, and thalamus (38), and the GHR in the choroid plexus, 
cortex, hippocampus, hypothalamus, striatum and spinal cord, with levels being higher in 
females than in males (39). The human brain has a similar pattern of GHR expression 
with concentrations being highest in the choroid plexus, thalamus, hypothalamus, 
pituitary, putamen and hippocampus (40;41). The putamen plays an important role in the 
processing of social perceptions, with the hippocampal and perihippocampal regions 
playing roles in learning and memory (42-44). Interestingly GHR expression is two to 
four-fold higher in the hippocampus than elsewhere in the brain suggesting that GH may 
play an important role in memory formation. GHR concentration is highest in the fetal 
and infant brain when they are located specifically in areas known to be actively involved 
in neurogenesis within the juvenile brain, including the hippocampal dentate gyrus, the 
olfactory bulb and in the sub-ventricular zone (34;45). Subsequently GHR concentrations 
decline with increasing age (34;46). 
 
There is accumulating evidence that in addition to GH, IGF-1 also plays an important role 
in brain growth, development and myelination, and that it has an ongoing role in 
determining childhood and adult cognitive function (47;48). IGF-1 is actively transported 
across the blood brain barrier (49) acting to stimulate the viability and function of a 
variety of different neuronal cell-types through the IGF receptor family (50). It promotes 
neuronal DNA synthesis in addition to myelination, stabilises tubulin mRNA, enhances 
oligodendrocyte proliferation, increases neuron and glia survival and neuromuscular 
synaptogenesis (51;52). IGF-1 stimulates neuronal acetylcholine release (53) and 
activates the NMDA receptor. In addition to its neurotrophic effects it also has several 
36 
 
neuroprotective effects, limiting neuronal loss after ischaemic injury (54) and improving 
neurological functioning in rats when administered after spinal cord injury (55;56). IGF-1 
gene expression has been found in humans in the hypothalamus, hippocampus, olfactory 
bulb, cerebellum, neocortex and striatum (51) with IGF-1 receptors being most dense in 
the hippocampus, amygdala, caudate nucleus, cortex, cerebellum, prefrontal and 
parahippocampal cortex (57). Together these regions make up the neural circuit known as 
the social brain (58).  
 
The importance of GH and IGF-1 in neural development is highlighted by findings in GH 
and IGF-1 deficient animal and human disease models. Transgenic mice over-expressing 
IGF-1 have increased brain size with a marked increase in myelin content, whereas mice 
with a targeted IGF-1 gene deletion have reduced brain size (59). GHR knockout mice are 
of a normal size at birth, IGF-1 knockout mice are 60% of their normal birth weight, 
whereas mice lacking both IGF-I and GHR are only 17% of their normal size at birth 
(60). These findings suggest that whilst IGF-I is an important fetal growth factor, GH 
also has some growth-promoting effects independent of IGF-I. Human disease models 
also exist where either the IGF-I gene is deleted or there is impairment in the functioning 
of the GHR leading to reduced production of IGF-1. Deletion of the insulin-like growth 
factor I gene is universally associated with significant intrauterine growth retardation, 
microcephaly, significant cognitive impairment and postnatal growth failure (48). On the 
other hand, individuals with GHR mutations have varying cognitive phenotypes. 
Guevara-Aguirre et al have reported on an Ecuadorian population with a single-point 
mutation (E180 splice mutation) in the GHR preventing dimerisation and normal 
functioning (56). In this population, who have elevated concentrations of GH but 
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undetectable IGF-1, intelligence has been found to be normal or slightly higher than in 
the general population (61;62). This contrasts with the initial reports of GH-insensitivity 
or Laron syndrome in an Israeli cohort with a different pathogenic mutation, in which 
affected individuals were found to have significantly reduced cognitive performance 
(63;64). The normal functioning of the GHR does not therefore appear to be a 
prerequisite for normal cognitive development. Scheepens et al (65) have suggested that 
this may indicate, ‘some central role for high levels of GH acting via a receptor that does 
not require homodimerization.’ The evidence that IGF-1 is not important in brain 
development is not however conclusive as studies of affected adults with GHR deficiency 
have found that they have significantly higher circulating concentrations of both IGF-1 
and Insulin-like growth factor binding protein-3 (IGFBP-3) than affected children 
(66;67). It may therefore be that alternative pathways to the classical GH-GHR pathway 
are leading to IGF-1 production in these individuals.  
 
Additional evidence to support the hypothesis that the concentration and activity of CNS 
IGF-1 impacts on cognition, in addition to promoting neural growth, comes from murine 
studies. These have shown that intraventricular infusion of IGF-1 improves cognitive 
performance, in particular in the domains of working and reference memory, and that 
conversely the inhibition of IGF-1 binding to its receptor leads to impairment in learning 
and reference memory (68). 
 
In humans, fetal cord IGF-1 and IGFBP-3 concentrations have been reported to be 
related to head circumference at birth (69) and in childhood one study found that serum 
IGF-1 concentrations correlated positively with verbal intelligence (70). Amongst 
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elderly subjects, those with higher concentrations of IGF-I perform better on tests of 
cognitive function and have lower rates of cognitive decline (71). 
 
Several neuropsychological studies have documented impairments in cognitive 
functioning in adults with childhood-onset GHD (CO GHD) (72;73) and adult-onset 
GHD (AO GHD) (65;72;74-76). They have also reported improvements in cognitive 
performance, especially in the domains of memory and attention, when GH is replaced 
(73;77-79) (Table 1). Concerns raised about previous studies in a recent meta-analysis 
of the literature included the use of healthy controls (i.e. non-short stature controls), the 
inclusion of heterogeneous patient groups with a variety of aetiologies (post-radiation, 
childhood onset, adult-onset) and duration of their GHD, the wide age-ranges of the 
patients included, and the lack of uniformity in the cognitive tests used to measure 
performance (80). In addition many studies have not adjusted their statistical analyses to 
account for type 1 error despite performing multiple comparisons. Despite these 
failings, Falletti et al concluded that when compared to matched controls individuals 
with GHD have consistently been found to have impairments in attention, memory and 
executive function and that there is some evidence for improvements in certain areas of 
cognitive functioning (memory and attention tasks) with GH treatment (80). 
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Table 1  Studies which assessed cognitive performance in Adults with GHD 
 
Baseline studies investigating whether GHD impairs cognitive performance in 
individuals not receiving GH treatment 
Author(s) 
(age of 
recruits) 
Number 
participants 
(diagnosis) 
Assessment 
Used 
Conclusions Problems 
Deijen  
1996 (73) 
(19-37yrs) 
48 
(31 MPHD) 
(17 CO-GHD) 
41 healthy 
controls 
Groninger 
Intelligence 
Test 
long and short 
term memory 
tasks 
Subnormal memory 
performance 
associated with 
GHD 
Mixed patient  
groups, 
healthy 
controls 
Lijffijt 
2003 (75) 
(17-40yrs) 
10 (CO-GHD)  
10 controls 
Selective 
attention task  
Target detection was 
sig impaired in GHD 
group compared to 
controls i.e. selective 
attention affected 
Healthy aged-
matched 
controls 
Meyer-
Bahlburg 
1978 (81)   
29 patients with 
CO-GHD 
(MPHD, IGHD) 
Intelligence 
quotient (IQ) 
Normal IQ 
distribution 
MPHD lower IQ 
than IGHD (not 
significant) 
No control 
group 
Bulow 
2002 (82) 
(39-77yrs) 
33 women with 
AO-GHD and 
MPHD (lots had 
visual 
impairment (VI), 
radiotherapy or 
surgery to brain) 
with matched 
controls 
Wechsler Adult 
intelligence 
Scale (WAIS)  
Swedish 
vocabulary test 
WAIS-R digit 
symbol test 
Block design 
test 
Reduced 
performance on 
neuropsychological 
tests evaluating 
perceptual and fine-
motor speed. Lower 
median scores than 
controls on vocab, 
digit symbol test, the 
Healthy aged-
matched 
controls 
Mixture of 
aetiologies 
Large number 
of individuals 
with VI 
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Cronholm-
Molander 
verbal memory 
test 
Austin maze and 
attention process 
training inhibition 
tasks 
Peace 
1998  (83) 
 
69 
(Post-treatment 
pituitary gland 
tumour) 
23 controls 
 
Digit span 
Auditory-verbal 
learning test 
Story recall test 
(immediate and 
delayed) 
Controlled oral 
word 
association test 
Block design 
Performance in all 
patient groups was 
significantly below 
that in controls on 
story recall and 
auditory verbal 
learning tests 
Patients all 
had pituitary 
tumours 
Prospective studies in adults assessing the effect of rhGH on cognitive function 
Almqvist 
1986 (84) 
(22-36yrs) 
5 
(IGHD)  
Face 
recognition 
Simple addition 
(speed and 
accuracy) letter 
substitution 
4wks of GH sig 
improved 
performance on face 
recognition tasks 
Short follow 
up, small 
number of 
patients 
Lasaite 
2004 (85) 
(21-40yrs) 
18 (MPHD) 
No controls 
Digit Symbol 
Test (DST) and 
the Digit Span 
Subset (DSS) of 
the Wechsler. 
Quality of life 
(QOL) 
questionnaire 
Improvement in 
mood 
& cognition after 
GH treatment.  
Statistically 
significant 
differences were 
observed on Profile 
of Mood State and 
on scores of DST. 
Other 
hormonal 
deficits 
No control 
group 
Sartorio 
1995 (79) 
8  
(CO-GHD) 
Bem Sex role 
test 
Psychological 
difficulties improve 
Small number 
of patients 
41 
 
(29.6yrs) Non-verbal 
scales of WAIS 
State-trait 
anxiety 
inventory 
Experiential 
world inventory 
Draw a person 
test 
with GH treatment 
After 6 months 
performance 
significantly better 
on the symbol-
number associated 
compared with 
baseline. 
Baum 
1998 (86) 
(24-64 yr) 
40 
(IGHD 
&MPHD) 
WAIS-Revised 
Wechsler 
Memory Scale-
Revised 
No significant 
changes in cognitive 
function or quality 
of life after 18mths 
GH treatment 
Differing 
aetiologies-
brain 
tumour/IGHD 
Pavel 
2003 (87) 
 
16 MPHD Pupillographic 
sleepiness test 
and a choice 
reaction time 
test. 
Improvement in 
sleep latency and 
quality. 
Small group 
Short term 
follow up 
Arwert  
2005 (77) 
(mean 
28yrs) 
23 CO-GHD 
(IGHD&MPHD) 
Associate 
learning task 
Delayed 
recognition task 
Memory scores were 
significantly better 
at 2, 5, and 10 years 
than at baseline. 
Mixed patient 
groups 
Blinded placebo controlled trials assessing the effect of GH on cognitive function 
Degerblad 
1990 (88) 
(20-38yrs) 
6 
(MPHD) 
Verbal learning 
Non-verbal 
learning 
Reaction time 
Symbol digit 
substitution 
Finger tapping  
No sig differences 
between placebo and 
GH treated groups 
Small group 
Deijen  
1996 (73) 
48  
(MPHD-31, 
Sensory register 
(iconic 
Baseline: Impaired 
memory 
Healthy age-
matched 
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IGHD-17) age-
matched 
controls-41 
memory) 
Short-term 
memory (STM) 
(including 
recognition and 
recall) 
Long term 
memory (LTM) 
performance (STM, 
LTM and iconic 
memory) and lower 
intelligence scores 
After 2yrs GH 
(placebo control): 
normalization of 
memory 
performance, but not 
of perceptual motor 
skill or emotional 
well-being 
controls 
Oertel 
2004 (89) 
(21-63yrs) 
18 AO-IGHD & 
MPHD  
Raven standard 
progressive 
matrices test 
Verbal STM 
and LTM 
Test 
reproduction 
tasks 
After 6mths GH 
significant 
improvement in 
attention functioning 
compared to 
placebo. No change 
in verbal memory 
and non-verbal 
intelligence 
Mixture of 
aetiologies, 
wide age-
range 
P300 auditory event related potentials (ERP) studies in adults with GHD 
Tanriverdi 
(90) 
 19 GHD, 
18 acromegalic 
patients & 16 
age, education 
and sex matched 
healthy controls 
Evoked 
response 
potential (ERP) 
Prolongation of 
P300 latencies in 
patients with severe 
GH deficiency and 
reduction of P300 
amplitudes in 
patients with 
acromegaly 
Healthy aged-
matched 
controls 
Golgeli 
(78) 
(mean age 
14 patients with 
Sheehan’s 
syndrome  
ERP Before GH therapy, 
P300 latencies were 
prolonged compared 
Healthy age-
matched 
controls 
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49.5yrs) 10 controls to controls. 
Improved after 
6mths GH. 
 
There are only a small number of studies in the literature pertaining to the cognitive 
impact of GHD in children (Table 2). In one study children with GHD were found to 
score lower in two subtests of the Leistungsprtif system intelligence test, measuring 
spatial orientation and speed of closure when compared to controls despite there being no 
difference in full scale IQ between the two groups (91;92). The largest study to date was 
carried out by Stabler et al who investigated the benefit of GH treatment in 72 individuals 
with IGHD and 59 with idiopathic short stature (ISS) (88). IQ, academic achievement, 
social competence and behaviour problems were assessed before and yearly after GH 
treatment for 3yrs. IQ and achievement scores did not change with GH therapy. However, 
after GH treatment, child behaviour checklist scores for total behaviours were improved. 
This effect was found to be more significant in those with GHD (p<0.001) than in those 
with ISS (p<0.003) (93). GH treatment in individuals with GHD also improved scores on 
internalizing subscales (withdrawn: p<0.007, somatic complications p<0.001, 
anxious/depressed p<0.001) and on attention, social problems and thought problems 
(p=0.001).  
 
In the majority of studies assessing the impact of GH on neurodevelopment, children with 
idiopathic GHD have been reported to have a normal IQ. However, despite having IQ’s 
within the normal range, a high percentage of patients with GHD have to repeat a class 
(94-96) and have difficulties with problem solving (97). 
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Conversely children with MPHD have consistently been found to have cognitive deficits 
(98). This may be due to the other hormonal abnormalities, including thyroid hormone 
and cortisol deficiency, present in children with MPHD. Both thyroid hormones and 
cortisol are known to be important determinants of cognitive function and brain 
development. Children with MPHD are also at greater risk than those with IGHD of 
having hypoglycaemic episodes in infancy, hypoglycaemia early in life being an 
independent risk factor for poor cognitive outcome (99). 
 
In the paediatric literature, similar to the adult literature, many of the studies investigating 
the effect of GH on cognition have significant limitations. The studies have included 
small, heterogeneous, poorly defined patient groups and have frequently lacked 
appropriate control groups. Findings from previous studies have varied according to 
diagnosis, timing of diagnosis (infancy or onset later in childhood), presence of IGHD, 
MPHD or SOD, research methodologies, GH type, dose and duration of treatment. They 
have also tended to include individuals with visual impairment (VI), but not to control for 
the neurodevelopmental impact of the visual problems (93). This has made drawing 
conclusions regarding the cognitive benefits of GH treatment, if any, in children 
extremely difficult.  
 
Motor skills have also been evaluated in children with IGHD and MPHD by assessing 
individuals ability to copy a number of designs. In these combined (IGHD & MPHD) 
cohorts abnormalities in visual-motor skills were identified (100;101). However again the 
existence of pituitary hormone abnormalities other than isolated GHD in these studies 
makes it hard to extrapolate these findings to children with IGHD. Specific assessment of 
motor skills have not previously been performed in individuals with IGHD (101).  
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Table 2  Studies which assessed the impact of growth hormone deficiency and 
growth hormone replacement on cognition in the paediatric population 
Author(s) 
(age of 
recruits) 
Number 
participants 
(diagnosis) 
Assessment 
Used 
Conclusions Problems 
Steinhausen, 
Stahnke 
1976 (91) 
(9-19 years, 
mean 14.9 
years) 
16 GHD  
(6 IGHD/10 
MPHD) 
 
16 short stature  
controls 
 
Assessed before 
GH treatment 
Thurstones test 
of primary 
mental abilities 
Wechsler scales 
Personality test 
(questionnaire 
assessing: 
extraversion, 
neuroticism, 
aggressiveness) 
Children’s 
personality 
questionnaire of 
Cattell 
Impaired social and 
coping behaviour in 
all short children 
Reduced spatial 
orientation and 
speed of closure 
No difference in IQ 
Less aggressive, 
less excitable, less 
dominant, more 
conscientious and 
less tense than the 
short stature 
controls 
Mixed 
patient 
group 
Stabler 1998 
(93) (5-16 
years) 
 
72 IGHD 
 
59 ISS 
 
Assessed before 
and after 3yrs 
GH 
IQ 
Child behaviour 
checklist 
IQ and achievement 
scores did not 
change with GH 
therapy.  
After GH treatment, 
child behaviour 
checklist scores for 
total behaviours 
were improved. 
(effect larger in 
those with GHD 
(p<0.001) than in 
Did not 
include 
detailed 
assessment 
of 
attention 
measures 
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Stabler 1998 
(93) (5-16 
years) 
 
72 IGHD 
 
59 ISS 
 
Assessed before 
and after 3yrs 
GH 
IQ 
Child behaviour 
checklist 
IQ and achievement 
scores did not 
change with GH 
therapy.  
After GH treatment, 
child behaviour 
checklist scores for 
total behaviours 
were improved. 
(effect larger in 
those with GHD 
(p<0.001) than in 
those with isolated 
short stature 
(p<0.003)) 
 GH improved 
scores on 
internalizing 
subscales 
(withdrawn: 
p<0.007, somatic 
complications 
p<0.001, 
anxious/depressed 
p<0.001) and on 
attention, social 
problems and 
thought problems 
(p=0.001). 
Did not 
include 
detailed 
assessment 
of 
attention 
measures 
Abbott 1982 
(100) 
 
11 children 
MPHD 
Before and after 
one yr GH 
Treatment 
Standardized 
personality and 
intelligence 
measures used 
Records of 
school 
achievement 
 
Consistent 
disturbance in 
visual-motor 
integration 
Small 
group 
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F.  Can magnetic resonance imaging assess the effect of growth hormone 
deficiency on neural development?  
Since its introduction in the mid 1980s MRI has proved valuable in defining the gross 
structural abnormalities present in individuals with pathological conditions. For example, 
in individuals with IGHD the anterior pituitary gland is frequently small, the posterior 
pituitary ectopic and the infundibulum thin or absent (102). More recently advances in 
MRI have enabled more detailed examination of the structure of white matter in the brain, 
so that volumes of different regions within the brain can be determined (103;104) and 
visualization of brain activity during cognitive tasks can be performed (105). All of these 
techniques can be used to investigate the phenotype of individuals with pathological 
conditions in more depth. Newer MRI methods have also enabled the detailed study of 
brain maturation during childhood in the healthy population (106). 
 
However, whilst significant relationships between IGF-1, IGFBP-3 and neural volumes 
(total brain volume, unmyelinated white matter and cerebellum) have been described in 
children born extremely preterm (<31weeks at birth) in whom there is a relative IGF-1 
and IGFBP-3 deficiency postnatally (107), the relationship between neural volumes and 
IGF-1 and IGFBP-3 concentrations have not previously been studied in healthy children.  
 
The only previous MRI studies using the advances outlined above in individuals with 
GHD have been performed in adults with CO-GHD using functional MRI (fMRI) (77). 
Arwert et al investigated the influence of growth hormone status in adults using fMRI, a 
non-invasive technique which enables visualization of brain activity during a cognitive 
task. The effects of 6 months of GH treatment were studied in 13 adults with CO-GHD 
using neuropsychological tests and fMRI, comparing the findings in individuals with CO-
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GHD to those of 13 age, sex and education matched healthy controls (77). Using a 
working memory paradigm, they observed subnormal memory speed (with normal 
memory performance) in conjunction with increased activity in the 
dorsolateral/ventrolateral prefrontal cortex, anterior cingulate cortex, parietal and motor 
cortices as well as in the thalamus and precuneus area in patients with CO-GHD (77). 
Increasing task load was associated with an increase in brain activity in similar areas in 
patients compared to control subjects. They concluded that these findings suggest that the 
memory performance is not impaired due to the compensatory recruitment of dorsal 
prefrontal brain regions in those with CO-GHD.  
 
Their follow-up study (108) used the same fMRI paradigm to examine the effects of GH 
treatment on cognitive function in CO-GHD patients. fMRI showed activation during 
the working memory task in prefrontal, parietal, motor, and occipital cortices, as well as 
in the right thalamus and anterior cingulate cortex. Decreased activation in the 
ventrolateral prefrontal cortex was observed after GH treatment as compared with 
placebo treatment, indicating decreased effort and more efficient recruitment of the 
neural system involved. These studies indicate how the GH/IGF-1 axis contributes to 
prefrontal functioning in GHD patients and how the benefits of GH in terms of 
cognitive functioning can be visualized using neuroimaging.  
 
DTI is a non-invasive MRI technique which can provide quantitative indices of brain 
development, enabling the visualization of white matter microstructure and 
characterization of white matter anatomy including the degree of connectivity between 
different regions of the brain (103;109). The majority of white matter fasciculi can be 
identified from birth, with slow modifications occurring during the second year of life, 
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after which they remain relatively stable (110). White matter tracts are compiled of 
axons surrounded by myelin sheaths aligned in a parallel fashion. Within large white 
matter tracts this structure limits the Brownian motion of water molecules, leading to 
the preferential diffusion of water molecules along the tract as opposed to perpendicular 
to it (103;111). DTI describes the diffusion profile of water molecules in every voxel in 
a three-dimensional Gaussian function. This is classically represented as an ellipsoid, 
with the direction and lengths of the three principal axes of the ellipsoid being termed 
eigenvectors and eigenvalues respectively. The, ‘major axis’, or predominant direction 
of the white matter tract within a given voxel is represented by the eigenvector with the 
highest eigenvalue and is considered to be orientated along the dominant direction of 
the white matter tract. The diffusion of water molecules within the brain is affected by 
the underlying tissue microstructure; this enables the study of the orientation and 
integrity of neural fibres, a useful tool when assessing the impact of physiological and 
pathological processes on neurological development (112). The principal disadvantage 
of DTI is found in areas where white matter tracts come together or intersect, although 
so called high angular resolution diffusion imaging and appropriate reconstruction 
approaches can overcome this problem. Classically DTI identifies the one principal 
direction of fibre orientation within a voxel, this limits its ability to describe regions of 
more complex white matter structure. 
 
Fractional anisotropy (FA), which describes the degree of diffusion directionality and is 
related to axonal density and degree of myelination, and ranges from 0 for isotropic 
diffusion to 1 for anisotropic diffusion, is calculated by relating the amount of diffusion 
along the major axis to that along the minor axes (109;112). FA can be affected by a 
range of microstructural differences in neural tissue including axonal membranes, 
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myelin sheaths, percentage brain water, compactness of fibre tracts and amount of 
axonal space (112). Studies conducted in the healthy paediatric population have found 
that FA correlates with neurocognitive function (113).  
 
Since the basic principles of diffusion MRI were established in the mid-1980s many 
clinical studies have found that abnormalities in the brain’s white matter tracts can be 
identified in a wide range of pathological conditions (e.g. multiple sclerosis, 
Alzheimer’s disease and depression) (114-116). Studies in these conditions have, for 
example, improved the ability of MRI to identify clinically important white matter 
lesions in multiple sclerosis which were previously unseen on conventional MRI 
sequences (117). They have also enabled the identification of defects in conditions not 
classically associated with abnormalities on conventional neuroimaging, such as ASD 
(118;119).  
 
Studies of white matter integrity require group contrast analysis where the patient group 
of interest is compared to an age-matched control group (120). Comparisons can either 
be made by looking at the white matter tracts across the whole brain (e.g. tract based 
spatial statistics (TBSS) or voxel based morphometry (VBM)) or by identifying tracts of 
interest, a technique which increases the statistical power of the study (tractography) 
(120;121). By averaging the measurements of FA over an entire white matter tract, a 
quantitative measure of tract organization can be generated (122).  
 
In contrast with VBM analysis which examines FA throughout the white matter of the 
brain, TBSS looks only at the major white matter tracts in a computer generated, ‘white 
matter skeleton’. This reduces the likelihood of registration errors and bias occurring 
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and removes the requirement for arbitrary smoothing of the data necessary for VBM 
analysis (121).  
 
VBM is a technique which can be used to analyse 3D MRI datasets, such as T1-
weighted MRI to detect subtle structural differences in neural architecture that may not 
be identified by visual inspection of MRI scans (123). FreeSurfer is a method developed 
by Fischl et al which generates neural volumes for total brain, cortical and sub-cortical 
grey and white matter structures (104). There is a large body of evidence from fMRI 
and voxel-based analyses detailing the neural regions most consistently associated with 
IQ, attention and memory (124). Although both IGF-1 and IGFBP-3 concentrations 
have been shown to relate to total brain, cerebellar and unmyelinated white matter 
volumes in children born extremely preterm, these relationships have not been studied 
in a healthy cohort. Neither VBM nor FreeSurfer have previously been used to look at 
MRI datasets in individuals with GHD.  
 
These methods could potentially be used in this cohort both to assess whether there are 
changes in regions known to be important in memory, attention and executive function, 
all domains which appear to be affected consistently in adult studies (80), and to assess 
whether regions of the brain where there are very high levels of GH and IGF-1 receptors 
are different in individuals with GHD when compared to those without GHD (e.g. 
cerebellum, hippocampus, parahippocampal gyrus) (40;41;53;57).  
 
G.  Summary  
Inter-child variability in IGF-I concentrations within the normal range relates to measures 
of cognition, but has not been related to anatomical studies of brain structure and 
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myelination. Previous studies in children with GHD have focussed on assessment of 
cognitive function but have not investigated whether differences found, for example in 
memory, correlate with neural structure and volume changes in brain regions known to be 
important in memory (e.g. hippocampus and parrahippocampal gyrus) (125;126). 
Clinicians prescribe GH therapy with the aim of optimising final height, maintaining 
normoglycaemia and minimising the metabolic effects (increased fat mass and reduced 
muscle bulk) of GHD. If GH has a significant impact on cognitive and psychosocial 
outcomes this may change the timing of treatment in individuals with GHD in whom 
currently the main aim is to optimize final height.  
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1.2  Behavioural problems in children with optic nerve hypoplasia and 
septo-optic dysplasia  
A.  Optic nerve hypoplasia and septo-optic dysplasia  
ONH, a developmental abnormality of the optic nerves, is one of the leading causes of 
VI in the developed world, with a reported prevalence of 10.9 per 100,000 in England 
(2006) (127;128). All studies assessing the prevalence of ONH have only included 
individuals with a diagnosis of VI, therefore the true incidence of ONH is likely to have 
been underestimated because individuals with isolated ONH and mild VI have been 
excluded. The diagnosis of SOD is a clinical one and can be made when two or more 
features of the classical triad of (i) ONH, (ii) pituitary hormone abnormalities and (iii) 
midline brain defects, including agenesis of the septum pellucidum and/or corpus 
callosum, are present (129). The severity of the clinical presentation is highly variable 
with some children manifesting only mild VI in association with IGHD and others 
having the full spectrum of clinical abnormalities including panhypopituitarism, severe 
VI, hearing impairment, developmental delay, obesity, sleep disturbance and 
behavioural abnormalities (130).  
 
B. The prevalence of behavioural problems in children with septo-optic 
dysplasia and optic nerve hypoplasia 
Neuro-developmental delay is common in children with SOD with different studies citing 
incidences ranging from 46-73% (131). Behavioural problems are also frequent with 
aberrant behaviours within the Autistic spectrum being particularly common. Margalith et 
al reported that 21% of the cohort they studied (51 children) had behavioural difficulties 
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including attention deficit hyperactivity disorder (ADHD) and autistic spectrum disorder 
(ASD) (132). Subsequently Parr et al found that 46% of the children recruited into their 
study with ONH and severe/profound VI had developmental impairments related to ASD 
(133). Increased behavioural problems have also been associated with impaired cognition 
in previous studies (133). The presence of the associated learning difficulties present in 
many of the children previously studied makes it difficult to assess the true presence of 
isolated behavioural problems in children with ONH. 
 
Children and adolescents with severe visual impairment (VI), secondary to varying 
aetiologies, have a significantly increased prevalence of behavioural and social 
communication problems (134-136). The neural basis for these behavioural problems is 
unknown. There are no studies reporting the prevalence of behavioural problems in 
children with mild/moderate VI in whom functionally normal or near normal vision is 
preserved. This is significant since previous studies have attributed the increased 
prevalence of behavioural problems in children with ONH to the absence of normal 
visual cues they experience.  
 
C. The psychosocial burden of behavioural problems 
Behavioural abnormalities are diagnosed using rating scales, which through application 
of cut-off scores identify children with common characteristics (137). Behavioural 
difficulties can be categorized as internalizing or externalizing. Externalizing behaviours 
include defiance, impulsivity, disruptiveness, aggression, antisocial features, and 
overactivity, whilst internalizing behaviours include withdrawal, dysphoria and anxiety 
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(138;139). Associations between academic underperformance and behavioural difficulties 
have long been recognized (140), with externalising behaviours diagnosed in childhood 
being associated with an increased risk of adult antisocial behaviour and substance abuse 
(141). Children who are underachieving academically are also at increased risk of other 
problems including deficits in self-esteem, difficulties with acquiring language skills and 
an increased prevalence of interpersonal difficulties (142).  
 
D. Can magnetic resonance imaging help us to understand the increased 
prevalence of behavioural problems found in children with optic nerve 
hypoplasia? 
To date conventional methods of neuroimaging have been unable to detect neural 
abnormalities, other than hypoplastic optic nerves, in individuals with isolated ONH. 
Only two studies have been published using DTI to better define the phenotype in ONH 
and SOD. Both have been in small numbers of subjects with severe VI (one and two 
individuals) and have focused solely on the optic tracts (143;144). These studies 
concluded that children with SOD have both pre- and post-chiasmatic diffusion tensor 
abnormalities in the visual pathway. 
 
There is a wide literature debating the reasons as to why children with VI, secondary to 
a wide range of aetiologies, are at increased risk of behavioural and social 
communication difficulties.  However, thus far, the underlying reason for this increased 
prevalence remains unknown (145). It has, however, previously been suggested that 
reductions in exposure to visual social cues and visually guided experiences in children 
with VI may predispose them to developing social development abnormalities (146). 
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Whilst the increased prevalence of behavioural deficits found in children with ONH and 
severe VI may be related to their underlying VI and reduced visual experience, we 
hypothesized that on the basis of the emerging literature regarding neuroimaging and 
social communication disorders such as ASD (119), the underdevelopment of other 
white matter tracts may also contribute to the behavioural abnormalities found in this 
cohort.  
 
E. Summary 
Previous studies investigating the prevalence of behavioural difficulties in children with 
ONH have all been in children with severe VI (133;134). Children with ONH and 
severe/profound VI frequently have co-morbidities which may potentially confound 
behavioural and DTI assessments, including significant learning difficulties, attention 
deficit disorder, seizures, and cerebral palsy (132;147-150).  
 
We therefore firstly aimed to assess whether children with isolated ONH with vision 
ranging from normal range acuity to mild to moderate VI and no developmental delay 
have an increased prevalence of behavioural problems compared to a control group of 
typically developing children without ONH. Secondly we aimed to perform detailed 
DTI studies in this cohort to identify whether specific white matter abnormalities, not 
previously identified on standard structural brain MRI scans, are present that may 
provide neural correlates for any behavioural abnormalities identified.  
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1.3  Circadian rhythm abnormalities in children with septo-optic 
dysplasia 
A. Circadian rhythm 
The circadian clock controls daily cycles of physiology and behaviour, including the 
sleep-wake cycle, temperature and hormone production (151). These rhythms are 
regulated by environmental cues including food intake and light-dark cycles. In humans 
circadian rhythms are predominantly entrained by the transmission of light from the 
retina via the retinohypothalamic tract to the master clock or suprachiasmatic nucleus 
(SCN), located in the hypothalamus (152).  Melatonin (N-acetyl-5-methoxytryptamine) is 
subsequently released from the pineal gland in response to the reduced light stimulus 
stimulating drowsiness and lowering body temperature. Melatonin is secreted in a 
circadian pattern. It is normally produced in the pineal gland in the evening with blood 
concentrations peaking at approximately 3am, after which levels fall, with secretion being 
extremely low during daylight hours (152). Sleep onset is associated with a peak in 
melatonin concentrations, however a subsequent effect of melatonin on maintaining sleep 
is less evident (153). Melatonin deficiency, regardless of its cause, is in the main factor 
associated with sleep abnormalities (154). 
 
Circadian rhythm sleep disorders (CRSD) are diagnosed in individuals with a persistently 
disturbed sleep pattern (155). There are various aetiological factors underlying CRSD, 
which include structural abnormalities in the circadian timekeeping system such as 
absence of the pineal gland or SCN (156).  
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B.  The prevalence and impact of disordered sleep patterns in children with 
septo-optic dysplasia 
Thirty-two percent of children with SOD have disordered sleep patterns; these include 
free-running rest-activity cycles, fragmented and arrhythmic sleep (157). Free-running 
rest-activity patterns are most commonly found in individuals who have no light 
awareness and are therefore unable to register light cues. Abnormal sleep patterns 
impact significantly both on the child’s well being and on the family’s overall lifestyle 
and ability to cope with their child’s complex condition, and can adversely impact on 
children’s cognitive development (152;158).  
 
C. The pathophysiology of circadian rhythm abnormalities in septo-optic 
dysplasia 
Arendt et al showed that light perception is all that is required for synchronization with 
the SCN, with normally entrained circadian rhythms being found in the majority of 
individuals with light perception only, despite significant VI (159). It is therefore 
unlikely that the sleep abnormalities found in individuals with SOD are secondary to 
their VI as the majority have light perception. The pathophysiology of the sleep 
abnormalities found in SOD has therefore been hypothesized to be secondary to 
abnormalities at other stages in the pathway of melatonin production. For example, the 
neurons of the paired SCN have been shown to be absent in one patient with SOD 
(156). Abnormalities in melatonin production could therefore potentially arise either 
secondary to dysfunction of the SCN or to abnormalities of the pineal gland which is the 
main producer of melatonin (160). It is also possible that abnormalities in the pineal 
gland or SCN could lead to a failure in the feedback loop which plays a role in 
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regulating melatonin production, leading to a relative insensitivity to melatonin action 
(161). 
 
No objective measurement of sleep/activity patterns with 24-hour melatonin profiles have 
been published in individuals with SOD. The pathophysiological basis underlying sleep 
disorders in SOD therefore remains largely unknown. 
 
D.  The management of sleep disorders in septo-optic dysplasia 
A trial of melatonin treatment in children with SOD and sleep disruption is accepted 
clinical practice in many centres. However as stated above, no objective measurement 
of sleep/activity patterns with 24 hour melatonin profiles have been published for these 
individuals, and the pathophysiological basis underlying sleep disorders in SOD 
remains largely unknown. 
 
A recent review on the use of melatonin in the treatment of sleep disorders stated that, 
‘the use of melatonin is frequently based on anecdotal evidence or small clinical trials’ 
(162). There are possible side-effects associated with melatonin use with one study 
suggesting that melatonin may have pro-convulsant effects (163) and others suggesting 
that it impacts on the hypothalamo-pituitary axis, potentially affecting the patterns of 
oxytocin, adrenocorticotropic hormone (ACTH), vasopressin and GH release, although 
it remains difficult to predict whether these endocrine effects will have long-term 
clinical outcomes (152;164;165).  
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E. Summary 
In view of the uncertainty surrounding the aetiology of the sleep abnormalities found in 
individuals with SOD, and consequently the optimum management of this problem, we 
aimed to establish whether children with SOD who experience sleep pattern disorders 
also have defective melatonin production. 
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1.4  The genetics of pituitary development 
A.  The pituitary gland 
The pituitary gland acts as a central co-ordinator for growth, reproduction and 
homeostasis (129). It is situated in the sella turcica at the base of the brain and plays a key 
role in the transmission of information between the brain, hypothalamus and peripheral 
target organs; including the adrenals, gonads and thyroid (5). The hypothalamus regulates 
the pituitary gland via the secretion of trophic factors which act to modulate cell 
proliferation, hormone synthesis and secretion. 
 
The pituitary is made up of two anatomically and functionally distinct components, the 
adenohypophysis, which consists of the anterior and intermediate lobes and the 
neurohypophysis or posterior lobe (5). The anterior lobe contains 5 different cell types 
each of which secretes a different hormone (Table 3). The posterior lobe of the pituitary 
is made up of axonal terminals of the magnocellular neurons, encircled by specialized 
astroglia known as pituicytes, it releases oxytocin (important during parturition and 
lactation) and ariginine vasopressin (AVP) (involved in regulation of osmotic balance). 
Oxytocin and AVP are produced in the hypothalamus and transported to the posterior 
lobe in hypothalamic axons. 
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Table 3  Anterior pituitary gland: Cell types and hormones released 
 
Cell type Hormones produced  Action 
Anterior Lobe 
Somatotropes GH Regulates linear growth and 
metabolism 
Lactotropes Prolactin  Regulates milk production in 
females 
Corticotropes ACTH Regulates metabolic function 
through stimulation of 
glucocorticoid synthesis in the 
adrenal gland 
Thyrotropes Thyroid-stimulating 
hormone (TSH) 
Promotes thyroid follicle 
development, thyroid hormone 
secretion and modulates skeletal 
remodelling 
Gonadotropes Lutenising hormone 
(LH)  
Follicle-stimulating 
hormone (FSH) 
Act on the gonad to initiate sexual 
maturation and maintain 
reproductive function 
Intermediate lobe 
Melanotropes α-Melanocyte-
stimulating hormone 
(α-MSH) 
Corticotrophin-like 
intermediary peptide   
Β-endorphin 
γ-lipotropin 
MSH controls production and 
distribution of melanin by 
melanocytes 
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B.  The genetics of pituitary development 
The mature pituitary gland is made up of two distinct lobes with different functions and 
developmental origins. The anterior and the intermediate lobes of the pituitary originate 
from the oral ectoderm, whilst the neurohypophysis (posterior pituitary) is derived from 
neural ectoderm (166).  
 
The majority of our knowledge regarding pituitary development has been derived from 
extensive rodent studies (167;168); however the stages of pituitary development appear to 
be similar in all vertebrates (22). Development occurs in 4 distinct stages (Figure 3) 
culminating in the formation of a complex secretory organ consisting of 5 different cell 
types secreting 6 different hormones (Table 3).  
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Figure 3  Stages of pituitary development (Sheng and Westphal 1999) 
 
 
Key Figure 3 Mouse pituitary development in sagittal section. Stages of development 
are indicated in days post-coitum; AL-anterior lobe, AN-anterior neural pore, DI-
diencephalon, F-forebrain, H-heart, HB-hindbrain, I-infundibulum, MB-midbrain, N-
notochord, NP-neural plate, O-oral cavity, OC-optic chiasm, OM-oral membrane, P-
pontine flexure, PL-posterior lobe, PO-pons, RP-Rathke’s pouch, SC-sphenoid 
cartilage. 
 
It is now clear that normal anterior pituitary development is critically dependent upon a 
complex genetic cascade of signalling molecules and transcription factors that play a 
crucial role in organ commitment, cell proliferation, cell patterning and terminal 
differentiation (169). Complex genetic interactions direct normal pituitary development, 
with repression and activation of target genes enabling normal development to occur. In 
contrast with the large amount of information available on pituitary development in the 
rodent, there is minimal information pertaining specifically to human pituitary 
development (22). However, there appear to be significant similarities between 
transcription factors which govern both murine and human pituitary development, with 
insights into human pituitary disease having mainly been made by studying spontaneous 
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or experimentally introduced mutations affecting the mouse hypothalamo-pituitary axis 
(166;170;171).  
 
There is significant phenotypic variability in individuals with pituitary hormone deficits, 
some of which may be secondary to the underlying aetiology of their condition. In those 
individuals in whom a genetic abnormality can be identified as the cause of their pituitary 
developmental abnormality the phenotype can be more clearly defined (Table 4). 
Consequently in individuals with a defined genetic aetiology we are better able to counsel 
the patient and their parents regarding likely associated clinical features and disease 
evolution.  
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Table 4  Human mutations causing abnormal hypothalamo–pituitary development 
and function.  
Gene Phenotype  MRI Inheritance 
Isolated Growth hormone deficiency 
GH-1 IGHD. No GH response to stimulation. 
Evolution of endocrinopathy with Type 
2 AD GHD. 
Hypoplastic or 
normal AP 
Recessive, 
dominant. 
GHRHR IGHD Hypoplastic AP Recessive 
Multiple pituitary hormone deficiency  
 POU1F
1 
GH, TSH, prolactin deficiencies; 
usually severe. 
Hypoplastic or 
normal AP 
Recessive, 
dominant 
 PROP1 GH, TSH, LH, FSH, prolactin 
deficiencies; evolving ACTH 
deficiency. 
Small, normal or 
enlarged AP 
Recessive 
Specific syndrome 
HESX1 IGHD, CPHD, SOD. APH, EPP, absent 
infundibulum, 
ACC 
Recessive, 
dominant 
LHX3 MPHD (GH, TSH, LH, FSH, prolactin, 
ACTH deficiencies), short neck, limited 
rotation; short cervical spine, 
sensorineural hearing loss. 
Small, normal or 
enlarged AP 
Recessive 
LHX4 MPHD (GH, TSH, ACTH deficiencies) Small AP, EPP, 
cerebellar 
abnormalities 
Dominant 
SOX3 IGHD, mental retardation, 
panhypopituitarism. 
APH, infundibular 
hypoplasia, EPP 
X Linked 
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SOX2 Hypogonadotrophic hypogonadism; 
APH, bilateral 
anophthalmia/microphthalmia, 
abnormal CC, learning difficulties, 
oesophageal atresia, sensorineural 
hearing loss. 
APH, hypoplasia of 
CC, abnormal 
hippocampi, 
hypothalamic 
hamartoma 
De novo 
GLI2 MPHD, Multiple midline defects. APH, 
holoprosencephaly,  
Dominant 
AP(H), anterior pituitary (hypoplasia); EPP, ectopic posterior pituitary; (A)CC, 
(agenesis of) corpus callosum. 
 
C.  Summary 
Currently we are able to identify genetic mutations in approximately 10% of those with 
IGHD and in <1% of those with SOD/ONH (130). Understanding the genetic basis for 
pituitary hormone deficiency may help us to further characterise any cognitive deficits, 
behavioural and neurological abnormalities we identify in this heterogeneous group of 
patients. I therefore aim to screen all patients recruited for mutations in genes 
previously implicated in pituitary development.   
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1.5  Study aims 
A. To define the neurodevelopmental and behavioural phenotype of children with 
IGHD. 
B. To identify whether MRI abnormalities can be identified using VBM and DTI in 
children with IGHD. 
C. To investigate whether it is possible to identify neural correlates of any 
cognitive/motor skills deficits identified in children with IGHD. 
D. To assess the prevalence of behavioural problems in children with isolated ONH 
and mild to moderate or no visual impairment. 
E. To identify whether MRI abnormalities can be identified using DTI in children 
with isolated ONH and mild to moderate or no VI. 
F. To investigate whether it is possible to identify neural correlates of any 
behavioural problems identified in children with isolated ONH and mild to 
moderate or no VI. 
G. To evaluate whether any white matter abnormalities identified in children with 
isolated ONH are more widespread when children with SOD (restricted to those 
without brain MRI abnormalities [other than those in the hypothalamo-pituitary 
axis] visible on standard brain MRI) are also included in the DTI analysis.  
H. Evaluate the pathophysiology of circadian rhythm abnormalities in SOD using 
sleep actigraphy and serum melatonin profiling.  
I. To screen all individuals with IGHD, ONH and SOD recruited to the study for 
mutations in genes previously implicated in pituitary development. 
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2.  STUDY SUBJECTS, PROTOCOLS, MATERIAL AND 
METHODS 
A. Ethics 
Ethical permission was granted for this study from the Joint Research Ethics Committee 
of Great Ormond Street Hospital/Institute of Child Health. Prior to participating in the 
study all parents/subjects gave written informed consent/assent as appropriate according 
to the Declaration of Helsinki (BMJ 1991; 302: 1194) (Appendices 8.A and 8.C). 
 
B. Recruitment 
 
 Patients with IGHD, ISS, SOD or ONH (inclusion and exclusion criteria below) 
attending the paediatric endocrine clinic and/or the developmental vision clinic at Great 
Ormond Street Hospital for Children between 20th December 2007 and 20th December 
2009 were recruited prospectively. Our control groups for the cognitive assessments 
performed in children with IGHD and ONH were individuals with ISS. As children with 
ISS have been shown to have reduced IQ when compared to normal stature controls, we 
chose children with ISS as our “controls”, thereby controlling for the effect of stature and 
isolating the effect of GHD (25). As these children had normal development and no VI 
they were also used as controls for the study looking at behaviour, cognitive function and 
brain structure in children with ONH. 
 
• Inclusion criteria IGHD 
o Aged 5-11years at entry into study 
o Prepubertal i.e. boys with testes volume >3 ml, girls with Tanner breast 
stage of ≥2, and patients with Tanner pubic hair stage ≥2 were excluded. 
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o Peak GH on stimulation <7ng/ml 
o Height velocity <-0.8SDS 
 
• Exclusion criteria IGHD 
o Subjects with chronic renal failure or liver failure 
o Previous/current brain tumour and/or cranio-spinal irradiation 
o Previously on GH treatment 
o Coeliac disease 
o Bone age >10years 
o Other pituitary hormone abnormalities 
o Seizures, ASD, Attention deficit hyperactivity disorder (ADHD) 
 
• Inclusion criteria ISS 
o Aged 1-11years at entry into study 
o Prepubertal i.e. boys with testes volume >3 ml, girls with Tanner breast 
stage of ≥2, and patients with Tanner pubic hair stage ≥2 were excluded. 
o Peak GH on stimulation >10ng/ml 
o IGF-1 within the normal range (defined as -2 to +2 SDS) 
o Height <2SDS below mean for population 
o Normal growth velocity (>-0.8SDS) 
 
• Exclusion criteria ISS 
o Intrauterine growth retardation: defined as birth weight <10th centile for 
gestational age  (independent risk factor for neurodevelopmental delay) 
o Chronic illness 
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o Bone age >10years 
o Seizures, ASD, Attention deficit hyperactivity disorder (ADHD) 
 
• Inclusion criteria SOD 
o Presence of two or more features of the classical triad of  
(i) ONH 
(ii) pituitary hormone abnormalities  
(iii) midline brain defects, including agenesis of the septum pellucidum 
and/or corpus callosum 
 
• Exclusion criteria SOD 
o Seizures 
o Associated brain abnormalities including schizencephaly, cerebellar 
hypoplasia and aplasia of the fornix. 
 
• Inclusion criteria ONH 
o Isolated ONH 
o Normal range visual acuity to mild/moderate reduction in visual acuity 
o Normal cognition 
 
• Exclusion criteria ONH 
o Pituitary hormone abnormalities  
o Midline brain defects, including agenesis of the septum pellucidum and/or 
corpus callosum 
o Seizures 
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o Developmental delay 
o Severe VI 
 
C. Definition of clinical phenotype and determination of pituitary hormone 
function  
i. Subject characteristics 
Data including age at entry to the study, date of birth, ethnicity, antenatal 
and delivery history, birth weight, handedness, maternal highest educational 
level and paternal employment were collected on a questionnaire from all 
patients on entry to the study (Appendix 8.B). Socioeconomic status was 
calculated using the Standard Occupational Classification (172). Maternal 
highest educational level and socioeconomic status were used as a proxy for 
parental IQ. 
 
ii. Vision assessment in children with septo-optic dysplasia and optic 
nerve hypoplasia 
Visual acuity was assessed using the Sonksen LogMAR Test of Visual 
Acuity, Kay Picture cards (letter, symbol naming or matching), or the Keeler 
card (preferential looking) tests. These different acuity tests were selected 
depending on the child’s developmental age, level of vision and ability to co-
operate and communicate.  
 
iii. Anthropometry 
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At -6 and 0 months the following measurements were taken from all study 
subjects. The serial measurements were performed by the same trained 
auxologist at each visit. 
 
• Sitting and standing height to the nearest mm with a stadiometer 
(Doherty).  
• Weight was measured by Seca scale. 
• Head circumference (cm). 
• The body mass index (BMI), defined as the ratio of the subject’s weight 
in kilograms to the square of the subject’s height in meters, was 
calculated from this data.  
 
Height velocity was calculated at baseline, over a period of not less than 4 
months, to determine annual growth rate in centimetres per year. Individuals 
with a height velocity ≤2SDS below the mean for age were further 
investigated as outlined below.  
 
iv. Measurement of IGF-1 and IGFBP-3 
IGF-1 and IGFBP-3 were measured in duplicate on all study subjects using 
the Immulite® 2500 solid-phase, enzyme-labeled chemiluminescent 
immunometric assay. The within-assay coefficients of variation (CVs) for 
IGF-1 were 3.9% and 3.0% at 77 and 689 mg/L respectively. The between-
assay CVs for IGF-1 were 7.7% and 8.1% at 77 and 689 mg/L, and the 
detection limit of the assay was 25 mg/L. The within-assay CVs for IGFBP-
3 were 4.4 % and 4.6 % at 0.91 and 4.82 mg/L respectively. The between-
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assay CVs for IGFBP-3 were 6.6 % and 7.3 % at 0.91 and 4.82 mg/L, and 
the detection limit of the assay was 0.5 mg/L.  
 
Normative data were required to interpret the IGF-1 and IGFBP-3 
concentrations we obtained in our study subjects to enable us to convert 
them in to age and sex specific standard deviation scores. IGF-1 and IGFBP-
3 reference values for the paediatric population were obtained from 
Immulite, and from 254 members of a twin study in whom serum samples 
had been taken at a mean age of 11.7 years (range 2.3 years), and IGF-1 and 
IGFBP-3 SDS were calculated using the LMS method developed by Tim 
Cole (173) (Figures 4-7). The twins were members of a study designed to 
assess how variability in birth weight between twin pairs (and therefore 
prenatal nutrition) impacts on cognitive and cardiovascular outcomes (174). 
230 of the 254 individuals who underwent measurement of IGF-1 and 
IGFBP-3 were twin pairs and 24 were siblings. All of them had normal 
height and weight. Mean serum IGF-1 and IGFBP-3 concentrations were 
257ng/ml (range: 66-644ng/ml) and 4.2ng/ml (range: 1.6-7.9ng/ml) 
respectively in the twin cohort.  
 
The LMS method was developed to enable SDS to be calculated for 
scenarios where a measurement is significantly affected by a covariate e.g. 
age. In this scenario the reference range changes as age increases and a 
centile chart is required to generate SDS. The variation in a variable with age 
is represented by the reference centile curves. The LMS method uses 3 
parameters to define the change in the distribution of a parameter with age. 
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These parameters are the median (M), coefficient of variation (S) and 
skewness (L), which is expressed as a Box-Cox power. The change in each 
of these parameters with age is represented by a graph, with the three curves 
being fitted as cubic splines with non-linear regression using penalised 
likelihood. When generating the graphs for each of these parameters, the 
equivalent degrees of freedom (EDF) for the L, M and S curves needs to be 
defined. The EDF measures the complexity of each fitted cubic spline curve. 
Deciding which value to use for EDF defines the smoothness of the curves 
for the individual parameters (L, M, S) and significantly affects the fit of the 
final SDS curves to the data. A high EDF leads to the curves being 
undersmoothed as the curves become relatively more complex.  
 
The chosen EDF for the L, M and S curves were 2, 7, 3 for IGFBP-3 in 
females and, and 2, 8 and 3 for IGFBP-3 in males. The chosen EDF for 
the L, M and S curves were 3, 10 and 3 for IGF-1 in both sexes. There were 
inadequate control data to create SDS curves for IGFBP-3 in children aged 
<5 years. 
 
Individuals with an IGF-1 ≤2SDS below the mean for age, a subnormal 
height velocity and a height ≤2SDS below the mean for age were further 
investigated with a glucagon stimulation test (protocol below). 
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Figure 4   IGF-1 in females standard deviation with age (years) (L,3 M,10 S,3) 
 
  
  
 
Figure 5  IGF-1 males standard deviation with age (years) (L,3 M,10 S,3) 
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Figure 6  IGFBP-3 in females standard deviation with age (years) (L,2 M,8 S,3) 
 
 
 
Figure 7  IGFBP-3 males standard deviation with age (years) (L,2 M,7 S,3) 
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Key Figures 4-7 LMS graph demonstrating the change in standard deviation scores for 
IGF-1 (Figures 4 and 5) and IGFBP-3 (Figures 6 and 7) with increasing age (over the 
range 0-25 years). The variation in IGF-1 and IGFBP-3 with age is represented by the 
reference centile curves. The LMS method uses 3 parameters to define the change in the 
distribution of a parameter with age. These parameters are the median (M), coefficient 
of variation (S) and skewness (L), which is expressed as a Box-Cox power. The change 
in each of these parameters with age is represented by the graphs in Figures 4-7. 
  
v.  Bone age 
In all children presenting with short stature, (height <2SDS below mean for 
population) a plain radiograph was performed of the left hand and wrist. 
Bone age was determined using the Tanner-Whitehouse method (175). The 
same investigators (Dr Emma Webb and Professor Mehul Dattani) 
calculated bone age in all patients. 
 
vi. Pubertal stage 
One paediatric endocrinologist (Dr Emma Webb) performed pubertal staging 
(Tanner method) on all children (176).  
 
vii. Endocrine assessment 
Subjects were admitted to the endocrine ward at Great Ormond Street 
Hospital at 08.00 hours having fasted from midnight the night before. Sex-
steroid priming was not performed as all children were prepubertal and had a 
bone age <10years. A heparin locked cannula was placed in a forearm vein 
30 minutes prior to glucagon administration. Baseline bloods for basic 
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haematology and biochemistry, thyroid function, prolactin, erythrocyte 
sedimentation rate and tissue transglutaminase were taken at the time of 
cannula insertion.  
 
Serum prolactin was measured in duplicate using the Immulite® 2500 
solid-phase, two-site chemiluminescent immunometric assay. The 
within-assay CVs for prolactin were 2.8% and 2.5% at 187 and 1018 mU/L 
respectively. The between-assay CVs for prolactin were 8.2% and 6.9 % at 
187 and 1018 mU/L respectively, and the detection limit of the assay was 20 
mU/L.  
 
A standardised glucagon stimulation test was then performed by the ward 
staff. Samples for measurement of blood glucose and serum GH 
concentrations were obtained at time -30 and 0, and 30, 60, 90, 120, 150 and 
180 minutes after intramuscular (IM) injection of 100microgrammes/kg 
body weight glucagon (maximum 1 mg). Peak GH response to glucagon 
testing of ≤6.7ng/ml was diagnostic of GHD. Peak GH response to glucagon 
testing of ≥10ng/ml was defined as normal. Children with peak GH response 
to stimulation between 7 and 10ng/ml were excluded from participation in 
the study. Serum GH was measured in duplicate using the Immulite® 2500 
solid-phase, two-site chemiluminescent immunometric assay. The within-
assay CVs for GH were 3.5% and 2.9% at 2.6 ug/L and 7.9 ug/L 
respectively. The between-assay CVs for GH were 6.5% and 4.2% at 2.6 
ug/L and 7.9 ug/L, and the detection limit of the assay was 0.1 ug/L. 
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In all children diagnosed with GHD, SOD and ONH a 24 hr cortisol profile 
(24-hour two-hourly blood samples to measure cortisol and glucose), was 
performed according to standardised protocols to exclude cortisol deficiency. 
Mean cortisol of >145nmol/L over a 24 hour period and/ or a morning peak 
cortisol of >175nmol/L were defined as normal (177). Serum cortisol was 
measured in duplicate using the Immulite® 2500 solid-phase, competitive 
chemiluminescent enzyme immunoassay. The within-assay CVs for cortisol 
were 6.0% and 6.2% at 91 and 717 nmol/L respectively. The between-assay 
CVs for cortisol were 8.1% and 7.3% at 91 and 717 nmol/L, and the 
detection limit of the assay was 28 nmol/L. 
 
D. MRI acquisition 
MR imaging was performed on an Avanto 1.5 Tesla MRI scanner (Siemens, Erlangen, 
Germany). A standard brain and pituitary scan (3mm thick image acquisition of the 
pituitary, in the sagittal and coronal planes using a combination of T1 and T2-weighted 
sequences), was performed on all subjects recruited to the study. All images were 
reviewed by a single experienced neuroradiologist, who was blinded to the clinical data 
(Dr Kling Chong). Posterior pituitary gland location was established. Hypoplastic 
anterior pituitary gland was a subjective diagnosis, defined by the visual appearance of 
the anterior gland on all slices. A diagnosis of ONH and laterality of disease were 
determined by one experienced pediatric neuroradiologist (Dr Kling Chong) blinded to 
the clinical data who reviewed all images. The diagnosis of ONH was confirmed by 
ocular fundus photography performed by a pediatric ophthalmologist. 
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3D FLASH (TR 11 ms, TE 4.94 ms, FOV 256 mm, voxel size 1 mm3) (acquisition time 
5mins) and 3D FLAIR (TR 6000 ms, TE 353 ms, TI 2200 ms, FOV 256 mm, voxel size 
1 mm3) (acquisition time 15mins) datasets were acquired. Diffusion tensor imaging was 
also performed. Twenty diffusion sensitised directions were acquired with a b value of 
1000 s mm-2 along with 1 image at b=0 for normalisation. This protocol was repeated 3 
times to improve signal to noise ratio.  The image dimensions for the diffusion sequence 
are 96 × 96 × 45, consisting of 2.5mm isotropic voxels.  
 
E. MRI analysis 
i) FreeSurfer analysis:   IGHD AND ISS GROUPS 
Neural volumes were acquired using FreeSurfer, an MRI brain imaging 
software package which performs whole brain segmentation and automated 
labelling of the neuroanatomical structures based on probabilistic 
information estimated from a manually labelled atlas using the T1-weighted 
images (104;178).  
 
To generate hypotheses as to which structures in the brain could be affected 
by IGF-1 and IGFBP-3 deficiency and, in order to reduce the number of 
multiple comparisons made, a literature search for articles pertaining to the 
distribution of brain GH and IGF-1 expression was performed (summarized 
in Introduction). Human brain GH receptor expression is highest in the 
choroid plexus, thalamus, hypothalamus, pituitary, putamen and 
hippocampus (40). IGF-1 gene expression has been found in humans in the 
hypothalamus, hippocampus, olfactory bulb, cerebellum, neocortex and 
striatum (179) with IGF-1 receptors most dense in the hippocampus, 
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amygdala, caudate nucleus, cortex, cerebellum and prefrontal cortex 
(53;179). On the basis of this literature we hypothesized that IGF-1 and 
IGFBP-3 SDS would correlate with total brain volume and the volumes of 
the thalamus, putamen, hippocampus, amygdala, caudate nucleus, 
parahippocampal gyrus, prefrontal cortex and cerebellum. As several of 
these structures form part of the basal ganglia, volumes for all components 
of the basal ganglia generated by FreeSurfer (104;178) were acquired. We 
also selected structures based on cognitive findings in children with IGHD 
using previous studies correlating cognitive performance with neural 
abnormalities (180-182). The automated parcellation of the neural volumes 
acquired was reviewed to assess that the correct structures had been 
extracted and that the structure margins defined by freesurfer were 
appropriate. 
 
The volumetric data for the two groups were compared using t-tests. Where 
regions of significant difference (p<0.05) were identified neural volumes 
were compared using analysis of covariance, controlling for age at scan, sex 
and total brain volume (to ensure that differences found in specific structure 
volumes were not secondary to a generalized effect of variability in total 
brain volume). As multiple correlations were performed, the p-values for 
significance were adjusted to control for the false discovery rate (FDR) 
(183). Stepwise linear regression was also performed to assess the 
significance of study group in determining neural volumes with age, sex, 
study group and total brain volume being entered into the model. 
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ii) Voxel-based morphometry:  IGHD AND ISS GROUPS 
The 3D MRI data sets were also processed using statistical parametric 
mapping software version 8 (SPM8; Wellcome Trust Centre of 
Neuroimaging, Institute of Neurology, University College of London) 
running in Matlab R2009a (version 7.8.0) (184). The same investigator (EW) 
located the anterior commissure in each dataset and reoriented datasets to set 
the origin to 0,0,0 at the anterior commissure. Images were segmented using 
the segmentation tool in SPM8. The Diffeomorphic anatomic registration 
through exponentiated Lie algebra algorithm (DARTEL) toolbox (185)  was 
then used to generate a template and to co-register the images. Registration 
achieved using DARTEL is superior to standard voxel based morphometry 
in which scans are spatially normalized to a standard template. DARTEL 
adjusts for the fact that different brains vary in shape and size and results in 
improved inter-subject alignment as compared with previous methods. This 
toolbox is especially useful in paediatric studies where collecting large 
amounts of control data to collate templates from can be challenging. By 
using DARTEL warping the images to an adult template and thus distorting 
findings is avoided. DARTEL was used to derive Jacobian scaled 
(modulated) warped tissue class images for white and grey matter. The 
modulated warped gray and white matter images were subsequently 
smoothed with an 8mm full width half-maximum isotropic Gaussian kernel, 
and then entered into statistical analyses. Smoothing reduces the effect of 
inter-subject anatomical variability, which may remain after image co-
registration. The final smoothed modulated warped images had a normalized 
voxel size of 1.5 x 1.5 x 1.5mm. 
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Voxel based analysis was then performed using independent t-test on the 
smoothed, modulated, and segmented gray and white matter images with a 
voxel threshold of p < 0.05, family-wise error (FWE)-corrected to compare 
the maps of the 2 groups of subjects (IGHD and ISS) (all t-tests corrected for 
age and sex). Previous studies in children have shown that age has a 
significant effect on grey and white matter (186); age was therefore used as a 
covariate in all analyses. Where a significant difference in grey or white 
matter is present, voxels are displayed on an output map (statistical 
parametric map [SPM]).  
 
iii) Diffusion tensor imaging:  IGHD, ISS AND ONH GROUPS 
Diffusion-weighted images were initially processed using the Functional 
Magnetic Resonance Imaging of the Brain Software Library (FSL; 
http://www.fmrib.ox.ac.uk/fsl).  
 
Data were inspected for movement artefacts and then correction for eddy 
current induced distortions, brain extraction, and calculation of diffusion 
tensor FA and mean diffusivity (MD) maps was carried out using FSL tools 
(http://www.fmrib.ox.ac.uk/fsl). Participants were excluded from image 
analysis if data quality was poor, for example secondary to excessive head 
movement or if the acquisition was incomplete. 
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iv) Tract Based Spatial Statistics: IGHD, ISS AND ONH GROUPS 
The FA images were initially processed using TBSS (121;187), and 
automated, observer-independent, voxel-by-voxel whole-brain between-
group analysis performed.  
 
Initially, every FA image was aligned to every other one using the -n flag. 
This selects the most representative study image as a target image which is 
then affine-aligned into MNI152 standard space. Other study images were 
then transformed into 1x1x1mm MNI152 space by combining the nonlinear 
transform to the target FA image with the affine transform from that target to 
MNI152 space. Secondly the mean of all FA images was created using the -s 
option. The mean image was subsequently thinned and thresholded at an FA 
value of 0.2 to create a white matter tract skeleton representing the center of 
the tracts common to all subjects. FA data projected onto these skeletons was 
then used in voxel-wise statistical comparisons using the Threshold-Free 
Cluster Enhancement option (which is fully corrected for multiple 
comparisons across space). 
 
v) Tract Based Spatial Statistics: IGHD AND ISS GROUPS 
TBSS was used to calculate tract-based differences in FA values between the 
GHD group and the ISS control group. TBSS has the advantage over VBM 
that it does not require smoothing. However it only compares the 
skeletonised white matter tracts between subjects and regions of FA outside 
the white matter tracts i.e. in the hippocampus are not assessed. Values for 
corpus callosum and corticospinal tract FA were extracted from the TBSS 
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analysis by masking the mean skeleton with the appropriate structure label 
from the Johns Hopkins University white-matter tractography atlas (188). 
 
FA and MD of the total white matter skeleton, corpus callosum and cortico-
spinal tract were compared using Analysis of Covariance (ANCOVA). Age 
and sex are known to affect brain growth and myelination and were therefore 
used as a covariates in all analyses. Total brain volume (TBV) was compared 
using ANCOVA, controlling for age at scan, and sex. For all other neural 
volumes, TBV was used as an additional covariate. 
 
vi) Tract Based Spatial Statistics: ONH AND ISS GROUPS 
The FA images were analyzed using tract-based spatial statistics (121;187), 
an automated, observer-independent, voxel-by-voxel whole-brain between-
group analysis technique, as described above. All analyses were corrected 
for age and sex. Values for the ventral cingulum, corpus callosum and optic 
radiation FA were extracted from the TBSS analysis by masking the mean 
skeleton with the appropriate structure label from the Johns Hopkins 
University white-matter tractography atlas (188). 
 
F. Rest-activity pattern assessment 
i. Actigraphy 
All patients with SOD, IGHD and ISS wore the Actiwatch mini® (CamNtech 
Ltd), which detects and logs movement intensity and duration using an 
internal accelerometer, on the wrist of their non-dominant hand for a 2 week 
period. The actiwatch has been validated against polysomnography for the 
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assessment of sleep wake patterns and sleep efficiency in children (189). 
Actigraphy is more useful than laboratory based sleep studies when 
assessing circadian rhythm as it enables data collection over a longer time 
period, with a large body of evidence supporting its use in describing sleep-
wake cycles and the identification of sleep abnormalities (190). The watches 
were calibrated by the manufacturer prior to use to ensure that data 
collection and sensitivity were comparable between the devices used.  
 
ii. Sleep diary 
Parents of children with SOD, IGHD and ISS were asked to keep a detailed 
sleep diary over the 2 week period recording the time of sleep onset and 
offset, and the number and length of night awakenings, daytime naps and 
actiwatch removal. 
 
iii. Analysis of actiwatch data 
Actiwatch data were analyzed in conjunction with the sleep diary. Sleep 
wake patterns were ascertained and actual time asleep and sleep efficiency 
calculated using Actiware software (Minimitter). Sleep efficiency was 
defined as the ratio of total sleep time to sleep period (191). Actogram 
analysis was used to define the sleep pattern as normal (tau 24hrs), free 
running (tau>24hrs), fragmented (sleep efficiency <85%), or arrhythmic (no 
discernable rhythmicity) (157). When these definitions are applied to healthy 
control populations very few individuals are identified with free running, 
fragmented or arrhythmic sleep patterns (157;190). Sleep efficiency in 
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children with SOD was compared to that of the healthy controls using the 
independent Student’s t test. 
 
iv. Melatonin profile 
Children with SOD were admitted to hospital on the morning of the 
melatonin profile. Plasma samples were collected hourly over a 24hr period 
by Dr Emma Webb from an indwelling venous cannula, with overnight 
samples being taken under dim light (20:00-06:00). Samples were collected 
into lithium heparin tubes, mixed by inversion and spun immediately in a 
refrigerated centrifuge. Plasma was then removed and stored at -20oC until 
assayed. 
 
v. Melatonin analysis 
Melatonin concentrations were measured by Stockgrand Ltd. Within assay 
CVs for melatonin were 11.8%, 9.6%, 8.1%, 7.8% and 5.5% at 18, 26, 50, 
88 and 107 pg/ml. Between-assay CVs for melatonin were 13.1%, 11.3%, 
7.7% and 8.1% at 14, 33, 90 and 118 pg/ml, and the detection limit of the 
assay was 3.3 pg/ml. The melatonin results were compared to historical 
controls collected by Waldhauser et al to assess normality (192). 
 
G. Behavioural data acquisition 
All parents were asked to complete the Child Behaviour Checklist (CBCL) (193), a 
standardized and validated rating scale that screens for emotional, social, and behavioural 
problems. The checklist includes 8 domains of behaviour: Social Withdrawal, Somatic 
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Complaints, Anxiety/Depression, Social Problems, Thought Problems, Attention 
Problems, Delinquent Behaviour, and Aggressive Behaviour. Each category is a 
compilation of observations about the child’s behaviour with Likert scale values: 0 = no, 
1 = sometimes, and 2 = very often; the sum of the values in each category signifies the 
severity of the behaviour. The scores for internalising and externalising problems and 
total scores were also calculated. Internalising problems consist of syndrome scales for 
emotionally reactive behaviour, anxious/depressed behaviour, somatic complaints and 
withdrawn behaviour. Externalising problems consist of syndrome scales for attention 
problems and aggressive behaviour. For these scores, cut-offs for subclinical and clinical 
problems were set at the 84th and 90th percentiles, respectively, following the CBCL 
manual.  
 
H. Behavioural data analysis 
Behavioural assessment scores were compared using ANCOVA controlling for 
socioeconomic status and maternal educational attainment (IGHD vs ISS and ONH vs 
ISS). Partial correlations were also used to assess the relationships of plasma IGF-1 and 
IGFBP-3 SDS to behavioural measures, adjusted for socioeconomic status and maternal 
educational attainment in children with IGHD. As multiple comparisons were 
performed, the p-values for significance were adjusted to control for the false discovery 
rate (FDR) (183). 
 
I. Cognitive data acquisition 
One assessor (Dr Michelle O Reilly) blinded to participant group performed all 
cognitive assessments.  
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i. IGHD AND ISS GROUPS 
A detailed assessment of cognitive function was performed at baseline. Intellectual 
functioning was assessed using the Wechsler Intelligence Scales for Children IV edition 
(WISC-IV). Full-Scale IQ, Verbal Comprehension Index, Perceptual Reasoning Index, 
Working Memory and Processing Speed indices (FSIQ, VCI, PRI, WMI and PSI 
respectively) were calculated (population mean=100, SD=15) (194). Younger 
participants (one child in the IGHD group and two children in the SS control group) 
were assessed using the Wechsler Preschool and Primary Scale of Intelligence-Third 
Edition (WPPSI-III UK), with Full Scale IQ, Verbal and Performance IQ and 
Processing Speed scores generated. For the sake of brevity, these children’s Verbal IQ 
was designated as VCI data and Performance IQ as PRI data. In our clinical experience 
we have found that parents of children with IGHD frequently report that they have 
delayed motor development when compared to their siblings. Therefore neuromotor 
function was assessed with the Movement Assessment Battery for Children 2nd Edition 
(M-ABC2) (195;196). Standard scores for the three motor skills components of manual 
dexterity, aiming & catching and balance and for the total test score are based on a 
distribution with a mean of 10 and a standard deviation of 3.  
 
Attention, memory, executive function and language were assessed using the 
Developmental NEuroPSYchological Assessment (NEPSY) and CANTAB (Cambridge 
Neuropsychological Test Automated Battery) neuropsychological test batteries. 
Measures of memory included Memory for Faces, Memory for Names, Narrative 
Memory and List Memory from the NEPSY-II battery (197), and Pattern Recognition 
Memory, Spatial Working Memory and Paired Associate Learning tests from the 
CANTAB (198). Attention was assessed using the Big/Little Circle, Intra-dimensional 
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Extra-dimensional Set shift, Rapid Visual Information Processing tests from CANTAB. 
The Inhibition and Word Generation tests from the NEPSY-II battery and Intra-
dimensional Extra-dimensional Set shift from CANTAB were used to assess Executive 
Function. 
 
ii. ONH AND SOD GROUPS 
Children aged over 6 years were assessed using WISC-IV; FSIQ, VCI, PRI, WMI and 
PSI were calculated (population mean=100, SD=15) (199). Younger participants were 
assessed using the WPPSI-III UK, with FSIQ, Verbal and Performance IQ scores 
generated (200). The SOD group and the two ONH participants who were too young for 
the WPPSI assessment were assessed using the semi-standardized Reynell-Zinkin 
Scales (RZS) (201). The RZS were performed as part of routine clinical assessment by 
clinical psychologists and paediatricians, who were experienced in assessing children 
with visual impairment. Raw scores were converted to age equivalent levels from the 
normative values in the RZS manual that are appropriate for the child’s level of vision. 
Developmental Quotients were derived from the mid-points of the age equivalent level 
divided by the chronological age of the child at the time of assessment (200). Normal 
developmental status is typically defined as developmental quotient ≥ 80 (134), and 
FSIQ ≤ 80 is considered below average (200). 
 
J. Cognitive data analysis 
In the IGHD and ISS groups total scores for FSIQ, CBCL and Movement ABC were 
compared using ANCOVA controlling for socioeconomic status and maternal 
educational attainment. Scores were adjusted to control for FDR. Where total scores 
showed significant differences between groups sub-test analysis was then performed. 
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Partial correlations were used to assess the associations between plasma IGF-1 and 
IGFBP-3 SDS and cognitive measures, adjusted for socioeconomic status and maternal 
educational attainment in children with IGHD [in population based studies both 
maternal IQ and socioeconomic status have been found to be strong predictors of a 
child’s IQ (202)].  As multiple comparisons were performed, the p-values for 
significance were adjusted to control for the FDR (183). 
 
K. DNA collection and analysis 
DNA samples were collected as 2 x 5-10 ml EDTA blood samples from all individuals 
with IGHD, ONH and SOD for genetic studies. The Institute of Child Health DNA 
laboratory processed the EDTA samples and generated DNA in 250 mg/ml aliquots of 
differing volumes. DNA was sequenced for mutations in the following genes (IGHD: 
GH-1 and GHRHR; ONH and SOD: HESX-1, SOX-2 and SOX-3), depending on the 
phenotype (Table 4) using Polymerase Chain Reaction, a method for amplifying a DNA 
base sequence, producing a rapid and highly specific amplification of the desired region. 
DNA was amplified using primers designed to include coding and splicing regions of 
individual exons for GH1, GHRHR, HESX1, SOX2, and SOX3 as previously described 
(203-208). For any novel mutations identified, the sequence change was ascertained by 
screening 100 samples derived from an appropriate control population to establish 
whether the change was polymorphic.  
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 3.  THE EFFECT OF ISOLATED GROWTH HORMONE 
DEFICIENCY ON COGNITION, MOTOR FUNCTION 
AND BRAIN STRUCTURE 
 
‘Even among human beings, children when compared with adults, and dwarf adults, 
when compared with others, may have some characteristics in which they are superior, 
but in intelligence at any rate, they are inferior. And the reason is that in many of them 
the principle of the soul is sluggish and corporeal…’ 
 
(Aristotle, Parts of animals, IV.x.) 
A.  Introduction 
Evidence is accumulating that both IGF-1 and IGFBP-3 play an important role in 
normal brain growth and development (209), with an ongoing role in determining 
childhood and adult cognitive function (13;48;210). There is also evidence to suggest 
that IGF-1 and IGFBP-3 deficiency such as that found in children and adults with GHD, 
and in children born extremely preterm (<31weeks at birth) in whom there is a relative 
IGF-1 and IGFBP-3 deficiency postnatally (107), is associated with cognitive deficits 
and changes in brain structure. 
 
The impact of IGF-1 and IGFBP-3 deficiency on cognitive function has primarily been 
studied in adults and children with GHD. In adults (with childhood and adult onset GHD) 
cognitive function deficits, principally in the domains of memory and attention, have 
previously been documented. These deficits are ameliorated by GH replacement 
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(73;80;94). In the majority of studies examining children with GHD, IQ has been found 
to be within the normal range. Despite this, a significant proportion of children with GHD 
have difficulties with education particularly in the domains of reading, spelling and 
arithmetic (211). However, to date, the precise nature of the cognitive impairments 
associated with childhood IGHD remains unclear with the findings from previous studies 
being difficult to interpret due to: (1) the definition of GHD used (e.g. If GHD is defined 
as a peak GH response of <10µg/L, and normal as a peak GH response of >10µg/L, some 
individuals will be misclassified), (2) the inclusion of heterogeneous patient groups with 
varying aetiologies (e.g. post-radiation GHD, congenital GHD, multiple pituitary 
hormone deficiency), (3) variation in the duration of GHD, (4) the wide age-range of 
patients studied, and (5) the lack of uniformity in the cognitive tests used to measure 
performance (80).  
 
Motor skills have previously been evaluated in children with IGHD and MPHD by 
assessing their ability to copy a number of designs. In this combined (IGHD & MPHD) 
cohort abnormalities in visual-motor skills were identified (100;101). However again the 
existence of pituitary hormone abnormalities other than isolated GHD in this study makes 
it hard to extrapolate these findings to children with solely IGHD. Specific assessment of 
motor skills have not previously been performed in individuals with IGHD (101).  
 
Detailed neuroimaging studies using techniques such as volumetric MRI and DTI brain 
have not previously been performed in individuals with IGHD. MRI can be used to 
identify correlations between neural volumes, FA and parameters of interest such as 
IGF-1 and IGFBP-3 SDS to further assess the role of GH in neural development. The 
only similar population studied to date using some of these techniques is children born 
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extremely preterm, in whom there is a relative IGF-1 and IGFBP-3 deficiency post-
natally. In these children Hansen-Pupp et al identified significant associations between 
IGF-1 and IGFBP-3, verbal IQ and total brain volume (107).  
 
To further analyse the roles of IGF-1 and IGFBP-3 in brain development, we therefore 
investigated a cohort of children with IGHD using cognitive and motor assessment 
together with MRI, DTI and VBM and compared the findings with those of a cohort of 
children with ISS.  
 
We hypothesized that in children with IGHD, IQ would correlate significantly with 
IGF-1 and IGFBP-3 SDS, and that FA, TBV and the volumes of the thalamus, putamen, 
hippocampus, amygdala, caudate nucleus, parahippocampal gyrus, prefrontal cortex and 
cerebellum (regions of the brain with the highest GHR, IGF-1 receptor and IGF-1 gene 
expression (40) (57;179)) would be significantly lower than in the ISS control group.  
 
B.  Methods 
i. Study subjects 
Two cohorts (IGHD and ISS, aged 5-11 years) were recruited prospectively from the 
paediatric endocrine clinic at Great Ormond Street Hospital between 2007 and 2009. 
IGHD was diagnosed in children with a height and growth velocity ≤2 SDS below the 
mean for age, a peak GH <6.7µg/L on two tests of GH release (glucagon and clonidine), 
or on one stimulation test in association with a pathologically low IGF-1 concentration 
for age and sex (below -2 SDS). Bone age delay was also used to support the diagnosis 
of IGHD. The presence of other hormonal abnormalities was excluded in children with 
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IGHD. ISS was diagnosed in children with a height ≤2 SDS below the mean for age, a 
normal height velocity, normal brain and pituitary MRI, normal IGF-1 concentration for 
age and sex (defined as between -2 and +2 SDS), and a normal peak GH in response to 
stimulation (>10 µg/L). 
 
ii. Baseline characteristics 
IGF-1, IGFBP-3 and growth velocity were measured and brain DTI and volumetric 
MRI acquired. All study subjects (IGHD and controls) completed 2 weeks actigraphy 
and a detailed sleep diary. Actiwatch data were analyzed in conjunction with the sleep 
diary.  
 
iii. Cognitive (intellectual and neuromotor) and behavioural assessment 
One assessor (MOR) blinded to participant group performed all cognitive assessments. 
Intellectual functioning was assessed using the full WISC-IV. FSIQ, VCI, PRI, WMI 
and PSI were calculated (population mean=100, SD=15) (200). Younger participants 
(aged 5-6 years, 1 IGHD, 2 ISS) were assessed using the WPPSI-III UK, with FSIQ, 
Verbal and Performance IQ and processing speed index scores generated. Neuromotor 
function was assessed with the M-ABC2 (195). Behaviour was assessed using the 
CBCL. 
 
iv. MRI analysis 
MRI data was processed using FreeSurfer 5.0 and volumes extracted for the basal 
ganglia, thalamus, hippocampus and corpus callosum, (51;113;212;213). Structures 
were selected based both on studies detailing the expression pattern of GH and IGF-1 
receptors in the brain and on previous studies correlating cognitive and motor skills 
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performance with neural abnormalities (57;180-182). Total brain volume was also 
calculated. No other neural volumes were extracted from the FreeSurfer analysis to 
ensure all analyses performed were hypothesis driven. The difference in total brain 
volume between groups was compared using ANCOVA, controlling for age at scan, and 
gender. For all other neural volumes, total brain volume was used as an additional 
covariate. Freesurfer segmentation was checked for all neural volumes extracted. As 
multiple ANCOVA’s were carried out to compare the difference in neural volumes 
between the two groups, the p-values for significance were adjusted to control for the 
FDR (183). Volumetric data were also processed using VBM with SPM8 software 
(Wellcome Department of Cognitive Neurology, Institute of Neurology), running in 
Matlab R2009a (version 7.8.0) (184). Voxel based analysis was then performed using 
independent t-test on the smoothed, modulated, and segmented gray and white matter 
images with a voxel threshold of p < 0.05, FWE corrected to compare the maps of the 2 
groups of subjects (IGHD and ISS) (all t-tests corrected for age and sex). FA and MD 
images were processed using TBSS and automated, observer-independent, voxel-by-
voxel whole-brain between-group analysis performed (corrected for age) (121). Values 
for corpus callosum and corticospinal tract FA were extracted from the TBSS analysis 
(detailed description in Methods). FA and MD of the total white matter skeleton, corpus 
callosum and cortico-spinal tract were compared using ANCOVA. Age and sex are 
known to affect brain growth and myelination and were therefore used as a covariate in 
all analyses. 
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v. Statistics 
Baseline characteristics of the two groups, including age, sex, birth weight, gestational 
age, handedness, maternal highest educational level and socioeconomic status, peak GH 
(µg/L), IGF-1 SDS and IGFBP-3 SDS, height SDS, growth velocity SDS and BMI SDS 
were compared using independent Student’s t test. Total scores for FSIQ, CBCL and 
Movement ABC were compared using ANCOVA controlling for socioeconomic status 
and maternal educational attainment. Scores were adjusted to control for FDR. Where 
total scores showed significant differences between groups sub-test analysis was then 
performed. 
 
Partial correlations were used to assess the relationships between plasma IGF-1 and 
IGFBP-3 SDS and cognitive and motor skills assessment scores, (adjusted for 
socioeconomic status and maternal educational attainment) in children with IGHD and 
in the group as a whole (IGHD and ISS). Partial correlation was used to assess the 
relationship between neural volumes and the processing speed index, verbal 
comprehension index and IGF-1 and IGFBP-3 SDS (controlled for age at scan, sex and 
TBV). 
 
Partial correlation was used to assess the relationship between neural volumes (where 
there was a significant difference in volumes of brain structures between the 2 groups) 
and FA of the corpus callosum and cortico-spinal tract to FSIQ, the Perceptual 
Reasoning Index, Verbal Comprehension Index and scores on the M-ABC2 and IGF-1 
and IGFBP-3 SDS (controlled for age at scan, gender and total brain volume) in 
children with IGHD. 
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As children with ISS do not have an entirely normal GH-axis (as demonstrated by their 
mean IGF-1 SDS which falls below 0) partial correlation was also performed to assess 
the relationship between IGF-1 and IGFBP-3 SDS and MRI measures in the whole 
study group (IGHD and ISS) (controlled for age at scan, gender and total brain volume). 
 
vi. Genetic analysis 
Children with ectopic posterior pituitary gland and IGHD were screened for mutations 
in SOX-3. All children with IGHD were screened for mutations in GH-1 and HESX-1. 	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C.  Results 
i. Subject	  characteristics	  
Fifteen children (mean 8.6yrs) with IGHD (peak GH <6.7µg/l [mean 3.9µg/l]), and 14  
(mean 8.5yrs) with ISS (peak GH >10µg/l [mean 14µg/l] and normal growth rate) were 
recruited (3 children with ISS declined to participate). All children were right-handed, 
had no abnormal neurological findings and were in mainstream schooling. No subjects 
were hypoglycaemic (blood glucose <3.5mmol/L) after a 12hour fast. No children had 
abnormal cortisol profiles. Two children with IGHD and one with ISS did not tolerate the 
DTI scan but completed all other study components. Subject characteristics are 
summarised in Table 5. Table 6 outlines the baseline endocrinology of the two groups, 
and the anthropometric characteristics of the two groups are summarized in Table 7. No 
mutations in any of the genes screened (HESX-1, 15 children screened, GH-1, 15 children 
screened, and SOX-3, 7 individuals screened) were identified. Actigraphic studies were 
normal in all children with IGHD and all ISS controls. 
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Table 5 Subject characteristics  
 
 IGHD ISS p-
value* 
Subject characteristics 
Number 15 14  
Mean Age (SD, Standard Error (SE)) 8.75 (1.8, 0.5) 8.36 (1.65, 0.4) 0.55 
% Male (Number) 80 (12/15) 64 (9/14) 0.62 
Gestational Age (SD) 39.4 (1.4) 39 (0.6) 0.97 
Birth weight (g) (SD, SE) 3.56 (0.9, 0.2) 3.28 (0.3, 0.1) 0.3 
% Right Handed 100 100  
Social Status (SD, SE) 2.6 (1.1, 0.3) 2.85 (0.8, 0.2) 0.48 
Maternal Education Status (SD, SE) 2.5 (1.2, 0.3) 3.1 (1, 0.28) 0.15 
% Hypoplastic anterior pituitary on 
MRI (number) 
60 (9/15) 0 (0/14)  
% Ectopic posterior pituitary on MRI 
(number) 
47 (7/15) 0 (0/14)  
 
• Baseline characteristics of the two groups (IGHD & ISS) were compared using 
independent Student’s t test. 
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Table 6  Baseline endocrinology 
 
 (SD, SE) IGHD ISS p-value* 
GH baseline µg/L  0.8 (1.4, 0.4) 3 (2.7, 1) 0.03 
GH peak µg/L  3.5 (2.3, 0.6) 15 (5.7, 1.9) 0.001 
IGF-1 SDS  -2 (0.7, 0.2) -0.5 (0.8, 0.2) 0.001 
IGFBP-3 SDS  -1 (0.8, 0.2) 0.1 (0.7, 0.2) 0.001 
Fasting blood glucose (mmol/L)  3.9 (0.4, 0.1) 4.1 (0.21, 0.1) 0.3 
Free thyroxine (pmol/L) 16 (3.3, 0.9) 16.2 (2.2, 0.7) 0.86 
Thyroid stimulating hormone (mU/L) 3.1 (2.1, 0.55) 3 (1.9, 0.5) 0.88 
Prolactin (mU/L) 212 (180, 46) 234 (256, 74) 0.79 
Peak cortisol (nmol/L) 747 (208, 55) 713 (230, 87) 0.74 
 
*p-values highlighted in bold remained significant after adjustment to control for FDR 
(183)
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Table 7 Anthropometric characteristics 
 IGHD ISS p-value* 
Baseline (SD, SE) 
Mean Age  8.75 (1.8, 0.5) 8.36 (1.65, 0.4) 0.55 
Growth velocity (cm/yr)  3.8 (1.3, 0.3) 5.8 (1.4, 0.5) 0.006 
Growth velocity SDS -1.6 (1, 0.29) -0.3 (1, 0.34) 0.009 
Target height SDS  -0.54 (0.8, 0.3) -0.74 (1.1, 0.3) 0.61 
Height SDS  -2.9 (0.7, 0.2) -2.5 (0.5, 0.2) 0.85 
Weight SDS  -2.3 (1.5, 0.4) -1.7 (0.56, 0.2) 0.4 
BMI SDS -0.2 (1.1, 0.3) -0.1 (0.6, 0.2) 0.8 
Occipitofrontal circumference SDS -1.7 (1.2, 0.4) -1.8 (0.9, 0.4) 0.8 
Bone Age 6.2 (2.3, 0.6) 6.7 (1.8, 0.4) 0.62 
*p-values highlighted in bold remained significant after adjustment to control for FDR 
(183)  
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ii. Cognitive	  (intellectual)	  and	  behavioural	  assessment	  
When compared to controls, children with IGHD had significantly lower FSIQ 
(p<0.02), verbal comprehension index (p<0.006) and processing speed index (p<0.05) 
scores (Table 9). Scores for Perceptual Reasoning Index and Working Memory Index 
were also lower in children with IGHD than in children with ISS, however these 
differences did not reach statistical significance (p=0.09, p=0.2). Examination of the IQ 
data showed that there were 2 outliers (defined as Z score > or < 2). The IQ data were 
reanalyzed without these 2 outliers, and significant group differences in FSIQ (p<0.01) 
and the Verbal Comprehension Index (p<0.01) remained. There was no significant 
difference in executive function, attention and memory measures (performance on the 
CANTAB and NEPSY) between children with IGHD and ISS controls (Table 8). There 
were no significant difference in scores on the CBCL between children with IGHD and 
controls (Table 8). One child with ISS had behavioural scores in the borderline range, 
no children with IGHD had CBCL scores in the borderline or clinical range. 
 
iii. Neuromotor	  assessment 
 When compared to controls, children with IGHD had significantly lower scores on the 
manual dexterity (p<0.03), balance (p<0.008) and total scores (p<0.008) of the M-
ABC2 test (Table 8).  
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Table 8 Difference between cognitive, memory, behavioural and motor skills 
assessment scores in children with isolated growth hormone deficiency 
and idiopathic short stature 
 
Wechsler Intelligence Scale for 
Children IV * 
IGHD ISS p-value 
Full Scale IQ (SD, SE) 92.8 (16, 4.2) 102.6 (8.6, 2.4) 0.01 
Perceptual Reasoning Index (SD, SE) 98.5 (18.6, 4.8) 107.7 (11, 3) 0.09 
Verbal Comprehension Index (SD, SE) 91 (14, 3.7) 106 (10, 2.9) 0.01 
Working Memory Index (SD, SE) 93.6 (22, 4.1) 95.9 (13, 2.1) 0.2 
Processing Speed Index (SD, SE) 85.3 (16.6, 2.4) 95.7 (13, 1.8) 0.05 
NEPSY* IGHD ISS p-value 
Inhibition total error (SD, SE) 10.2 (3.1, 0.8) 10.4 (3.6, 1) 0.9 
Inhibition naming time (SD, SE) 9.2 (4, 1) 10.4 (3.9, 1.1) 0.50 
Inhibition switching time (SD, SE) 9.7 (4, 1.1) 11.7 (3, 0.9) 0.19 
List memory (SD, SE) 9 (4.2, 1.1) 9.1 (3.4, 1) 0.96 
Memory faces (SD, SE) 9.3 (4.6, 1.2) 9.9 (2.6, 0.8) 0.68 
Memory names (SD, SE) 9.4 (2.4, 0.6) 10.7 (3.7, 1.1) 0.28 
Phonic processes (SD, SE) 10.9 (1.6, 0.6) 12.2 (1.9, 0.9) 0.21 
Word generation (SD, SE) 10.8 (4.6, 1.2) 12.2 (3.5, 1) 0.4 
Memory faces (SD, SE) 9.3 (4.6, 1.2) 9.9 (2.6, 0.8) 0.68 
Memory names (SD, SE) 9.4 (2.4, 0.6) 10.7 (3.7, 1.1) 0.28 
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Phonic processes (SD, SE) 10.9 (1.6, 0.6) 12.2 (1.9, 0.9) 0.21 
Word generation (SD, SE) 10.8 (4.6, 1.2) 12.2 (3.5, 1) 0.4 
Behavioural Assessment* IGHD ISS p-value 
CBCL Total Score (SD, SE) 53 (4.7, 1.3) 53.6 (5.5, 1.6) 0.88 
Movement-ABC2 (scaled scores)* IGHD ISS p-value 
Total score (SD, SE) 6.9 (2.5, 0.7) 9.8 (2.6, 0.7) 0.008 
Manual Dexterity (SD, SE) 7.2 (2.3, 0.6) 9.3 (2.6, 0.7) 0.03 
Aiming & Catching (SD, SE) 7.7 (2.9, 0.7) 8.8 (2.8, 0.7) 0.3 
Balance (SD, SE) 7.9 (3, 0.8) 10.4 (2.4, 0.6) 0.009 
 
*Results corrected for socioeconomic status and maternal educational attainment 
* Total scores for FSIQ, CBCL and Movement ABC were adjusted to control for 
FDR. Where total scores showed significant differences between groups sub-test 
analysis was then performed. P-values highlighted in bold remain significant after 
adjustment to control for FDR. 
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iv. Associations	   between	   cognitive	   assessment	   scores,	   IGF-­1	   and	  
IGFBP-­3	  SDS	  
Children with IGHD 
In children with IGHD, verbal comprehension index scores correlated significantly with 
IGF-1 and IGFBP-3 SDS (r=0.7, p<0.03; r=0.7, p<0.02) (Figure 8) and FSIQ correlated 
significantly with IGFBP-3 SDS (r=0.6, p<0.03), but not IGF-1 SDS (r=0.5, p=0.08).  
 
ISS Controls 
There were no significant correlations between IGF-1 and IGFBP-3 and IQ in the 
control group. 
 
Whole Cohort (IGHD & ISS combined) 
There was a significant positive correlation between whole cohort (IGHD and ISS) 
FSIQ and VIQ scores and plasma IGF1 SDS (r=0.4, p<0.04 and r=0.5, p<0.02, 
respectively) and IGFBP3 SDS (r=0.4, p<0.04, and r=0.5, p<0.015 respectively).  
 
v. Associations	  between	  neuromotor	  assessment	  scores,	  IGF-­1	  and	  
IGFBP-­3	  SDS 
There were no significant correlations between neuromotor assessment scores, IGF-1 
and IGFBP-3 SDS in children with IGHD, ISS controls or the whole cohort (IGHD and 
ISS combined). 
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Figure 8 Relationship between Verbal Comprehension Index (Verbal IQ), Insulin-
like growth factor-1 (IGF-1) and Insulin-like growth factor binding 
protein-3 (IGFBP-3) standard deviation scores (SDS) in children with 
isolated growth hormone deficiency 
 
Key Figure 8 Partial correlations were used to assess the relationships of plasma IGF-1 
and IGFBP-3 SDS to the VIQ, adjusted for socioeconomic status and maternal 
educational attainment in children with IGHD. In children with IGHD, the VIQ scores 
correlated significantly with IGF-1 and IGFBP-3 SDS (r=0.7, p<0.03; r=0.7, p<0.02). 
p<0.03   
r=0.7 
p<0.02   
r=0.7 
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vi. MRI:	  Volumetric	  (freesurfer)	  results	  
The splenium of the corpus callosum, right pallidum, left thalamus and right 
hippocampus volumes were significantly smaller in children with IGHD (p<0.01, 
p<0.007, p<0.01 and p<0.01 respectively) than in ISS controls after correction for the 
FDR (Table 9).  
 
vii. 	  Correlations	  between	  volumetric	  results	  and	  IGF-­1	  and	  IGFBP-­3	  
SDS	  	  
Children with IGHD 
IGF-1 and IGFBP-3 SDS did not correlate significantly with neural volumes in children 
with IGHD.  
 
Children with ISS 
IGF-1 and IGFBP-3 SDS did not correlate significantly with neural volumes in children 
with ISS.  
 
Whole Cohort (IGHD & ISS combined) 
Corpus callosum splenium, right pallidum and right hippocampus volumes correlated 
significantly with IGF-1 (P<0.02, p<0.04 and p<0.019, respectively) and IGFBP-3 SDS 
(p<0.02, p<0.01 and p<0.016, respectively) (Figure 9). Whole group left pallidum and 
left and right thalami volumes correlated significantly with IGFBP-3 SDS (p<0.04, 
p<0.05 and p<0.002, respectively) (Figure 9). 
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Table 9  The difference in Neural volumes between children with isolated growth 
hormone deficiency and idiopathic short stature  
 GHD ISS p-value 
Neural volumes (mm3)** (SD, SE)    
Total brain volume 1.3 (2.1) 1.4 (1) 0.25 
Splenium corpus callosum  1020 (220, 43) 1300 (210, 64) 0.01 
Left caudate   3470 (780, 208) 3720 (606, 168) 0.7 
Right caudate   3493 (747, 200) 3821 (581, 161) 0.3 
Left pallidum  1600 (210, 50) 1780 (210, 56) 0.04 
Right pallidum  1480 (190, 51) 1700 (220, 58) 0.007 
Left putamen   5530 (772, 193) 5740 (575, 159) 0.54 
Right putamen   5419 (660, 176) 5723 (570, 158) 0.2 
Left amygdala 1455 (177, 30) 1519 (160, 33) 0.6 
Right amygdala 1445 (164, 37) 1546 (170, 41) 0.63 
Left hippocampus  4103 (430, 123) 4310 (260, 72) 0.12 
Right hippocampus  4083 (460, 115) 4320 (280, 115) 0.01 
Left thalamus  7040 (800, 218) 7600 (520, 167) 0.01 
Right thalamus  7070 (782, 209) 7430 (530, 170) 0.056 
Left cerebellum  71552  
(10150, 1803) 
72754 
8856, 1952) 
0.67 
Right cerebellum 72538  
(10879, 1845) 
72586  
(7779, 1998) 
0.36 
 
** Results corrected for age at scan, gender and total brain volume, p-values significant 
at p<0.01 corrected to control for the FDR 
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Figure 9  Significant associations between IGF-1 and IGFBP-3 standard deviation 
scores and neural volumes in children with isolated growth hormone 
deficiency and isolated short stature 
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112 
 
  
 
	  	  
Key Figure 9 Corpus callosum splenium, right pallidum and right hippocampus 
volumes correlated significantly with IGF-1 (P<0.02; p<0.04 and p<0.019, respectively) 
and IGFBP-3 SDS (p<0.02; p<0.01 and p<0.016, respectively) in children with IGHD. 
Whole group (IGHD and ISS) left pallidum and left and right thalami volumes 
correlated significantly with IGFBP-3 SDS (p<0.04, p<0.05 and p<0.002, respectively). 
	  
	  
	  
	  
	  
 
G 
p<0.04 H 
p<0.05
  
I 
p<0.002 
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viii. MRI:	  Voxel	  Based	  Morphometry	  results	  
No significant differences in grey or white matter volumes (including in the regions of 
the parahippocampal gyrus and prefrontal cortex) were identified between children with 
IGHD and ISS controls using VBM.  
	  
ix. MRI:	  TBSS	  Results	  
The TBSS analysis is summarized in Figure 8. Corpus callosum FA was significantly 
lower in children with IGHD (p<0.05) (Figure 10). Left cortico-spinal tract MD was 
significantly higher (p<0.03) and bilateral FA significantly lower (p<0.045, p<0.05) in 
children with IGHD (Figures 10 and 11).  
	  
x. Correlations	  between	  TBSS	  results	  and	  IGF-­1	  and	  IGFBP-­3	  SDS	  	  
IGF-1 and IGFBP-3 SDS did not correlate significantly with FA or MD in children with 
IGHD or in the group as a whole (IGHD and ISS). 
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Figure 10 The association between Isolated Growth Hormone Deficiency and 
Fractional Anisotropy (Tract Based Spatial Statistics Analysis comparing 
isolated growth hormone deficiency to idiopathic short stature controls) 
 
Key Figure 10 Mean FA skeleton overlaid on the mean FA map. Regions of the 
mean FA skeleton in green represent areas where there were no significant differences 
in FA values in the IGHD infants compared to idiopathic short stature (ISS) controls. 
Areas in red/yellow are regions where the FA was significantly lower in the IGHD 
group, and can be observed in the (a) corpus callosum, (b) right cortico-spinal tract, and 
(c) left cortico-spinal tract. Colour map indicates the degree of significance for red and 
yellow regions. 
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Figure 11 Difference in left corticospinal tract fractional anisotropy and mean 
diffusivity between children with isolated growth hormone deficiency 
and idiopathic short stature 
 
 
                                    P<0.045           p<0.03 
ISS: Idiopathic short stature, IGHD: Isolated growth hormone deficiency, FA: fractional anisotropy, 
MD: mean diffusivity. 
 
Key Figure 11 FA and MD (x10-3 mm2 s-1) of the cortico-spinal tract were 
compared using Analysis of Covariance. Age and gender are known to affect brain 
growth and myelination and were therefore used as a covariate in all analyses. Left 
cortico-spinal tract FA was significantly lower (p<0.045) and MD significantly higher 
(p<0.03) in children with IGHD 
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xi. Significant	   associations	   between	   volumetric	   MRI	   findings	   and	  
cognitive	  assessment	  scores	  
The significant associations between neural volumes and cognitive and motor skills 
assessment scores are summarized in Figure 12. The volume of the splenium of the 
corpus callosum correlated significantly with VIQ (p<0.05) and the total M-ABC2 score 
in children with IGHD (p<0.05). The volumes of the left and right pallidum, left 
thalamus and left accumbens correlated significantly with the performance on the 
balance (p<0.03, p<0.006, p<0.05 and p<0.001) and total (p<0.04, p<0.02, p<0.008 and 
p<0.02) scores of the M-ABC2 in children with IGHD. 
	  
xii. Significant	  associations	  between	  TBSS	  MRI	  findings	  and	  cognitive	  
assessment	  scores	  
The significant associations between FA and cognitive and motor skills assessment 
scores are summarized in Figure 13. In children with IGHD, left cortico-spinal tract FA 
correlated significantly with performance on the M-ABC2 aiming and catching 
component (r=0.6, p<0.04) and with Perceptual Reasoning Index (r=0.5, p<0.04) and 
right cortico-spinal tract FA correlated significantly with the aiming and catching and 
balance components of the M-ABC2 (r=0.4, p<0.02; r=0.5 p<0.04) and Processing 
Speed Index (r=0.4, p<0.02). Corpus callosum FA correlated significantly with FSIQ 
(r=0.5, p<0.05) and Processing Speed Index (r=0.8, p<0.009).  
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Figure 12 Significant associations between neural volumes, cognitive function and 
motor skills assessment scores in children with isolated growth hormone 
deficiency 
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Key Figure 12 Partial correlations were used to assess the relationships between 
scaled scores on the M-ABC2 test (mean score 10, standard deviation 3), and neural 
volumes (controlled for age at scan and gender) in children with isolated growth 
hormone deficiency (IGHD). The volume of the corpus callosum splenium correlated 
significantly with total score of the M-ABC2 test in children with IGHD (A. p<0.05). 
The volumes of the left and right pallidum, left thalamus and left accumbens correlated 
significantly with the performance on the balance (B. p<0.03, C. p<0.006, D. p<0.05 
and E. p<0.001) and total (F. p<0.04, G. p<0.02, H. p<0.008 and I. p<0.02) scores of the 
M-ABC2 in children with IGHD 
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Figure 13 The significant associations between cognitive function tests, 
corticospinal tract and corpus callosum fractional anisotropy in children 
with isolated growth hormone deficiency 
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Key Figure 13 Partial correlations were used to assess the relationships between 
scaled scores on the M-ABC2 test (mean score 10, standard deviation 3), cortico-spinal 
tract and corpus callosum FA (controlled for age at scan and gender) in IGHD. In 
children with IGHD, left cortico-spinal tract FA correlated significantly with 
performance on the aiming and catching component of the M-ABC2 (A) (p<0.04) and 
with the Perceptual Reasoning Index (B) (p<0.03) and right cortico-spinal tract FA 
correlated significantly with the Aiming and Catching (C) and Balance components of 
the M-ABC2 (D) (p<0.02, p<0.04) and the Processing Speed Index (E) (p<0.02). 
Corpus callosum FA correlated significantly with FSIQ (F) (p<0.05) and the Processing 
Speed Index (G) (p<0.009). Average MD is expressed in units of mm2 s−1 × 10−3, FA is 
a dimensionless index. 
G 
p<0.009   
r=0.8
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 D. Discussion 
We aimed to identify whether children with IGHD have abnormalities in cognitive 
function and brain structure. We found that children with IGHD have a significantly 
lower FSIQ, Verbal Comprehension Index and processing speed than controls. We also 
identified significant impairments in motor skills in children with IGHD. These have not 
previously been described and for the first time to our knowledge we have demonstrated 
structural brain differences in children with IGHD.  
 
Children with IGHD had a significantly lower FSIQ and Verbal Comprehension Index 
than children with ISS although the mean FSIQ and Verbal Comprehension Index of 
both groups lay within the average WISC-IV range (as in previous studies) (94-96;211). 
FSIQ and Verbal Comprehension Index correlated significantly with IGF-1 SDS, with 
concentrations of IGF-1 and IGFBP-3 explaining 49% of the variance in Verbal 
Comprehension Index in the IGHD group. Verbal IQ has previously been shown to 
correlate positively with IGF-1 (70), and IGFBP-3 SDS has been shown to predict 
verbal IQ independent of age, social class, maternal educational level, IGF-1 SDS, 
height or TBV (t=2.245, p=0.032) (182) in healthy children but not in children with 
IGHD.  
 
Although our cognitive findings parallel those found in normal children in whom serum 
IGF-1 concentrations correlate with verbal IQ (40;179), we did not identify the same 
pattern of cognitive deficits in children with IGHD as have previously been found in 
adults with GHD (namely deficits in attention and memory). It has previously been 
hypothesized that the cognitive abnormalities found in adults with GHD may be 
secondary to changes in the hippocampus which has a high density of IGF-1 receptors, 
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although there have been no previous imaging studies performed to further investigate 
this hypothesis.  
 
Based on the results of the cognitive and motor skills assessment scores we focused our 
volumetric MRI analysis specifically on the basal ganglia (40;41;53;57) (which play an 
important role in motor function), and the corpus callosum (53) (in which volume 
changes have previously been shown to correlate with IQ). We also extracted 
hippocampal volume as this is the brain region with the highest density of IGF-1 
receptors (214). In light of these previous studies, which have demonstrated associations 
between neural volumes and cognitive abilities, our observations of significantly smaller 
basal ganglia and corpus callosum volumes, and significantly lower corpus callosum and 
cortico-spinal tract FA in individuals with IGHD, are entirely consistent with the 
cognitive results.  
 
Interestingly, the pattern of neural volume changes we identified was not limited to areas 
with a high density of GH and IGF-1 receptor expression (prefrontal cortex, cerebellum, 
thalamus, putamen, hippocampus, caudate) (40;41;53;179), but was restricted to certain 
structures (the right hippocampus, globus pallidum, left thalamus and corpus callosum), 
suggesting that these structures may be more vulnerable to variations in the GH-IGF-1 
axis.  As not all structures with a high concentration of GH and IGF-1 receptors were 
affected it may be that the effects of variations in the GH-IGF-1 axis are being mediated 
via the activation of other biochemical processes. For example, IGF-1 has also been 
found to stimulate acetylcholine release from hippocampal neurons (53), and to impact on 
N-methyl-D-aspartate-R2a and R2b receptor density. Normal central nervous system 
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functioning is dependent on glutamate signalling through the N-methyl-D-aspartate 
receptor (212).  
 
Another possibility is that these findings are secondary to the selective neuronal 
vulnerability of these brain regions to the underlying disease process (215). In animal 
models of GHD a significant reduction in glucose metabolism throughout the brain has 
been identified, with levels of glucose utilization being significantly reduced in the 
thalamus and hippocampus (216). The thalamus and globus pallidum form an integral 
part of the motor system and therefore require high concentrations of energy in the form 
of adenosine triphosphate (ATP) to function normally. GH and IGF-1 act centrally to 
modulate neural ATP concentrations (217). ATP controls neurotransmitter synthesis, 
release and reuptake, and is also required to maintain the transmembrane ion gradients 
necessary for signal conduction (218). Regions of high energy demand such as the 
thalamus and globus pallidum are more susceptible to injury than other brain regions with 
lower energy requirements (selective neuronal vulnerability). The increased sensitivity of 
these neural regions to reduced ATP availability may lead to increased cell injury or cell-
death, which may in turn be visualised on brain MRI as reduced neural volumes in these 
areas.  
 
In children with IGHD, bilateral cortico-spinal tract FA correlated significantly with 
performance on the M-ABC2 and with processing speed index (which has many motor 
components) and corpus callosum FA correlated significantly with FSIQ.  No previous 
studies have investigated neuromotor performance in individuals with IGHD or the 
relationship between the GH-IGF-1 axis and corticospinal tract structure in humans. 
However there is evidence to suggest that IGF-1 may play a specific role in 
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corticospinal tract development with murine in vivo and in vitro studies having 
previously found that IGF-1 acts specifically to significantly enhance corticospinal 
motor neuron outgrowth, development and maturation (219). This study provides 
evidence to suggest that abnormalities in the GH-IGF-1 axis also affect corticospinal 
tract development in humans, leading to reduced FA in individuals with GHD; and that 
these changes have functional consequences, namely impairment in motor skills 
performance. 
 
In children with IGHD, corpus callosum volume and FA were also significantly reduced, 
with these structural changes correlating with reductions in cognitive and motor skills 
scores. Corpus callosum size also correlated significantly with IGF-1 and IGFBP-3 SDS 
suggesting that the differences in the size of the corpus callosum identified are not 
secondary to midline brain abnormalities which have not been identified by conventional 
MRI acquisition, but are related to the severity of the underlying GHD.  
 
E. Study limitation 
IGHD is a rare condition (1 in 4,000-1 in 10,000 live births (20)) and it is therefore 
difficult to recruit large numbers of carefully phenotyped children to studies such as this. 
The reduction in IQ that we have identified, despite our small cohort size, is likely to 
reflect the rigorous criteria we have used to define IGHD as compared with previous 
studies.  
 
We are confident that our IQ findings represent reliable differences between IGHD and 
ISS groups even though the numbers studied were small. Even when the 2 outliers were 
removed, re-analysis of the IQ data revealed a very similar pattern of findings (namely 
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significant differences in FSIQ and Verbal Comprehension Index). Seven participants in 
the IGHD group had FSIQ scores below the ‘average’ range, compared to 8/12 having 
scores in the average range and 4/12 in the ‘high’ average range in the ISS group.  
 
Children with IGHD are at risk of hypoglycaemia, which in itself can be associated with 
cognitive and neuroradiological abnormalities. It is however unlikely that the differences 
found are secondary to hypoglycaemia (no children had a history, were symptomatic or 
displayed evidence of hypoglycaemia), although premature infants with recurrent 
hypoglycaemia have a cognitive profile that is reminiscent of that of children with IGHD, 
with a reduced IQ and motor scores. In addition, studies in patients with diabetes mellitus 
with recurrent hypoglycaemia (and hyperglycemia) have identified different MRI 
findings to those that we have demonstrated in children with IGHD, with reduced FA 
present only in the posterior corona radiata and optic radiations. The later age at 
presentation in these children also makes it unlikely that they were at risk of neonatal 
hypoglycaemia. 
 
F. Summary 
Our findings provide evidence that the GH-IGF-1 axis plays a role in brain and 
cognitive development. Currently the main aims of GH treatment are to optimise final 
height, bone mass and body composition. Treatment is therefore often not started in 
infancy when GH is not the main driver of growth. Early intervention studies are now 
required to determine whether GH treatment can rectify some of these abnormalities in 
brain and cognitive functioning as this would have major implications for clinical 
practice. 
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4. ASSESSMENT OF THE PREVALENCE AND NEURAL 
CORRELATES OF BEHAVIOURAL PROBLEMS IN 
CHILDREN WITH ISOLATED OPTIC NERVE 
HYPOPLASIA  
 
A.  Introduction 
Children and adolescents with severe VI, secondary to varying aetiologies, have a 
significantly increased prevalence of behavioural and social communication problems 
(134-136). The neural basis for these behavioural problems is unknown. 
Underdevelopment of the optic nerves early on in embryogenesis leads to ONH, one of 
the leading causes of VI in the developed world, with a prevalence of 10.9/100,000 
(127;129). A recent study in children with severe/profound VI and ONH, reported that 
26% had clinically significant behavioural difficulties (social, communicative or 
repetitive behaviours) (133). Interestingly children with severe profound VI and isolated 
ONH are diagnosed with behavioural and developmental abnormalities at a similar rate 
to children with SOD, who, in addition to ONH, have other midline brain and/or 
pituitary hormone abnormalities (133). However, the prevalence of behavioural 
difficulties in children with mild to moderate or no VI and ONH has not previously 
been recorded in the literature. Additionally, to date conventional methods of 
neuroimaging have been unable to detect neural abnormalities, other than ONH, in 
individuals with isolated ONH. 
 
DTI is a non-invasive imaging technique, which can provide quantitative indices of 
brain microstructure and enables the visualization of white matter microstructure 
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(103;109). Since the basic principles of DTI were established in the mid-1990s many 
clinical investigations have found that abnormalities in the white matter tracts of the 
brain can be identified in a wide range of pathological conditions (e.g. multiple 
sclerosis, Alzheimers disease and depression) (114;116). They have also enabled the 
identification of defects in conditions not classically associated with abnormalities on 
conventional neuroimaging, such as ASD (118;119;148). Previous neuroimaging 
studies in children with ONH have been limited to those using qualitative radiological 
assessments of conventional MR images, and to two small studies (one and two 
individuals) using DTI to better define the phenotype in ONH and SOD. Both have been 
in small numbers of subjects with severe VI (one and two individuals) and have focused 
solely on the optic tracts (143;144). There is a wide literature debating the reasons as to 
why children with VI, secondary to a wide range of aetiologies, are at increased risk of 
behavioural and social communication difficulties.  However, thus far, the underlying 
reason for this increased prevalence remains unknown (145). It has, however, 
previously been suggested that reductions in exposure to visual social cues and visually 
guided experiences in children with VI may predispose them to developing social 
development abnormalities (146). Whilst the increased prevalence of behavioural 
deficits found in children with ONH and severe VI may be related to their underlying 
visual impairment and reduced visual experience, we hypothesized that, on the basis of 
the emerging literature regarding neuroimaging and social communication disorders 
such as ASD (119), the underdevelopment of white matter tracts may also contribute to 
the behavioural abnormalities found in this cohort.  
 
Previous studies investigating the prevalence of behavioural difficulties in children with 
ONH have all been in children with severe VI (133;134). Children with ONH and 
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severe/profound VI frequently have co-morbidities, which may potentially confound 
behavioural and DTI assessments including significant learning difficulties, attention 
deficit disorder, seizures, and cerebral palsy (132;147-150). We therefore firstly aimed 
to assess whether children with isolated ONH with vision ranging from normal range 
acuity to mild to moderate VI and no developmental delay have an increased prevalence 
of behavioural problems compared to a control group of typically developing children 
without ONH. Secondly we aimed to perform detailed DTI studies in this cohort to 
identify whether specific white matter abnormalities, not been previously identified 
using conventional MRI, are present that may provide neural correlates for any 
behavioural abnormalities identified. Volumetric datasets were also acquired and 
analysed to assess whether children with isolated ONH have subtle structural brain 
abnormalities not easily identifiable on conventional T1-weighted MRI brain datasets. 
 
As children with SOD frequently have reduced white matter bulk and midline brain 
abnormalities including hypoplasia of the corpus callosum which may confound the 
DTI results, we initially performed our study in a cohort of children with isolated ONH. 
However, as a follow up to this initial study we also acquired DTI sequences in children 
with SOD to evaluate whether white matter abnormalities identified in children with 
isolated ONH were more widespread when children with SOD were also included in the 
analysis. The children with SOD included in this analysis were restricted to those 
without brain MRI abnormalities (other than those in the hypothalamo-pituitary axis) 
visible on standard MRI brain. 
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B.  Methods 
Children aged 1-11 years, diagnosed with isolated ONH or SOD by a paediatric 
ophthalmologist, paediatric neuroradiologist and paediatric endocrinologist, were 
recruited prospectively. A diagnosis of ONH and laterality of disease were determined 
by one experienced paediatric neuroradiologist (Dr Kling Chong) blinded to the clinical 
data who reviewed all images. The diagnosis of ONH was confirmed by ocular fundus 
photography performed by a paediatric opthalmologist. SOD was diagnosed when two 
or more features of the classical triad of (i) ONH, (ii) pituitary hormone abnormalities 
and (iii) midline brain defects were present.  
 
We investigated children with isolated ONH, normal range visual acuity to 
mild/moderate reduction in visual acuity (mild/moderate VI) and normal cognition to 
remove the confounding effects of severe or profound VI and learning difficulties 
(isolated ONH study). We recruited children with SOD with only abnormalities of the 
hypothalamo-pitutiary axis and optic nerves visible on brain MRI (i.e. no midline brain 
abnormalities) and without TSH deficiency (known to affect brain myelination 
(220;221)) (SOD study). A control group of typically developing children without ONH 
aged 1-11years, matched for age and gender, were recruited concurrently. The controls 
were all recruited from the endocrine clinic where they presented with short stature. We 
chose children with short stature as our controls as although they have no clinically 
significant medical condition their parents had been concerned enough regarding their 
health to seek specialist opinion at a tertiary referral hospital. The CBCL is a parental 
questionnaire, which may be biased for parents of children with perceived (e.g. short 
stature) or actual (e.g. VI) medical conditions. We therefore used children presenting to 
the tertiary referral hospital rather than sibling controls to control for the effect of this. 
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Participants with isolated ONH and controls were all asked to complete the CBCL and 
to undergo brain MRI and cognitive assessment. All children in the SOD group 
underwent brain MRI and a detailed developmental and behavioural assessment, which 
was performed by a clinical psychologist and paediatrician with a special interest in 
children with VI. CBCL data were not collected in the SOD group. Standardised 
measures of social communication and autism are not available for children with VI; the 
diagnosis of ASD was therefore made on the basis of clinical assessment of behaviour 
by clinicians during standardised developmental assessments (133). Deficits in social 
and communication skills and the presence of repetitive or restricted behaviours were 
then assessed according to ICD-10 criteria for ASD (222). All children with SOD and 
ONH were screened for mutations in HESX-1 and some with SOD were also screened 
for mutations in SOX-2 and SOX-3 depending on their phenotype (Table 4). 
 
iii. Isolated optic nerve hypoplasia study 
Volumetric analysis of the anatomical scans from the 3-D datasets was performed using 
the FreeSurfer technique of Fischl et al (223). This involves whole brain segmentation 
and automated labelling of the neuroanatomical structures based on probabilistic 
information estimated from a manually labelled atlas (224). Total brain, corpus 
callosum and cuneus (occipital lobe visual processing centre) volumes were extracted 
from this data. The difference in total brain volume between groups was compared 
using ANCOVA, controlling for age at scan, and gender. For the corpus callosum total 
brain volume was used as an additional covariate. 
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Diffusion-weighted images were initially processed using FSL software 
(http://www.fmrib.ox.ac.uk/fsl). The FA images were analyzed using TBSS (121;187). 
All analyses were corrected for age and gender. FA was found to be significantly 
reduced in the optic radiations, corpus callosum and ventral cingulum on the TBSS 
analysis (Figure 14). In order to assess whether there was any association between FA 
for these structures and behavioural scores, values for the ventral cingulum, corpus 
callosum and optic radiation FA were extracted from the TBSS analysis by masking the 
mean skeleton with the appropriate structure label from the Johns Hopkins University 
white-matter tractography atlas (188). 
 
Baseline characteristics including age and cognitive level were compared using the 
independent Student’s t test. Gender of the two groups (isolated ONH and control) was 
compared using the chi-squared test of equal proportions. Behavioural assessment 
scores were compared using the independent Student’s t test. Partial correlations were 
used to assess the relationship between the ventral cingulum, corpus callosum and optic 
radiation FA and CBCL scores (controlled for age at scan and gender).  
 
iv. Septo-optic dysplasia Study 
Children with SOD but without visible white matter abnormalities on conventional MRI 
brain (7 individuals) were added to the ONH cohort, and the TBSS analysis described 
above was rerun. Diffusion-weighted images were initially processed using FSL 
software (http://www.fmrib.ox.ac.uk/fsl). The FA images were analyzed using TBSS 
(121;187). All analyses were corrected for age and gender.  
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C.  Results 
i. Subject characteristics 
Isolated optic nerve hypoplasia study 
All children (mean age 5.9 years, 81% males) with ONH and 24 controls (mean age 6.4 
years, 68% males) were recruited. Of the eleven children with ONH, seven had bilateral 
ONH and four had unilateral ONH. Eleven children with ONH completed the 
developmental and behavioural assessment battery. Brain MRI was otherwise normal 
(including the hypothalamo-pituitary axis) in all subjects. Significant motion artefact 
was not noted in any study participants. Visual acuity in the better eye was between 6/6 
and 6/24 Snellen (6/6 in 4 children, 6/9 in 2 children, 6/15 in 2 children, 6/19 in 2 
children and 6/24 in 1 child), indicating that the vision of the ONH children was within 
the functionally normal to mild/moderate VI range. IGF-1 and IGFBP-3 concentrations, 
thyroid function tests and glucose and cortisol profiles were normal in all children. No 
mutations in any of the genes screened were identified. 
 
Twenty-four controls were recruited, of whom 15 completed the developmental 
assessment and 11 completed the behavioural questionnaires. The time required to 
undertake the developmental assessment precluded some controls from consenting to 
undergo this component of the study. Subject characteristics are summarised in Table 
10.  
 
There were no significant differences between the age, cognitive level and gender of 
subjects and controls (Tables 10 and 11). All children were right-handed, had no 
abnormal neurological findings, were in the average range for cognition and were in 
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mainstream schooling. There were no significant differences in age and gender between 
those children who underwent behavioural assessment and those who did not consent to 
behavioural assessment (Table 10). No significant group differences in full scale IQ, 
verbal or non-verbal indices were observed (Table 11). All study recruits underwent 
brain MRI and data quality was deemed to be adequate in all subjects (visual inspection 
by an experienced observer (Dr Chris Clark)). 
 
Septo-optic dysplasia study 
Seven children with SOD (mean age 5.93 years, 2 males) were recruited. Of the seven 
children five had bilateral ONH and 2 had unilateral ONH. Brain MRI was otherwise 
normal (excluding the hypothalamo-pituitary axis) in all subjects; findings summarized 
in Table 12. Significant motion artefact was not noted in any study participants. Six of 
the children with SOD had severe or profound VI, with only one having mild VI. All 
children with SOD were GHD, two children with SOD also had a diagnosis of ACTH 
deficiency. Three children in the SOD group had a diagnosis of ASD. There was a wide 
range in cognitive abilities within this group; detailed subject characteristics are 
summarised in Table 12. 
134 
 
Table 10  Number of participants, age and gender for the children with isolated 
optic nerve hypoplasia and controls (whole group) and for the group with 
only behavioural and MRI data available.  Significance levels from 
statistical tests comparing the two sub-groups are also presented  
 
Variable Total group 1  P values  Behavioural group 2 P values  
Group ONH Control  ONH Control  
Number 11 24  11 11  
Age (SD) 5.9 (3.3) 6.4 (3) 0.56 5.9 (3.3) 6.8 (3.1) 0.58 
Male (%) 9 (81) 17 (68) 0.78 9 (81) 10 (91) 0.91 
 
1 MRI only 2 MRI, developmental and behavioural data available. 
 
  
135 
 
Table 11 Cognitive and Child Behaviour Checklist standard score means (SD) for 
the optic nerve hypoplasia and control participants (significant values 
p<0.05 in bold) 
 ONH* Control* p value 
Full Scale IQ                                             101.1 (22.5) 102.9 (7.1) 0.8 
Verbal Comprehension/Verbal IQ                                                     98.4 (22.6) 106.9 (7.4) 0.3 
Perceptual Reasoning/Performance IQ                                               96.5 (19.5) 105.4 (9.9) 0.18 
CBCL Anxious/Depressed  61.3 (11.6) 50.8 (2.4) 0.014 
CBCL Withdrawn  63.5 (10.3) 52.5 (6.2) 0.006 
CBCL Somatic Complaints  61 (8.2) 53.6 (10.7) 0.086 
CBCL Social Problems  63.5 (10.7) 53.4 (10.1) 0.053 
CBCL Thought Problems  65.8 (8.8) 51.5 (2.3) 0.002 
CBCL Attention  68.3 (14.6) 53.1 (3.7) 0.006 
CBCL Rule Breaking  58.6 (11.9) 52.7 (4.6) 0.151 
CBCL Aggressive  61.8 (11.8) 51.3 (2.6) 0.015 
CBCL Internalizing  63 (10.7) 51.7 (7.5) 0.01 
CBCL Externalizing  60.6 (10.1) 51.3 (4.8) 0.015 
CBCL Total Score  63.6 (11.4) 51.3 (6.4) 0.006 
 
*11 children with ONH underwent behavioral and IQ assessment; *15 controls 
underwent IQ assessment, 11 of the controls who underwent IQ assessment also 
completed the behavioral questionnaires. 
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Table 12 Characteristics of study subjects with septo-optic dysplasia 
 1     2     3    4    5    6 7 
Age (years) 9.94 4.93 13.73 9.46 3.2 1.67 1.8 
Gender F F M F F F M 
Degree Visual 
Impairment 
(size of object 
visualised at 
30cm) 
Severe 
(2.5mm) 
Mild Severe 
(5mm) 
Profound 
(light 
awareness) 
Severe 
(2.5mm) 
Severe 
(2.5mm) 
Severe 
(5mm) 
Hormonal 
Abnormalities 
GHD GHD GHD, 
ACTHD 
GHD GHD, 
ACTHD 
GHD GHD 
MRI findings Small AP 
Normal 
PP  
B/L 
ONH  
Small AP 
Normal 
PP  
U/L 
ONH  
Small AP 
Normal 
PP  
Absent 
SP 
B/L 
ONH 
Small AP  
Normal PP 
B/L ONH                                                                                                                                                                                                                                                                                                                                                                                                               
Immature 
myelinatio
n 
Small AP 
Normal 
PP B/L
ONH  
Small AP 
Normal 
PP  
B/L 
ONH 
Small AP  
Normal 
PP  
U/L 
ONH 
Cognitive 
Assessment 
(RZS, VI 
norms (225)) 
Severe 
delay 
ASD 
Age 
Appropri
ate 
Mixed 
profile: 
delayed 
non-
verbal 
cognition 
ASD 
Severe 
delay 
Severe 
delay 
ASD 
Age 
Appropri
ate 
Mixed 
profile: 
delayed 
non-
verbal 
cognition 
 
AP: anterior pituitary gland; PP: posterior pituitary gland; SP: septum pellucidum; 
ONH: optic nerve hypoplasia; CC corpus callosum, GHD: growth hormone deficiency, 
TSHD: thyroid stimulating hormone deficiency; ACTHD: ACTH deficiency; DI: 
diabetes insipidus; B/L: bilateral; U/L: unilateral.  
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ii. Cognitive results 
No significant group differences in FSIQ (p=0.8), verbal (p=0.3) or non-verbal (p=0.18) 
indices were observed (Table 11) (ONH versus controls).  
 
iii. Behavioural assessment 
Isolated optic nerve hypoplasia Group 
Independent samples t tests revealed significantly more behaviour problems (indicated 
by higher CBCL scores) in the ONH compared to the control group (Total scores 
p<0.006, Table 11). This pattern was found across most of the CBCL’s component 
subscales. Four out of the 11 children who underwent behavioural assessment (36%) in 
the ONH group had scores in the ‘clinical’ range (indicating more problems than were 
reported for 97% of the normative range), 1 of the 4 had unilateral ONH. One child, 
with bilateral ONH, had a score within the ‘borderline’ range, with the remainder 
reported as within the ‘normal’ range. One child in the control group had a score in the 
borderline range with the remainder of the control participants having scores within the 
‘normal’ range.  
 
Septo-optic dysplasia Group 
Three children with SOD were diagnosed with ASD. 
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iv. Neuroimaging findings 
Isolated optic nerve hypoplasia group 
The volumetric analysis revealed no significant differences in total brain or corpus 
callosum volume between ONH subjects and controls (Table 13). 
FA was significantly reduced in the optic radiations (bilaterally), corpus callosum and 
ventral cingulum (bilaterally) in children with ONH when compared to control subjects 
(Figure 14) (TBSS analysis). There were no regions in which FA was found to be lower 
in the control subjects than in the children with ONH. 
 
Optic nerve hypoplasia and septo-optic dysplasia groups 
In the combined ONH and SOD groups FA was significantly reduced in the optic 
radiations (bilaterally), corpus callosum, prefrontal cortex and ventral cingulum 
(bilaterally) (Figure 15). There were no regions in which FA was found to be lower in 
the control subjects than in the children with SOD and ONH. 
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v. Correlations between imaging measures and behavioural scores in 
children with isolated optic nerve hypoplasia and controls 
Right ventral cingulum FA correlated significantly with total CBCL score (r=-0.52, 
p<0.02) and the externalising score on the CBCL (r=-0.46, p<0.049) (Figure 16), but 
not the internalising score on the CBCL (r=-0.45, p=0.056). Correlations between left 
ventral cingulum FA, total CBCL score and externalising and internalising scores on the 
CBCL did not reach statistical significance. There were no significant correlations 
between corpus callosum or optic radiation FA and CBCL scores. 
 
 
 
Table 13   The differences in neural volumes between children with isolated optic 
nerve hypoplasia and controls 
 
Neural volumes (mm3)**  ONH Controls p-value 
Total brain volume 1506607 1560102 0.78 
Splenium corpus callosum  647 786 0.12 
Corpus callosum Total   2561 2905 0.45 
Left Cuneus   3819 3696 0.93 
Right Cuneus  4347 3916 0.2 
 
** Results corrected for age at scan, gender and total brain volume 
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Figure 14  Difference in fractional anisotropy between children with isolated optic 
nerve hypoplasia and normal controls (Tract Based Spatial Statistics 
analysis) 
 
 
Key Figure 14 Mean FA skeleton overlaid on the mean FA map. Regions of the 
mean FA skeleton in green represent areas where there were no significant differences 
in FA values in the ONH children compared to controls. Areas in red/yellow are regions 
where the FA was significantly lower in the ONH group, and can be observed 
bilaterally in the (A) optic radiation, (B) corpus callosum, and (C) ventral cingulum. 
Colour map indicates the degree of significance for red and yellow regions. 
141 
 
Figure 15  Difference in fractional anisotropy between children with isolated optic 
nerve hypoplasia and septo-optic dysplasia and normal controls (Tract 
Based Spatial Statistics analysis) 
 
Key Figure 14  Mean FA skeleton overlaid on the mean FA map. Regions of the 
mean FA skeleton in green represent areas where there were no significant differences 
in FA values in the ONH+SOD children compared to controls. Areas in red/yellow are 
regions where the FA was significantly lower in the ONH/SOD group, and can be 
observed bilaterally in the (A) optic radiation, (B) corpus callosum, (C) ventral 
cingulum and (D) prefrontal cortex. Colour map indicates the degree of significance for 
red and yellow regions. 
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Figure 16 Correlations between child behaviour checklist performance and right 
ventral cingulum fractional anisotropy 
            
             
  
A. 
r=-0.52 
p<0.02 
B. 
r=-0.46 
p<0.049 
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Key Figure 16 Ventral cingulum fractional anisotropy (FA) was extracted from 
the tract based spatial statistics analysis. FA was significantly lower in the ventral 
cingulum in children with ONH as compared to controls. Partial correlations were used 
to assess the relationships between scores on the child behavioural checklist (CBCL) 
and right ventral cingulum FA (controlled for age at scan and gender). Higher scores on 
the CBCL indicate more behavioural problems. FA correlated significantly with the 
total (A. r=-0.52, p<0.02) and externalising score on the CBCL (B. r=-0.46, p<0.049). 
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D. Discussion 
Children with isolated ONH, normal development and mild to moderate or no VI 
have an increased prevalence of clinically significant behavioural problems. They 
also show evidence of reduced white matter integrity in the corpus callosum and 
ventral cingulum, the anterior optic pathway and optic radiations bilaterally, regions 
of the brain that are implicated in behavioural and emotional regulation and vision . 
The identified abnormalities in white matter fibre density in the ventral cingulum 
correlate significantly with behavioural scores. When children with ONH and SOD 
were grouped together they were found to have reduced FA in the corpus callosum, 
ventral cingulum and prefrontal cortex; together these structures form part of the 
social brain circuitry (148). The association between white matter abnormalities in 
the ventral cingulum and corpus callosum have previously been identified in adults 
with obsessive compulsive disorder and schizophrenia (226-228), which suggests 
that the behavioural difficulties experienced by children with ONH may not solely 
be due to reduced visual input, but may be related to other underlying 
neuroanatomical abnormalities which cannot be detected using conventional brain 
MRI.   
 
iv. Cognition 
Cognitive performance in children with isolated ONH was not significantly different 
to controls. This finding differs from previous studies that have documented 
developmental delay in children with ONH (147-149). This discrepancy is probably 
due to the associated pituitary hormone insufficiencies, midline brain abnormalities 
and more severe VI present in these cohorts. In support of this, the children with 
SOD included in the study had a high prevalence of moderate/severe developmental 
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delay. 
 
v. Behaviour 
We identified a similar prevalence of clinically significant behavioural difficulties 
(36%) in children with isolated ONH and mild to moderate or no VI to that reported 
in populations with severe VI (47 and 49%) (135;136;149). The CBCL profile 
showed increased scores on all subscales (except rule-breaking and somatic 
complaints) for the ONH group relative to the control group, suggesting that 
difficulties exist across most behavioural domains assessed by the CBCL. More 
specifically, the ONH group presented with a mix of internalizing and externalizing 
problems, showing significant elevations in attention problems, aggressive 
behaviour, and the anxious-depressed, withdrawn and thought problem scales of the 
CBCL (Table 11). Whilst we have not assessed the wider clinical significance of 
these behavioural difficulties, previous data demonstrate that children with a profile 
characterized by co-existing elevations in attention problems, aggressive behaviour, 
and anxious-depressed scales of the CBCL have increased rates of psychiatric 
disorders including paediatric bipolar disorder, suicide and a high rate of adult 
psychopathology (229). Our current findings highlight the importance of being alert 
to potential behaviour difficulties even in children with mild/moderate or no VI. 
Although it is not currently part of routine clinical care to perform behavioural 
assessment in children with ONH and mild to moderate or no VI, the incidence of 
clinically significant behavioural difficulties in our ONH sample (36%) is 
comparable to that reported previously in populations of children with severe VI (47 
and 49%) (135;136) in whom behavioural assessment is advocated. 
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vi. Neuroimaging 
Isolated optic nerve hypoplasia group 
In addition to the well-established abnormalities of the optic nerve, we have 
demonstrated that children with ONH also show evidence of reduced white matter 
integrity in the ventral cingulum bilaterally, the corpus callosum and the optic 
radiations bilaterally. We were unable to demonstrate concurrent reductions in grey 
matter volumes in the corpus callosum in children with ONH. 
  
The reduced white matter integrity (FA) identified in the ventral cingulum and 
corpus callosum is likely to reflect changes in underlying brain structure. Although 
FA changes can be attributed to a number of microstructural changes, including 
changes in axonal density, axon diameter distributions, myelin density, intra-voxel 
axon dispersion, unmasking due to selective tract degeneration, greater tract 
maturation in one tract compared to another in a crossing fibre situation in white 
matter, changes in cell membrane permeability, reduction in extra-cellular tortuosity 
as a result of increased water content in the extra-cellular space as might occur in a 
diffuse oedematous process and replacement gliosis, we expect that the axon density 
and myelin content explanation is the most plausible in ONH (112). Focal 
reductions in FA have also been described in other paediatric conditions in which 
there is an increased prevalence of behavioural problems. For example, DTI studies 
in children with autistism spectrum disorder report reduced FA in the corpus 
callosum, occipitotemporal tracts, and white matter structures adjacent to the 
ventromedial prefrontal cortex, anterior cingulate gyrus, fusiform gyrus, superior 
temporal gyrus, and amygdala (230;231), and studies in children born preterm have 
identified reduced FA in the corpus callosum, external capsule and the posterior 
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aspect of the posterior limb of the internal capsule (232). However, in these other 
disorders, the specific pattern of abnormalities we report has not been identified. 
 
The DTI findings we describe are novel in the context of ONH but perhaps 
unsurprising when one examines the wider literature pertaining to brain 
development. Murine studies have shown that axons from the cingulate cortex cross 
the midline prior to those of the corpus callosum, acting as pioneering axons for the 
corpus callosum (233;234). Nakata et al performed brain DTI in 12 individuals with 
agenesis of the corpus callosum to explore the hypothesis that callosal dysgenesis 
may represent the most obvious anatomical manifestation of a more widespread 
white matter developmental disorder. They identified concomitant abnormalities in 
the volume and structure of the ventral cingulum bundle in individuals with agenesis 
of the corpus callosum, concluding that this provides further evidence for a 
relationship between the embryonic formation of the ventral cingulum and corpus 
callosum (148). Corpus callosum abnormalities are frequently found in association 
with ONH in SOD, an early developmental abnormality of forebrain development 
occurring at 4-6 weeks gestation (130). The presence of reduced FA in the corpus 
callosum in the current study suggests that ONH may represent a milder end of the 
SOD spectrum.  
 
Reduced ventral cingulum FA was significantly associated with CBCL scores. The 
cingulum provides important white matter connections within the corticolimbic 
neural system which is involved in regulating emotion (235). Individuals with 
elevated CBCL scores in childhood are at increased risk of fulfilling criteria for 
Diagnostic and Statistical Manual of Mental Disorders fourth revised edition [DSM-
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IV] diagnoses in adulthood. In adults with obsessive-compulsive disorder and 
schizophrenia (both DSM-IV diagnoses) white matter abnormalities in the cingulum 
bundle and corpus callosum have been identified (226-228). The finding of reduced 
cingulum FA in association with increased CBCL scores therefore supports our 
initial hypothesis that white matter abnormalities not identifiable using conventional 
neuroimaging methods may help to explain the increased prevalence of behavioural 
problems found in children with ONH.  
 
In contrast with the two previous published studies using DTI to better understand 
SOD (143;144), both of which were performed in children classified as blind, we 
investigated a cohort of children with mild-moderate or no VI. Both previous studies 
have been in small numbers of subjects (one and two individuals respectively) and 
focused their analysis on the optic radiations. These studies demonstrated that 
children with SOD have both pre- and post-chiasmatic diffusion abnormalities in the 
visual pathway. Previous investigations concluded that the presence of reduced FA 
in the optic radiations demonstrated the need for an afferent input from the retina to 
the lateral geniculate nucleus to stimulate normal optic radiation development 
(143;144). It is therefore noteworthy that in our cohort of children with ONH and 
functionally normal vision to mild/moderate VI, we have also identified significant 
reductions in FA in the optic radiations. This suggests that either there is some other 
pathophysiological process underlying the reduced structural integrity of their optic 
radiations, or that even small reductions in visual stimulation can affect the 
development of the optic radiations. A genetic aetiology for SOD is currently only 
identified in <1% cases, and it has therefore been suggested that environmental 
factors including drugs, alcohol and anterior cerebral arterial supply may also be 
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impacting on normal forebrain development in SOD (<1%) (130). However, neither 
the genetic aetiologies nor the environmental factors hypothesized to impact on 
forebrain development would be expected to affect the development of the posterior 
optic radiations.  
 
Combined optic nerve hypoplasia and septo-optic dysplasia groups 
When children with SOD and isolated ONH were combined in the TBSS analysis 
FA was also significantly reduced in the prefrontal cortex, in addition to the 
previously identified structures (corpus callosum, optic radiations and ventral 
cingulum). This finding may reflect the increased power of the larger group studied. 
It is an interesting finding in view of the known association between the 
development of the prefrontal cortex and social and behavioural problems. The 
frontal lobe forms a key part of the neural network which makes up the ‘social 
brain’, together with the amygdala, superior temporal and cingulate gyri (58). 
Multiple previous neuro-imaging studies performed in individuals with autism, a 
condition defined by the social communication difficulties that individual’s 
experience (118), have identified structural and functional abnormalities in the 
prefrontal cortex. Structural studies describe increases in white matter volume in the 
brains of individuals with ASD (236;237), with functional studies showing reduced 
activation in the prefrontal and anterior cingulate cortex (238). DTI studies report 
reduced FA in the fusiform gyrus, superior temporal gyrus, amygdala, prefrontal 
cortex, anterior cingulate gyrus and corpus callosum (230;231). Serotonin 
production has also been found to be abnormal in the frontal lobes of individuals 
with ASD (239;240), thought possibly to reflect abnormal underlying connectivity 
of the frontal lobe. Previous studies in children with SOD have also identified an 
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increased prevalence of behavioural difficulties including ASD (133). Although the 
numbers of children with SOD included in this study were small, three of the 
children we included in our cohort had a diagnosis of ASD. Our data suggests that 
children with SOD may have abnormalities in the development of their social brain, 
namely their prefrontal cortex, corpus callosum and ventral cingulum and this may 
to some extent explain the increased prevalence of behavioural and social 
communication difficulties found within this group of children (58). This work will 
need to be repeated in larger cohorts of children with SOD and ASD to confirm 
these preliminary findings. 
 
E. Study limitations 
Although the present study was limited by small sample size, the numbers of 
children included in the study are significantly larger than in previous studies in 
children with ONH and SOD and the results are statistically significant. Ideally, the 
age-range of patients studied would have been narrower, as we know myelination 
varies significantly during childhood (241); however the subject and control groups 
were well-matched in terms of age. We recruited a group of children with ONH and 
mild-moderate or no VI and therefore were unable to assess whether the neuro-
anatomical, cognitive and behavioural abnormalities identified also relate to the 
degree of VI. The number of children with SOD and significant VI recruited were 
not large enough to further examine this question. To further investigate the 
relationship between developmental visual history and early and later levels of 
available functional vision and the development of the posterior optic radiations, 
this study should be repeated in children with a range of visual acuities, in the 
context of ONH (separating unilateral and bilateral ONH) and in VI secondary to 
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other pathologies (e.g. retinal dystrophy). To clarify whether the abnormal 
myelination/axon density in the posterior optic radiations is due to an antenatal 
insult or due to postnatal reductions in visual stimulation, the MRI component of 
this study would ideally be repeated in children at, or shortly after, birth.  
 
Children with SOD and severe-profound VI frequently have co-morbidities which 
may potentially confound DTI assessments. Although we selected children with 
SOD and no other midline brain abnormalities, no cerebral palsy or history of 
seizures and with limited endocrine hormone abnormalities, it is not ideal to have 
combined the cohort of children with SOD with those with isolated ONH. Future 
studies would ideally be able to recruit larger numbers of children in both cohorts to 
assess whether the abnormalities of the prefrontal cortex identified in the larger 
group of combined children reflects the greater power of the larger group or 
something specific about the children with SOD. 
 
Ideally we would have performed volumetric analysis of the ventral cingulum to 
assess whether DTI-based measures of white matter alone relate to behavioural 
problems in children with ONH or whether gray or white matter changes also 
impact on the behavioural pattern seen. Unfortunately, at present obtaining 
estimates of the volumes of white matter tracts remains a problem without a reliable 
solution, particularly in children. While a rough estimate of volume can in principle 
be obtained using diffusion tractography, partial volume effects in this narrow tract 
will be significant, and we therefore would not expect such a measure to be 
dependable enough to draw reliable conclusions from it. 
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F. Summary 
To our knowledge, this is the first study to present converging information from 
neuroimaging (DTI) and behavioural measures in children with ONH and SOD. 
Although the sample size is relatively small and has a wide age range, the sample is 
more homogeneous than previous studies performed in children with ONH. We 
have demonstrated that children with ONH, normal intelligence and mild/moderate 
or no VI have an increased prevalence of clinically significant behavioural 
problems. Our findings suggest that children with ONH require behavioural 
assessment to exclude the presence of behavioural problems. The behavioural 
difficulties are found in association with reduced structural integrity of the ventral 
cingulum, suggesting that they are of neuro-behavioural origin. The finding of 
reduced FA in the corpus callosum suggests that ONH may be part of the spectrum 
of SOD, a condition frequently associated with corpus callosum hypoplasia (130). 
These children with mild/moderate or no VI and isolated ONH also have 
abnormalities in their optic radiations. This raises the question of whether 
abnormalities in the optic radiation in children with ONH are solely secondary to 
reduced visual stimulation. Further research within this population, controlling for 
visual levels, and presence of uni- or bilateral ONH, is required to explore the 
possible mechanisms affecting neural visual development.  
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5.  EXPLORING THE SLEEP PHENOTYPE OF CHILDREN WITH 
SEPTO-OPTIC DYSPLASIA 
 
A.  Introduction 
Thirty-two percent of children with SOD have disordered sleep patterns; these include 
free-running rest-activity cycles, and fragmented and arrhythmic sleep (157). Abnormal 
sleep patterns impact significantly both on the child’s well being and on the families’ 
overall lifestyle and ability to cope with their child’s complex condition, and can 
adversely impact on children’s cognitive development (152;158). A trial of melatonin 
treatment in children with SOD and sleep disruption is accepted clinical practice in 
many centres. However, no objective measurement of sleep/activity patterns with 24 
hour melatonin profiles have been published for these individuals with the 
pathophysiological basis underlying sleep disorders in SOD remaining largely 
unknown. 
 
A recent review on the use of melatonin in the treatment of sleep disorders stated that, 
‘the use of melatonin is frequently based on anecdotal evidence or small clinical trials’ 
(162). There are possible side-effects associated with melatonin use with one study 
suggesting that melatonin may have pro-convulsant effects (163) and others suggesting 
that it impacts on the hypothalamo-pituitary axis, potentially affecting the patterns of 
oxytocin, ACTH, vasopressin and GH release, although it remains difficult to predict 
whether these endocrine effects will have long-term clinical outcomes (152;164;165).  
  
154 
 
We studied six children with rest-activity disturbances and SOD. All wore an 
Actiwatch-mini (a non-invasive method of detecting and recording movement intensity) 
for two weeks and were admitted to hospital for a 24-hour period during which hourly 
measurements of serum melatonin were taken. Sleep data were analyzed in conjunction 
with a detailed sleep diary. All children also underwent cognitive assessment, MRI 
brain scans and detailed endocrinological assessment.  
 
In view of the uncertainty surrounding the etiology of the sleep abnormalities found in 
individuals with SOD, and consequently the optimum management of this problem, we 
aimed to establish whether children with SOD who experience sleep pattern disorders 
also have defective melatonin production. 
 
B.  Methods 
Children aged 1-7 years with a diagnosis of SOD who reported significant rest-activity 
disturbances, but were naïve to melatonin treatment, were recruited prospectively. All 
were on adequate hormonal replacement at the time of recruitment to the study. All 
children were evaluated by an endocrinologist and an ophthalmologist, underwent brain 
MRI and completed a detailed sleep diary and 2 weeks actigraphy. A control group of 
children matched for age and gender; (4 aged 1-2 years (mean 1.4), and 6 aged 6-7 years 
(mean 6.8)); were recruited; all completed 2 weeks actigraphy and a detailed sleep 
diary. Participants were asked to complete the CBCL and to undergo brain MRI and 
cognitive assessment. 
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Actiwatch data were analyzed in conjunction with the sleep diary. Sleep wake patterns 
were ascertained and actual time asleep and sleep efficiency calculated using Actiware 
software (Minimitter). Sleep efficiency was defined as the ratio of total sleep time to 
sleep period (191). Actogram analysis was used to define the sleep pattern as normal 
(tau 24hrs), free running (tau>24hrs), fragmented (sleep efficiency <85%), or 
arrhythmic (no discernable rhythmicity) (157). When these definitions are applied to 
healthy control populations very few individuals are identified with free running, 
fragmented or arrhythmic sleep patterns (157;190). Sleep efficiency in children with 
SOD was compared to that of the healthy controls using the independent Student’s t 
test. 
 
Children with SOD were admitted to hospital on the morning of the melatonin profile. 
Plasma samples were collected hourly over a 24hr period from an indwelling venous 
cannula, with overnight samples being taken under dim light (20:00-06:00). The 
melatonin results were compared to historical controls collected by Waldhauser et al to 
assess normality (192). 
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C.  Results 
i. Subject characteristics 
Subject characteristics are outlined in detail in table 14. Six children with SOD (4 male) 
were assessed, all of whom had some degree of light perception. All completed all 
components of the study.   
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Table 14  Characteristics of actigraphy study subjects with septo-optic dysplasia 
 
 1      2     3    4    5    6     
Age (years) 1.62 1.27 1.67 6.4 6.12 1.8 
Gender M M F F M M 
Degree Visual 
Impairment 
(size of object 
visualised at 
30cm) 
Profound 
(light 
awareness) 
Profound 
 (light 
awareness) 
Severe 
(2.5mm) 
Severe 
(5mm) 
Severe 
(2.5mm) 
Severe 
(5mm) 
Hormonal 
Abnormalities 
GHD, 
TSHD, 
ACTHD 
GHD, 
TSHD, 
ACTHD, 
DI 
GHD GHD, TSHD, 
ACTHD 
GHD, 
ACTHD 
GHD 
MRI findings Small AP 
Normal PP  
B/L ONH 
Immature 
myelination  
Absent SP  
Small AP 
Absent PP  
U/L ONH 
Immature 
myelination 
Thin CC  
Small AP 
Normal PP  
B/L ONH 
Small AP  
Small PP 
B/L ONH                                                                                                                                                                                                                                                                                                                                                                                                               
Immature 
myelination, 
b/l parietal 
clefts, 
perisylvian, 
frontal & 
parietal 
polymicrogyria 
Small AP 
Normal 
PP B/L
ONH 
Absent 
CC 
Absent 
SP  
Small AP  
Normal PP  
U/L ONH 
Cognitive 
Assessment 
(RZS, VI 
norms (225)) 
Age 
Appropriate 
Mixed 
profile: 
delayed 
non-verbal 
cognition 
Age 
Appropriate 
Severe delay Severe 
delay 
Mixed 
profile: 
delayed 
non-verbal 
cognition 
Mean actual 
sleep time hrs* 
(normal 
reference range 
(242)) 
10.2 6.29  8.2  7.4  5.4  7.6  
Mean Sleep 
efficiency % 
(normal >85%) 
74.7 61 71.4 66.4 56 78 
Time of 
awakening  
h-min 
05.19-08.54 03.03-
09.35 
04.20-08.56 05.26-12.10 04.02-
10.14 
05.24-
08.06 
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Key Table 14  AP: anterior pituitary gland; PP: posterior pituitary gland; SP: 
septum pellucidum; ONH: optic nerve hypoplasia; CC corpus callosum, GHD: growth 
hormone deficiency, TSHD: thyroid stimulating hormone deficiency; ACTHD: ACTH 
deficiency; DI: diabetes insipidus; B/L: bilateral; U/L: unilateral.  
 
Sleep data: mean over 14 days of actiwatch recording, time of awakening: range over 14 
days of actiwatch recording.  
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ii. Sleep 
Actigraphic studies showed reduced sleep efficiency in all children with SOD, mainly 
due to frequent and often prolonged night awakenings (Figure 17). Only one child 
(child 2) presented with an arrhythmic sleep pattern. Actigraphic studies were normal in 
all controls. Sleep efficiency was reduced in all subjects studied when compared with 
controls (sleep efficiency: SOD mean 69.5, SD 10.6; normal controls mean 89.5, SD 
3.8; p<0.001) and total night-time sleep duration was >2 standard deviations below that 
of normal controls for age (242). 
 
iii. Melatonin 
Two children (child 4 and child 5) appeared to produce virtually no melatonin 
throughout the 24 hour period of measurement with a lack of clear circadian 
rhythmicity.  
  
None of the remaining children had an ‘inverted circadian rhythm’, with all showing a 
normal circadian pattern with mean serum concentrations being lowest during the day 
(mean 56pg/ml) and peaking overnight (mean 380pg/ml) (Figure 18). Dim-light 
melatonin onset times (a commonly used marker to determine sleep phase) were normal 
(19.00 hours) in three of the children, but harder to discern in child 2 where melatonin 
concentrations appear to rise early in the day (advanced phase) but then peak normally 
at night.  
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Figure 17 Actigrams of rest-activity patterns  
 
Example of a Normal sleep pattern Sleep efficiency (SE: 93%) 
    
                                      1st 24hr period          2nd 24hr period 
   
 
                   Awake          Sleep       Awake      Sleep  
            Onset              Onset   
 (data from normal individual [6.2year old boy wearing actiwatch mini© for a 12 day 
period]) 
 
Key Figure 17 Actigrams of rest-activity patterns in one normal individual and six 
children with septo-optic dysplasia. Actigraphic studies show reduced sleep efficiency 
(the ratio of total sleep time to sleep period) in all children with SOD, mainly due to 
frequent and often prolonged night awakenings (children 1, 3, 4, 5 & 6). Child 2 
displays an arrhythmic sleep pattern. 
Days of the 
week, 2 days 
actigraphic data 
per line 
Line 1 shows day1 /day2 
Line 2 shows day2 /day 3 
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Patient 1 (fragmented sleep [SE: 74.7%]) Patient 2 (arrhythmic sleep [SE: 61%]) 
 
   
 
Patient 3 (fragmented sleep [SE: 71.4%]) Patient 4 (fragmented sleep [SE: 66.4%]) 
 
   
  
Patient 5 (fragmented sleep [SE: 56%]) Patient 6 (fragmented sleep [SE: 78%]) 
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Figure 18 Melatonin profiles in children with sleep disturbance and septo-optic 
dysplasia 
 
 
 
 
 
Key Figure 18 Plasma melatonin profiles in six children with septo-optic dysplasia 
(n=6). Plasma samples were collected hourly over a 24hr period from an indwelling 
venous cannula, with overnight samples being taken under dim light (20:00-06:00). 
Two children (child 4 and child 5) produce virtually no melatonin throughout the 24 
hour period. The remaining children have a normal circadian pattern with mean serum 
melatonin concentrations being lowest during the day (mean 56pg/ml) and peaking 
overnight (mean 380pg/ml).  
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D. Discussion 
The commonest problem in this cohort of SOD patients is sleep fragmentation, even in 
the three children with normal 24-hour melatonin profiles. We can only speculate about 
the abnormal melatonin profiles found in the other children. Very low, or absent, 
production of melatonin is an unusual finding, rarely reported in the literature, which 
has been associated with genetic defects in the enzyme that allows melatonin to be 
produced from serotonin (243). Due to the heterogeneous patterns of brain abnormality 
seen in patients with SOD, any point in the pathway from the retina, to the SCN, to the 
pineal gland could be severely disrupted and cause such a picture. Even with current 
neuroimaging resolution, we are still not able to directly image structures as small as the 
SCN. It is possible that anomalies in sleep and melatonin production may both arise 
from perturbations in the clock without necessarily being inter-dependent, which is to 
some extent supported by the poor relationships in this series between melatonin 
profiles and objective sleep patterns.   
 
The SCN of the hypothalamus plays a principal role in the circadian regulation of sleep 
wake cycles and the diurnal release of endocrine factors including melatonin. This 
endogenous circadian rhythm can be modified by light exposure or exogenous 
melatonin administration. The pathophysiology of the disordered sleep patterns found in 
SOD could be caused by perturbations at any single, or indeed multiple points in the 
mechanisms responsible for normal, consolidated sleep-wake cycles. In individuals with 
light perception but significant VI, light will still entrain their circadian rhythms as this 
function is served by the non-image forming melanopsin ganglion cells (159). It is 
therefore unlikely that the sleep abnormalities found in individuals with SOD are 
secondary to their VI.  
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However, the circadian rhythm of melatonin, although entrained and suppressed by 
light, is endogenously driven by the SCN via a multisynaptic sympathetic noradrenergic 
pathway. Thus abnormalities in sleep and melatonin production could arise secondary to 
any dysfunction of the SCN itself (shown to be absent in one patient with SOD) (156), 
any disruption to the above complex pathways, or any abnormalities in the pineal gland.  
 
Other possible influential factors include the fact that the circadian clock is entrained 
not only by light but also by behavioural and social cues (zeitgebers) (244). An inability 
to correctly interpret these zeitgebers in children with neurodevelopmental disorders can 
lead to abnormalities in circadian rhythms (245). Fifty-seven percent of children with 
bilateral ONH have significant developmental delay (246). This may be impacting on 
their ability to interpret environmental zeitgebers, leading to difficulty in establishing 
normal sleep-wake cycles. Significant improvement in time to sleep onset has been 
shown in children with neurodevelopmental delay treated with melatonin; however 
since children in our cohort did not have abnormalities in sleep latency, melatonin may 
not be the most appropriate treatment option (247). 
 
With regard to treatment of sleep disorders in these children, we know that exogenous 
melatonin has a soporific effect, even in the presence of normal endogenous circadian 
melatonin production (e.g. sedation for MRI studies) (247). It is therefore unsurprising 
that some children with SOD benefit from melatonin treatment even in the presence of 
normal melatonin concentrations and circadian rhythm (248). However, the profiles we 
obtained do not suggest that delayed sleep phase syndrome, which has been suggested 
to be a good predictor of response to exogenous melatonin treatment, was present. This 
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differs from findings in conditions such as Rett and Angelman syndromes where 
behaviour and sleep disturbances have been shown to be associated with phase delay in 
melatonin secretion (165).  
 
E. Study limitations 
This study had several limitations including the small size of the cohort studied. This 
was in part due to the very intensive protocol used to ascertain melatonin peaks. The 
half life of melatonin is 30-53 minutes, and as it was previously unknown whether the 
normal circadian pattern of melatonin production would be maintained in children with 
SOD, hourly sampling over a 24 hour period was felt to be the most accurate way of 
ensuring peaks were not missed (249). Salivary melatonin measurement could offer an 
easier alternative means in the future of determining melatonin profiles in this group of 
patients. As a large amount of historical control data is available in the public domain; 
we did not therefore prospectively recruit age-matched controls because the number 
required to accurately delineate the significant variations found in melatonin 
concentrations with increasing age would have been extremely high (192).  
 
F.  Summary 
Our findings indicate that abnormalities in timing and amount of melatonin secretion 
vary, but do not account for the majority of the sleep abnormalities observed in these 
children, and suggest that there are other as yet unexplored factors contributing to their 
disordered sleep patterns. In view of the significant socioeconomic and neurocognitive 
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burden associated with sleep deprivation, other methods for treating the chronic sleep 
abnormalities found in this cohort need to be explored. 
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5.  DISCUSSION  
A. Introduction 
The studies summarized in the results chapters provide new data regarding the cognitive, 
behavioural and circadian rhythm difficulties experienced by children with midline brain 
abnormalities including IGHD, ONH and SOD. For parents of children with IGHD, their 
concerns regarding academic and motor skills performance often outweigh those 
regarding daily injections once the diagnosis of IGHD has been confirmed and treatment 
started. However, previously it has been hard for parents and physicians to know whether 
these children’s difficulties with, for example, motor skills, are related to or independent 
of their diagnosis of IGHD. Similarly in children with isolated ONH and functionally 
normal vision, ongoing paediatric follow-up has not previously been advocated. However 
the increased prevalence of clinically significant behavioural difficulties in this cohort 
highlights the need for a shift in management practice. Children with SOD have complex 
clinical needs, which include MPHD and learning difficulties. However, the disturbances 
in circadian rhythm found in individuals with SOD and the disruption that they can inflict 
on the whole family is often the most difficult component of the syndrome for both the 
family and physician to manage. Previously a lack of understanding of the aetiology and 
therefore best management of this problem has hampered progress in this area. Whilst we 
have made conclusions in many of the areas outlined above there remain many 
unanswered questions, these are outlined in detail below under the headings of IGHD, 
ONH and SOD. 
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B.  Isolated growth hormone deficiency 
In summary, the study to investigate the effect of IGHD on cognition, motor function 
and brain structure found that the hippocampus, corpus callosum, thalamus and globus 
pallidum are smaller (in relation to brain size) in children with IGHD compared to those 
with ISS, and that children with IGHD also have reduced coherence of white matter 
tracts in association with cognitive and motor dysfunction. Our findings provide 
evidence to suggest that the GH-IGF-1 axis plays a role in brain and cognitive 
development. This study was however unable to ascertain whether the abnormalities 
identified occur as a result of GH-deficiency or are part of the underlying disorder. We 
have also not been able to assess whether cognitive and motor skills performance scores 
improve with GH therapy. Future studies are therefore require to address the hypothesis 
that GH/IGF1 affects both structural brain growth as well as brain function and that 
GH-treatment improves cognitive function in children with GHD. 
 
Interestingly, the present study did not identify an increased prevalence of behavioural 
abnormalities in children with IGHD when compared to controls with ISS. This is 
surprising in the context of the one large previous study investigating the prevalence of 
behavioural problems in children with IGHD, which reported an increased prevalence of 
behavioural difficulties in children with IGHD (211;250).  At baseline, Stabler et al 
found that children with both IGHD and ISS showed significant discrepancy (p<0.01) 
between IQ and achievement scores in reading (6%), spelling (10%), and arithmetic 
(13%) and a higher-than-expected rate of behavioral problems (GHD, 12%, p<0.0001; 
ISS, 10%, p<0.0001) (211). There were however no between group differences for IQ 
or behavioural measures. This differs from our findings of significantly lower FSIQ 
(p<0.02), verbal comprehension index (p<0.006) and processing speed index (p<0.05) 
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scores in children with IGHD as compared to ISS controls. As one of our primary aims 
was to assess whether we could identify neural correlates for any cognitive/motor skills 
or behavioural abnormalities identified we wanted to compare the subjects to the least 
different control group possible. We therefore chose children with short stature as our 
controls as, although they have no identifiable medical condition their parents have been 
concerned enough regarding their health to seek a specialist opinion at a tertiary referral 
hospital. Additionally, children with ISS have previously been found to have reduced 
IQ when compared to normal stature controls (25). In choosing children with ISS as our 
“controls”, we thereby hoped to control for the effect of stature and isolate the effect of 
GHD. In addition the CBCL is a parental questionnaire, which may be biased for 
parents of children with perceived (e.g. short stature) or actual (e.g. VI) medical 
conditions. We therefore used children presenting to the tertiary referral hospital rather 
than sibling controls to control for the effect of this. However, in choosing short stature 
controls who are at increased of risk of having undiagnosed partial GH insensitivity or 
IGF-1 deficiency (251;252), we may have chosen a control population who are also at 
increased risk of neurological deficits due to subtle abnormalities of the GH axis. 
Looking at the concentrations of peak GH, baseline IGF-1 and IGFBP-3 (Table 7) of the 
controls with ISS, there is limited evidence to suggest the presence of either GH 
insensitivity or IGF-1 deficiency, with the mean GH peak of ISS controls not being 
excessively elevated at 15µg/L, and the IGF-1 SDS of ISS controls falling just below 0 
(-0.5 SDS). However, the ISS group may have included individuals with both partial 
GH insensitivity and IGF-1 deficiency making interpretation of the means of GH peak 
and IGF-1 SDS unhelpful (251;252). Ideally we would therefore have also have 
recruited a control group of age and gender matched children of normal stature with a 
normal GH axis to assess whether there were any differences in behavioural measures 
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between children with IGHD and normal controls, and/or between children with ISS 
and normal controls.  
 
Stabler et al also identified improvements in behavioural profiles following treatment 
with GH (93). This effect was found to be larger in those with GHD (p<0.001) than in 
those with ISS (p<0.003) (93). GH treatment in individuals with GHD also improved 
scores on internalizing subscales (withdrawn: p<0.007, somatic complications p<0.001, 
anxious/depressed p<0.001) and on attention, social problems and thought problems 
(p=0.001). We were not however able to follow our cohort up after GH treatment was 
started, and have not therefore been able to assess whether improvements in cognitive or 
behavioural measures were present after GH treatment was started. The cohort of 
children with IGHD we studied was relatively small and as two children with IGHD did 
not comply with GH treatment and two further children declined to participate in the 
follow-up component of the study the numbers of children remaining were not large 
enough to power follow-up, on treatment, studies. Future, larger, studies with a 12-24 
month follow up post onset of GH treatment are therefore required. 
 
Unlike adult studies in which individuals with GHD have consistently been found to have 
impairments in attention, memory and executive function we identified no abnormalities 
in attention, memory or executive function in children with IGHD (80). This may also 
have been due to the control group we selected. Assessing the difference in cognitive 
function, attention and memory skills performance and behaviour between children with 
IGHD and normal stature controls may have identified further cognitive abnormalities 
present in children with IGHD. It may also be that cognitive deficits in the domains of 
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attention, memory and executive function only become apparent in individuals with 
chronic untreated GHD (i.e. adults). 
 
Although we identified reductions in specific neural volumes (the right hippocampus, 
globus pallidum, thalamus, corpus callosum and cerebellum) with reduced corticospinal 
tract and corpus callosum FA in children with IGHD, which we hypothesized may either 
be mediated by mechanisms such as the stimulation of acetylcholine release by IGF-1 
from hippocampal neurons (53), or due to the selective neuronal vulnerability of these 
brain regions to the underlying disease process (215), we have been unable to further 
investigate the underlying pathogenesis of the abnormalities identified. One previous 
study performed in a cohort of adults with childhood onset GH deficiency (a combination 
of individuals with IGHD and MPHD) used nuclear magnetic resonance spectroscopy in 
conjunction with measurements of event-related potentials to further investigate this 
question (75;253). Magnetic resonance spectroscopy can be used to obtain in vivo 
measurements of brain metabolites such as N-acetylaspartate (a marker of neuronal 
density and integrity) and choline (a marker of membrane synthesis/breakdown). Future 
studies could use techniques such as magnetic resonance spectroscopy in addition to 
those used in the present study, to confirm the significant findings we have identified and 
to clarify the pathophysiology of the abnormalities present. It would also be extremely 
helpful to have follow-up MRI studies in children with IGHD and controls 12 months 
following the onset of GH treatment in patients. 
  
 
172 
 
C.  Optic nerve hypoplasia 
In the study to investigate the prevalence of behavioural problems in children with 
isolated ONH and to use DTI to identify neural abnormalities not detectable using 
conventional neuroimaging, we found that children with isolated ONH, normal 
development and mild to moderate or no VI have an increased prevalence of clinically 
significant behavioural problems. We also showed evidence of reduced white matter 
integrity in the corpus callosum and ventral cingulum, the anterior optic pathway and 
optic radiations bilaterally, regions of the brain that are implicated in behavioural and 
emotional regulation and vision. These identified abnormalities in white matter fibre 
density in the ventral cingulum correlated significantly with behavioural scores. When 
children with ONH and SOD were grouped together they were found to have reduced FA 
in the corpus callosum, ventral cingulum and prefrontal cortex, together these structures 
form part of the social brain (148).  
 
Currently children with isolated ONH do not undergo behavioural assessment as part of 
their routine clinical care. However, the association between abnormal behaviours in 
childhood and later psychiatric morbidity in other childhood cohorts highlights the need 
for the identification of behavioural abnormalities in these children with isolated ONH. In 
children with behavioural difficulties strategies could then be put into place to prevent 
later psychiatric illnesses. 
 
Although previous research in different clinical populations suggests that the behavioural 
abnormalities we have identified are likely to be clinically significant, we have not 
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assessed the wider clinical significance of these behavioural difficulties in children with 
ONH (229). Future long-term follow-up studies are therefore required to address this 
question. A more detailed assessment as to whether any of these behavioural problems 
are impacting on school performance would also be helpful. 
 
In addition to the well-established abnormalities of the optic nerve, we demonstrated 
that children with ONH also show evidence of reduced white matter integrity in the 
ventral cingulum bilaterally, the corpus callosum and the optic radiations bilaterally. We 
were unable to demonstrate concurrent reductions in gray matter volumes in the corpus 
callosum and occipital visual cortex in children with ONH although there was a trend 
for children with ONH to have smaller corpus callosum splenium volumes. This is 
interesting as Garcia-Filon et al previously reported that, in children with optic nerve 
hypoplasia, for each 2cm2 reduction in corpus callosum size the risk for developmental 
delay increased twofold (131). However, the majority of children (54/60) studied in that 
paper had SOD as opposed to isolated ONH. It would be interesting to repeat the 
current study in a much larger cohort to assess whether in children with isolated ONH 
corpus callosum splenium volume also correlates with cognitive performance.  
 
These children with mild/moderate or no VI and isolated ONH have abnormalities in 
their optic radiations. This raises the question of whether abnormalities in the optic 
radiation in children with ONH are, as previously hypothesized, solely secondary to 
reduced visual stimulation. Further research within this population, controlling for visual 
levels and uni- or bilateral ONH, is required to explore the possible mechanisms affecting 
neural visual development. 
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We recruited a group of children with ONH and mild-moderate or no VI and therefore 
were unable to assess whether the neuro-anatomical, cognitive and behavioural 
abnormalities identified also relate to the degree of VI. The number of children with 
SOD and significant VI recruited were not large enough to further examine this 
question. To further investigate the relationship between developmental visual history 
and early and later levels of available functional vision and the development of the 
posterior optic radiations this study should be repeated in children with a range of visual 
acuities, in the context of ONH (separating unilateral and bilateral ONH) and in VI 
secondary to other pathologies (e.g. retinal dystrophy). To clarify whether the abnormal 
myelination/axon density in the posterior optic radiations is due to an antenatal insult or 
due to postnatal reductions in visual stimulation, the MRI component of this study 
would ideally be repeated in children at, or shortly after, birth.  
 
Our data suggests that children with SOD may have abnormalities in the development 
of their social brain, namely their prefrontal cortex, corpus callosum and ventral 
cingulum and this may to some extent explain the increased prevalence of behavioural 
and social communication difficulties found within this group of children (58). This 
work will need to be repeated in larger cohorts of children with SOD and ASD to 
confirm these preliminary findings. 
 
D. Septo-optic dysplasia 
Abnormal sleep patterns impact significantly both on the child’s well being and on the 
families’ overall lifestyle and ability to cope with their child’s complex condition, and 
can adversely impact on children’s cognitive development (152;158). Thirty-two 
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percent of children with SOD have disordered sleep patterns; these include free-running 
rest-activity cycles, fragmented and arrhythmic sleep (157). In view of the uncertainty 
surrounding the aetiology of the sleep abnormalities found in individuals with SOD, and 
consequently the optimum management of this problem, we aimed to establish whether 
children with SOD who experience sleep pattern disorders also have defective 
melatonin production. Out of the six children studied five children had sleep 
fragmentation and one had a completely arrhythmic sleep pattern. All children had a 
significant reduction in sleep efficiency. Two children produced virtually no melatonin 
throughout the 24-hour period of measurement with a lack of clear circadian 
rhythmicity, with the remaining four children having relatively normal melatonin 
production profiles. We have therefore shown that the aetiology of the sleep 
disturbances found in children with SOD is complex, and not solely due to abnormal 
nocturnal melatonin production. These may be due to a vriability in the aetiology of 
SOD in the children we studied. These findings are clinically important as they question 
current clinical practice. Previous papers have recommended that circadian rhythm 
disturbance in children with SOD can be resolved by administering low doses (0.1-0.5 
mg) of melatonin in the evening, or soporific doses (3-5 mg) at bedtime. These 
recommendations form part of standard practice in many endocrine centres; however as 
stated in the above paper, and unsurprisingly in view of our findings, melatonin does 
not improve sleep dysregulation in all children with SOD (254). 
 
Whilst we have now demonstrated why not all children with SOD respond to treatment 
with melatonin there remain many unanswered questions. Three possible future studies 
to address these issues are outlined below. Firstly, studying a larger cohort of children 
with SOD and sleep abnormalities using a less intensive study protocol (for example, 
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samples to measure melatonin concentration could be taken in the evening only to 
assess whether the normal nocturnal rise in melatonin was present rather than aiming to 
assess the entire 24 hour pattern of melatonin production) and following them up with a 
trial of melatonin treatment may help to clarify which children with SOD are most 
likely to benefit from melatonin treatment. Secondly, as at present the majority of 
medication prescribed to regulate sleep patterns in children are either unlicensed of off-
label, it is difficult to know what the long-term safety profile of medications such as 
melatonin is. This reflects the limited number of therapeutic trials that have been 
performed in children with sleep disorders, not only in those with SOD (255). There are 
putative side-effects associated with melatonin use with one study suggesting that 
melatonin may have pro-convulsant effects (163) and others suggesting that it impacts 
on the hypothalamo-pituitary axis, potentially affecting the patterns of oxytocin, ACTH, 
vasopressin and GH release, although it remains difficult to predict whether these 
endocrine effects will have long-term clinical outcomes (152;164;165). Future long-
term studies assessing the safety of melatonin use in children are therefore required. 
Thirdly, as significant sleep disturbances have a significant adverse impact on cognitive 
functioning and behaviour (256), as well as affecting the family as a whole, other 
solutions for the extremely challenging sleep disorders found in children with SOD 
need to be identified. This will require trials of novel medications targeting sleep 
disruption in children with SOD.  
 
177 
 
6.  REFERENCES 
 
 1.  Borst SE, Millard WJ, Lowenthal DT. Growth hormone, exercise, and aging: the 
future of therapy for the frail elderly. J Am Geriatr Soc 1994; 42(5):528-535. 
 2.  Chapman GE, Rogers KM, Brittain T et al. The 20,000 molecular weight variant 
of human growth hormone. Preparation and some physical and chemical 
properties. J Biol Chem 1981; 256(5):2395-2401. 
 3.  Baumann G, Shaw M, Amburn K et al. Heterogeneity of circulating growth 
hormone. Nucl Med Biol 1994; 21(3):369-379. 
 4.  Savine R, Sonksen PH. Is the somatopause an indication for growth hormone 
replacement? J Endocrinol Invest 1999; 22(5 Suppl):142-149. 
 5.  Brook CG, Marshall N. Essential Endocrinology. 3rd ed. Blackwell Science, 
2000. 
 6.  Ihle JN. Cytokine receptor signalling. Nature 1995; 377(6550):591-594. 
 7.  Moutoussamy S, Kelly PA, Finidori J. Growth-hormone-receptor and cytokine-
receptor-family signaling. Eur J Biochem 1998; 255(1):1-11. 
 8.  Kanaley JA, Weatherup-Dentes MM, Jaynes EB, Hartman ML. Obesity 
attenuates the growth hormone response to exercise. J Clin Endocrinol Metab 
1999; 84(9):3156-3161. 
 9.  Vigas M, Tartar P, Jezova D et al. Nutritional and hemodynamic factors 
influencing adenopituitary function in man. Adv Exp Med Biol 1990; 274:407-
426. 
 10.  Vigas M, Malatinsky J, Nemeth S, Jurcovicova J. Alpha-adrenergic control of 
growth hormone release during surgical stress in man. Metabolism 1977; 
26(4):399-402. 
 11.  Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship between the novel 
peptide ghrelin and somatostatin/growth hormone-releasing hormone in 
regulation of pulsatile growth hormone secretion. Endocrinology 2003; 
144(3):967-974. 
 12.  Hindmarsh PC, Fall CH, Pringle PJ, Osmond C, Brook CG. Peak and trough 
growth hormone concentrations have different associations with the insulin-like 
growth factor axis, body composition, and metabolic parameters. J Clin 
Endocrinol Metab 1997; 82(7):2172-2176. 
 13.  Werther GA, Russo V, Baker N, Butler G. The role of the insulin-like growth 
factor system in the developing brain. Horm Res 1998; 49 Suppl 1:37-40. 
178 
 
 14.  Wetterau L, Cohen P. Role of insulin-like growth factor monitoring in 
optimizing growth hormone therapy. J Pediatr Endocrinol Metab 2000; 13 Suppl 
6:1371-1376. 
 15.  Rudman D, Feller AG, Nagraj HS et al. Effects of human growth hormone in 
men over 60 years old. N Engl J Med 1990; 323(1):1-6. 
 16.  Le RD, Scavo L, Butler A. What is the role of circulating IGF-I? Trends 
Endocrinol Metab 2001; 12(2):48-52. 
 17.  Lacey KA, Parkin JM. Causes of short stature. A community study of children 
in Newcastle upon Tyne. Lancet 1974; 1(7846):42-45. 
 18.  Rona RJ, Tanner JM. Aetiology of idiopathic growth hormone deficiency in 
England and Wales. Arch Dis Child 1977; 52(3):197-208. 
 19.  Vimpani GV, Vimpani AF, Lidgard GP, Cameron EH, Farquhar JW. Prevalence 
of severe growth hormone deficiency. Br Med J 1977; 2(6084):427-430. 
 20.  Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah Growth 
Study: growth standards and the prevalence of growth hormone deficiency. J 
Pediatr 1994; 125(1):29-35. 
 21.  Phillips JA, III, Cogan JD. Genetic basis of endocrine disease. 6. Molecular 
basis of familial human growth hormone deficiency. J Clin Endocrinol Metab 
1994; 78(1):11-16. 
 22.  Dattani MT. Novel insights into the aetiology and pathogenesis of 
hypopituitarism. Horm Res 2004; 62 Suppl 3:1-13. 
 23.  Hindmarsh PC, Brook CG. Auxological and biochemical assessment of short 
stature. Acta Paediatr Scand Suppl 1988; 343:73-76. 
 24.  Rosenfeld RG, bertsson-Wikland K, Cassorla F et al. Diagnostic controversy: 
the diagnosis of childhood growth hormone deficiency revisited. J Clin 
Endocrinol Metab 1995; 80(5):1532-1540. 
 25.  Voss LD, Bailey BJ, Mulligan J, Wilkin TJ, Betts PR. Short stature and school 
performance--the Wessex Growth Study. Acta Paediatr Scand Suppl 1991; 
377:29-31. 
 26.  Dorner S, Elton A. Short, taught and vulnerable. Spec Educ 1973; 62(2):12-16. 
 27.  Skuse D, Reilly S, Wolke D. Psychosocial adversity and growth during infancy. 
Eur J Clin Nutr 1994; 48 Suppl 1:S113-S130. 
 28.  Law CM. The disability of short stature. Arch Dis Child 1987; 62(8):855-859. 
 29.  Siegel PT, Clopper R, Stabler B. Psychological impact of significantly short 
stature. Acta Paediatr Scand Suppl 1991; 377:14-18. 
179 
 
 30.  Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM. Effects of 
stunting, diarrhoeal disease, and parasitic infection during infancy on cognition 
in late childhood: a follow-up study. Lancet 2002; 359(9306):564-571. 
 31.  Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and 
binding proteins. Endocr Rev 1991; 12(4):424-449. 
 32.  Donahue CP, Kosik KS, Shors TJ. Growth hormone is produced within the 
hippocampus where it responds to age, sex, and stress. Proc Natl Acad Sci U S 
A 2006; 103(15):6031-6036. 
 33.  Johansson JO, Larson G, Andersson M et al. Treatment of growth hormone-
deficient adults with recombinant human growth hormone increases the 
concentration of growth hormone in the cerebrospinal fluid and affects 
neurotransmitters. Neuroendocrinology 1995; 61(1):57-66. 
 34.  Lobie PE, Garcia-Aragon J, Lincoln DT, Barnard R, Wilcox JN, Waters MJ. 
Localization and ontogeny of growth hormone receptor gene expression in the 
central nervous system. Brain Res Dev Brain Res 1993; 74(2):225-233. 
 35.  Burman P, Hetta J, Wide L, Mansson JE, Ekman R, Karlsson FA. Growth 
hormone treatment affects brain neurotransmitters and thyroxine [see comment]. 
Clin Endocrinol (Oxf) 1996; 44(3):319-324. 
 36.  Hynes MA, Van Wyk JJ, Brooks PJ, D'Ercole AJ, Jansen M, Lund PK. Growth 
hormone dependence of somatomedin-C/insulin-like growth factor-I and insulin-
like growth factor-II messenger ribonucleic acids. Mol Endocrinol 1987; 
1(3):233-242. 
 37.  Burman P, Hetta J, Karlsson A. Effect of growth hormone on brain 
neurotransmitters. Lancet 1993; 342(8885):1492-1493. 
 38.  Hojvat S, Baker G, Kirsteins L, Lawrence AM. Growth hormone (GH) 
immunoreactivity in the rodent and primate CNS: distribution, characterization 
and presence posthypophysectomy. Brain Res 1982; 239(2):543-557. 
 39.  Mustafa A, Adem A, Roos P, Nyberg F. Sex differences in binding of human 
growth hormone to rat brain. Neurosci Res 1994; 19(1):93-99. 
 40.  Lai Z, Roos P, Zhai O et al. Age-related reduction of human growth hormone-
binding sites in the human brain. Brain Res 1993; 621(2):260-266. 
 41.  Lai ZN, Emtner M, Roos P, Nyberg F. Characterization of putative growth 
hormone receptors in human choroid plexus. Brain Res 1991; 546(2):222-226. 
 42.  McClelland JL, Goddard NH. Considerations arising from a complementary 
learning systems perspective on hippocampus and neocortex. Hippocampus 
1996; 6(6):654-665. 
 43.  MILNER B, PENFIELD W. The effect of hippocampal lesions on recent 
memory. Trans Am Neurol Assoc 1955;(80th Meeting):42-48. 
180 
 
 44.  PENFIELD W, MILNER B. Memory deficit produced by bilateral lesions in the 
hippocampal zone. AMA Arch Neurol Psychiatry 1958; 79(5):475-497. 
 45.  Turnley AM, Faux CH, Rietze RL, Coonan JR, Bartlett PF. Suppressor of 
cytokine signaling 2 regulates neuronal differentiation by inhibiting growth 
hormone signaling. Nat Neurosci 2002; 5(11):1155-1162. 
 46.  Harvey S, Lavelin I, Pines M. Growth hormone (GH) action in the brain: neural 
expression of a GH-response gene. J Mol Neurosci 2002; 18(1-2):89-95. 
 47.  Camacho-Hubner C, Woods KA, Clark AJ, Savage MO. Insulin-like growth 
factor (IGF)-I gene deletion. Rev Endocr Metab Disord 2002; 3(4):357-361. 
 48.  Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth 
retardation and postnatal growth failure associated with deletion of the insulin-
like growth factor I gene. N Engl J Med 1996; 335(18):1363-1367. 
 49.  Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain 
barrier. Endocrinology 1994; 135(5):1753-1761. 
 50.  Caroni P, Grandes P. Nerve sprouting in innervated adult skeletal muscle 
induced by exposure to elevated levels of insulin-like growth factors. J Cell Biol 
1990; 110(4):1307-1317. 
 51.  Sonntag WE, Lynch C, Thornton P, Khan A, Bennett S, Ingram R. The effects 
of growth hormone and IGF-1 deficiency on cerebrovascular and brain ageing. J 
Anat 2000; 197 Pt 4:575-585. 
 52.  Lynch CD, Lyons D, Khan A, Bennett SA, Sonntag WE. Insulin-like growth 
factor-1 selectively increases glucose utilization in brains of aged animals. 
Endocrinology 2001; 142(1):506-509. 
 53.  Araujo DM, Lapchak PA, Collier B, Chabot JG, Quirion R. Insulin-like growth 
factor-1 (somatomedin-C) receptors in the rat brain: distribution and interaction 
with the hippocampal cholinergic system. Brain Res 1989; 484(1-2):130-138. 
 54.  Pulford BE, Whalen LR, Ishii DN. Peripherally administered insulin-like growth 
factor-I preserves hindlimb reflex and spinal cord noradrenergic circuitry 
following a central nervous system lesion in rats. Exp Neurol 1999; 159(1):114-
123. 
 55.  Winkler T, Sharma HS, Stalberg E, Badgaiyan RD, Westman J, Nyberg F. 
Growth hormone attenuates alterations in spinal cord evoked potentials and cell 
injury following trauma to the rat spinal cord. An experimental study using 
topical application of rat growth hormone. Amino Acids 2000; 19(1):363-371. 
 56.  Scheepens A, Sirimanne E, Beilharz E et al. Alterations in the neural growth 
hormone axis following hypoxic-ischemic brain injury. Brain Res Mol Brain 
Res 1999; 68(1-2):88-100. 
181 
 
 57.  Adem A, Jossan SS, d'Argy R et al. Insulin-like growth factor 1 (IGF-1) 
receptors in the human brain: quantitative autoradiographic localization. Brain 
Res 1989; 503(2):299-303. 
 58.  Baron-Cohen S, Ring HA, Wheelwright S et al. Social intelligence in the normal 
and autistic brain: an fMRI study. Eur J Neurosci 1999; 11(6):1891-1898. 
 59.  Carson MJ, Behringer RR, Brinster RL, McMorris FA. Insulin-like growth 
factor I increases brain growth and central nervous system myelination in 
transgenic mice. Neuron 1993; 10(4):729-740. 
 60.  Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth 
hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 
2001; 229(1):141-162. 
 61.  Guevara-Aguirre J, Rosenbloom AL, Vaccarello MA et al. Growth hormone 
receptor deficiency (Laron syndrome): clinical and genetic characteristics. Acta 
Paediatr Scand Suppl 1991; 377:96-103. 
 62.  Kranzler JH, Rosenbloom AL, Martinez V, Guevara-Aguirre J. Normal 
intelligence with severe insulin-like growth factor I deficiency due to growth 
hormone receptor deficiency: a controlled study in a genetically homogeneous 
population. J Clin Endocrinol Metab 1998; 83(6):1953-1958. 
 63.  Laron Z. Laron-type dwarfism (hereditary somatomedin deficiency): a review. 
Ergeb Inn Med Kinderheilkd 1984; 51:117-150. 
 64.  Laron Z, Klinger B. Laron syndrome: clinical features, molecular pathology and 
treatment. Horm Res 1994; 42(4-5):198-202. 
 65.  Scheepens A, Moderscheim TA, Gluckman PD. The role of growth hormone in 
neural development. Horm Res 2005; 64 Suppl 3:66-72. 
 66.  Rosenbloom AL, Savage MO, Blum WF, Guevara-Aguirre J, Rosenfeld RG. 
Clinical and biochemical characteristics of growth hormone receptor deficiency 
(Laron syndrome). Acta Paediatr Suppl 1992; 383:121-124. 
 67.  Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) 
insensitivity due to primary GH receptor deficiency. Endocr Rev 1994; 
15(3):369-390. 
 68.  Markowska AL, Mooney M, Sonntag WE. Insulin-like growth factor-1 
ameliorates age-related behavioral deficits. Neuroscience 1998; 87(3):559-569. 
 69.  Geary MP, Pringle PJ, Rodeck CH, Kingdom JC, Hindmarsh PC. Sexual 
dimorphism in the growth hormone and insulin-like growth factor axis at birth. J 
Clin Endocrinol Metab 2003; 88(8):3708-3714. 
 70.  Gunnell D, Miller LL, Rogers I, Holly JM. Association of insulin-like growth 
factor I and insulin-like growth factor-binding protein-3 with intelligence 
quotient among 8- to 9-year-old children in the Avon Longitudinal Study of 
Parents and Children. Pediatrics 2005; 116(5):e681-e686. 
182 
 
 71.  Aleman A, Verhaar HJ, de Haan EH et al. Insulin-like growth factor-I and 
cognitive function in healthy older men. J Clin Endocrinol Metab 1999; 
84(2):471-475. 
 72.  Deijen JB, de Boer H, Blok GJ, van der Veen EA. Cognitive impairments and 
mood disturbances in growth hormone deficient men. 
Psychoneuroendocrinology 1996; 21(3):313-322. 
 73.  Deijen JB, de BH, van d, V. Cognitive changes during growth hormone 
replacement in adult men. Psychoneuroendocrinology 1998; 23(1):45-55. 
 74.  Burman P, Broman JE, Hetta J et al. Quality of life in adults with growth 
hormone (GH) deficiency: response to treatment with recombinant human GH in 
a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995; 
80(12):3585-3590. 
 75.  Lijffijt M, van Dam PS, Kenemans JL et al. Somatotropic-axis deficiency affects 
brain substrates of selective attention in childhood-onset growth hormone 
deficient patients. Neurosci Lett 2003; 353(2):123-126. 
 76.  van Dam PS. Neurocognitive function in adults with growth hormone 
deficiency. Horm Res 2005; 64 Suppl 3:109-114. 
 77.  Arwert LI, Veltman DJ, Deijen JB, van Dam PS, emarre-van deWaal HA, Drent 
ML. Growth hormone deficiency and memory functioning in adults visualized 
by functional magnetic resonance imaging. Neuroendocrinology 2005; 82(1):32-
40. 
 78.  Golgeli A, Tanriverdi F, Suer C et al. Utility of P300 auditory event related 
potential latency in detecting cognitive dysfunction in growth hormone (GH) 
deficient patients with Sheehan's syndrome and effects of GH replacement 
therapy. Eur J Endocrinol 2004; 150(2):153-159. 
 79.  Sartorio A, Molinari E, Riva G, Conti A, Morabito F, Faglia G. Growth 
hormone treatment in adults with childhood onset growth hormone deficiency: 
effects on psychological capabilities. Horm Res 1995; 44(1):6-11. 
 80.  Falleti MG, Maruff P, Burman P, Harris A. The effects of growth hormone (GH) 
deficiency and GH replacement on cognitive performance in adults: a meta-
analysis of the current literature. Psychoneuroendocrinology 2006; 31(6):681-
691. 
 81.  Meyer-Bahlburg HF, Feinman JA, MacGillivray MH, Aceto T, Jr. Growth 
hormone deficiency, brain development, and intelligence. Am J Dis Child 1978; 
132(6):565-572. 
 82.  Bulow B, Hagmar L, Orbaek P, Osterberg K, Erfurth EM. High incidence of 
mental disorders, reduced mental well-being and cognitive function in 
hypopituitary women with GH deficiency treated for pituitary disease. Clin 
Endocrinol (Oxf) 2002; 56(2):183-193. 
183 
 
 83.  Peace KA, Orme SM, Padayatty SJ, Godfrey HP, Belchetz PE. Cognitive 
dysfunction in patients with pituitary tumour who have been treated with 
transfrontal or transsphenoidal surgery or medication. Clin Endocrinol (Oxf) 
1998; 49(3):391-396. 
 84.  Almqvist O, Thoren M, Saaf M, Eriksson O. Effects of growth hormone 
substitution on mental performance in adults with growth hormone deficiency: a 
pilot study. Psychoneuroendocrinology 1986; 11(3):347-352. 
 85.  Lasaite L, Bunevicius R, Lasiene D, Lasas L. Psychological functioning after 
growth hormone therapy in adult growth hormone deficient patients: endocrine 
and body composition correlates. Medicina (Kaunas ) 2004; 40(8):740-744. 
 86.  Baum HB, Katznelson L, Sherman JC et al. Effects of physiological growth 
hormone (GH) therapy on cognition and quality of life in patients with adult-
onset GH deficiency. J Clin Endocrinol Metab 1998; 83(9):3184-3189. 
 87.  Pavel ME, Lohmann T, Hahn EG, Hoffmann M. Impact of growth hormone on 
central nervous activity, vigilance, and tiredness after short-term therapy in 
growth hormone-deficient adults. Horm Metab Res 2003; 35(2):114-119. 
 88.  Degerblad M, Almkvist O, Grunditz R et al. Physical and psychological 
capabilities during substitution therapy with recombinant growth hormone in 
adults with growth hormone deficiency. Acta Endocrinol (Copenh) 1990; 
123(2):185-193. 
 89.  Oertel H, Schneider HJ, Stalla GK, Holsboer F, Zihl J. The effect of growth 
hormone substitution on cognitive performance in adult patients with 
hypopituitarism. Psychoneuroendocrinology 2004; 29(7):839-850. 
 90.  Tanriverdi F, Yapislar H, Karaca Z, Unluhizarci K, Suer C, Kelestimur F. 
Evaluation of cognitive performance by using P300 auditory event related 
potentials (ERPs) in patients with growth hormone (GH) deficiency and 
acromegaly. Growth Horm IGF Res 2009; 19(1):24-30. 
 91.  Steinhausen HC, Stahnke N. Negative impact of growth-hormone deficiency on 
psychological functioning in dwarfed children and adolescents. Eur J Pediatr 
1977; 126(4):263-270. 
 92.  Steinhausen HC, Stahnke N. Psychoendocrinological studies in dwarfed children 
and adolescents. Arch Dis Child 1976; 51(10):778-783. 
 93.  Stabler B, Siegel PT, Clopper RR, Stoppani CE, Compton PG, Underwood LE. 
Behavior change after growth hormone treatment of children with short stature. 
J Pediatr 1998; 133(3):366-373. 
 94.  Frisch H, Hausler G, Lindenbauer S, Singer S. Psychological aspects in children 
and adolescents with hypopituitarism. Acta Paediatr Scand 1990; 79(6-7):644-
651. 
 95.  Holmes CS, Thompson RG, Hayford JT. Factors related to grade retention in 
children with short stature. Child Care Health Dev 1984; 10(4):199-210. 
184 
 
 96.  Holmes CS, Karlsson JA, Thompson RG. Social and school competencies in 
children with short stature: longitudinal patterns. J Dev Behav Pediatr 1985; 
6(5):263-267. 
 97.  Drotar D, Owens R, Gotthold J. Personality adjustment of children and 
adolescents with hypopituitarism. Child Psychiatry Hum Dev 1980; 11(1):59-66. 
 98.  Brown K, Rodgers J, Johnstone H et al. Abnormal cognitive function in treated 
congenital hypopituitarism. Arch Dis Child 2004; 89(9):827-830. 
 99.  Hershey T, Perantie DC, Warren SL, Zimmerman EC, Sadler M, White NH. 
Frequency and timing of severe hypoglycemia affects spatial memory in 
children with type 1 diabetes. Diabetes Care 2005; 28(10):2372-2377. 
 100.  Abbott D, Rotnem D, Genel M, Cohen DJ. Cognitive and emotional functioning 
in hypopituitary short-statured children. Schizophr Bull 1982; 8(2):310-319. 
 101.  Siegel PT, Hopwood NJ. The relationship of academic achievement and 
intellectual functioning and affective conditions of hypopituitary children. In: 
Stabler B, Underwood LE, editors. Slow Grows the Child: Psychosocial Aspects 
of Growth Delay. Hillsdale, NJ: Lawrence Erlbaum Associates, 1986: 57-71. 
 102.  Tillmann V, Tang VW, Price DA, Hughes DG, Wright NB, Clayton PE. 
Magnetic resonance imaging of the hypothalamic-pituitary axis in the diagnosis 
of growth hormone deficiency. J Pediatr Endocrinol Metab 2000; 13(9):1577-
1583. 
 103.  Basser PJ, Mattiello J, LeBihan D. Estimation of the effective self-diffusion 
tensor from the NMR spin echo. J Magn Reson B 1994; 103(3):247-254. 
 104.  Fischl B, Salat DH, Busa E et al. Whole brain segmentation: automated labeling 
of neuroanatomical structures in the human brain. Neuron 2002; 33(3):341-355. 
 105.  Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with 
contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A 1990; 
87(24):9868-9872. 
 106.  De Bellis MD, Keshavan MS, Beers SR et al. Sex differences in brain 
maturation during childhood and adolescence. Cereb Cortex 2001; 11(6):552-
557. 
 107.  Hansen-Pupp I, Hovel H, Hellstrom A et al. Postnatal decrease in circulating 
insulin-like growth factor-I and low brain volumes in very preterm infants. J 
Clin Endocrinol Metab 2011; 96(4):1129-1135. 
 108.  Arwert LI, Veltman DJ, Deijen JB, van Dam PS, Drent ML. Effects of growth 
hormone substitution therapy on cognitive functioning in growth hormone 
deficient patients: a functional MRI study. Neuroendocrinology 2006; 83(1):12-
19. 
185 
 
 109.  Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues 
elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 1996; 
111(3):209-219. 
 110.  Hermoye L, Saint-Martin C, Cosnard G et al. Pediatric diffusion tensor imaging: 
normal database and observation of the white matter maturation in early 
childhood. Neuroimage 2006; 29(2):493-504. 
 111.  Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di CG. Diffusion tensor MR 
imaging of the human brain. Radiology 1996; 201(3):637-648. 
 112.  Beaulieu C. The basis of anisotropic water diffusion in the nervous system - a 
technical review. NMR Biomed 2002; 15(7-8):435-455. 
 113.  Schmithorst VJ, Wilke M, Dardzinski BJ, Holland SK. Cognitive functions 
correlate with white matter architecture in a normal pediatric population: a 
diffusion tensor MRI study. Hum Brain Mapp 2005; 26(2):139-147. 
 114.  Lim KO, Helpern JA. Neuropsychiatric applications of. NMR Biomed 2002; 
15(7-8):587-593. 
 115.  Horsfield MA, Jones DK. Applications of diffusion-weighted and diffusion 
tensor MRI to white matter diseases - a review. NMR Biomed 2002; 15(7-
8):570-577. 
 116.  Le BD. Looking into the functional architecture of the brain with diffusion MRI. 
Nat Rev Neurosci 2003; 4(6):469-480. 
 117.  Roosendaal SD, Geurts JJ, Vrenken H et al. Regional DTI differences in 
multiple sclerosis patients. Neuroimage 2009; 44(4):1397-1403. 
 118.  Sundaram SK, Kumar A, Makki MI, Behen ME, Chugani HT, Chugani DC. 
Diffusion tensor imaging of frontal lobe in autism spectrum disorder. Cereb 
Cortex 2008; 18(11):2659-2665. 
 119.  Kumar A, Sundaram SK, Sivaswamy L et al. Alterations in Frontal Lobe Tracts 
and Corpus Callosum in Young Children with Autism Spectrum Disorder. Cereb 
Cortex 2009. 
 120.  Clayden JD, Storkey AJ, Munoz MS, Bastin ME. Reproducibility of tract 
segmentation between sessions using an unsupervised modelling-based 
approach. Neuroimage 2009; 45(2):377-385. 
 121.  Smith SM, Jenkinson M, Johansen-Berg H et al. Tract-based spatial statistics: 
voxelwise analysis of multi-subject diffusion data. Neuroimage 2006; 
31(4):1487-1505. 
 122.  Wahl M, Barkovich AJ, Mukherjee P. Diffusion imaging and tractography of 
congenital brain malformations. Pediatr Radiol 2009. 
186 
 
 123.  Wright IC, McGuire PK, Poline JB et al. A voxel-based method for the 
statistical analysis of gray and white matter density applied to schizophrenia. 
Neuroimage 1995; 2(4):244-252. 
 124.  Glascher J, Tranel D, Paul LK et al. Lesion mapping of cognitive abilities linked 
to intelligence. Neuron 2009; 61(5):681-691. 
 125.  Makris N, Biederman J, Valera EM et al. Cortical thinning of the attention and 
executive function networks in adults with attention-deficit/hyperactivity 
disorder. Cereb Cortex 2007; 17(6):1364-1375. 
 126.  Makris N, Biederman J, Monuteaux MC, Seidman LJ. Towards conceptualizing 
a neural systems-based anatomy of attention-deficit/hyperactivity disorder. Dev 
Neurosci 2009; 31(1-2):36-49. 
 127.  Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood 
blindness. J AAPOS 1999; 3(1):26-32. 
 128.  Patel L, McNally RJ, Harrison E, Lloyd IC, Clayton PE. Geographical 
distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest 
England. J Pediatr 2006; 148(1):85-88. 
 129.  Kelberman D, Dattani MT. Genetics of septo-optic dysplasia. Pituitary 2007; 
10(4):393-407. 
 130.  Webb EA, Dattani MT. Septo-optic dysplasia. Eur J Hum Genet 2010; 
18(4):393-397. 
 131.  Garcia-Filion P, Epport K, Nelson M et al. Neuroradiographic, endocrinologic, 
and ophthalmic correlates of adverse developmental outcomes in children with 
optic nerve hypoplasia: a prospective study. Pediatrics 2008; 121(3):e653-e659. 
 132.  Margalith D, Jan JE, McCormick AQ, Tze WJ, Lapointe J. Clinical spectrum of 
congenital optic nerve hypoplasia: review of 51 patients. Dev Med Child Neurol 
1984; 26(3):311-322. 
 133.  Parr JR, Dale NJ, Shaffer LM, Salt AT. Social communication difficulties and 
autism spectrum disorder in young children with optic nerve hypoplasia and/or 
septo-optic dysplasia. Dev Med Child Neurol 2010; 52(10):917-921. 
 134.  Sonksen PM, Dale N. Visual impairment in infancy: impact on 
neurodevelopmental and neurobiological processes. Dev Med Child Neurol 
2002; 44(11):782-791. 
 135.  Tirosh E, Shnitzer MR, Davidovitch M, Cohen A. Behavioural problems among 
visually impaired between 6 months and 5 years. Int J Rehabil Res 1998; 
21(1):63-69. 
 136.  Jan JE, Freeman RD, Scott EP. Visual impairment in children and adolescents. 
New York: Grune & Stratton, 1977. 
187 
 
 137.  Hinshaw SP. Externalizing behavior problems and academic underachievement 
in childhood and adolescence: causal relationships and underlying mechanisms. 
Psychol Bull 1992; 111(1):127-155. 
 138.  Achenbach TM, Edelbrock CS. The classification of child psychopathology: a 
review and analysis of empirical efforts. Psychol Bull 1978; 85(6):1275-1301. 
 139.  Achenbach TM, Edelbrock CS. The Child Behavior Profile: II. Boys aged 12-16 
and girls aged 6-11 and 12-16. J Consult Clin Psychol 1979; 47(2):223-233. 
 140.  McGee R, Williams S, Share DL, Anderson J, Silva PA. The relationship 
between specific reading retardation, general reading backwardness and 
behavioural problems in a large sample of Dunedin boys: a longitudinal study 
from five to eleven years. J Child Psychol Psychiatry 1986; 27(5):597-610. 
 141.  Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost 
grown up. I. Psychiatric status. Arch Gen Psychiatry 1985; 42(10):937-947. 
 142.  Mann VA, Brady S. Reading disability: the role of language deficiencies. J 
Consult Clin Psychol 1988; 56(6):811-816. 
 143.  Schoth F, Krings T. Diffusion-tensor imaging in septo-optic dysplasia. 
Neuroradiology 2004; 46(9):759-763. 
 144.  Salmela MB, Cauley KA, Nickerson JP, Koski CJ, Filippi CG. Magnetic 
resonance diffusion tensor imaging (MRDTI) and tractography in children with 
septo-optic dysplasia. Pediatr Radiol 2009. 
 145.  Tadic V, Pring L, Dale N. Are language and social communication intact in 
children with congenital visual impairment at school age? J Child Psychol 
Psychiatry 2010; 51(6):696-705. 
 146.  Hobson RP, Lee A, Brown R. Autism and congenital blindness. J Autism Dev 
Disord 1999; 29(1):45-56. 
 147.  Ek U, Fernell E, Jacobson L. Cognitive and behavioural characteristics in blind 
children with bilateral optic nerve hypoplasia. Acta Paediatr 2005; 94(10):1421-
1426. 
 148.  Nakata Y, Barkovich AJ, Wahl M et al. Diffusion abnormalities and reduced 
volume of the ventral cingulum bundle in agenesis of the corpus callosum: a 3T 
imaging study. AJNR Am J Neuroradiol 2009; 30(6):1142-1148. 
 149.  Fahnehjelm KT, Jacobson L, Hellstrom A, Lewensohn-Fuchs I, Ygge J. Visually 
impaired children with posterior ocular malformations: pre- and neonatal data 
and visual functions. Acta Ophthalmol Scand 2003; 81(4):361-372. 
 150.  Garcia ML, Ty EB, Taban M, David RA, Rogers D, Traboulsi EI. Systemic and 
ocular findings in 100 patients with optic nerve hypoplasia. J Child Neurol 2006; 
21(11):949-956. 
188 
 
 151.  Pittendrigh CS. Temporal organization: reflections of a Darwinian clock-
watcher. Annu Rev Physiol 1993; 55:16-54. 
 152.  Jan JE, Freeman RD, Fast DK. Melatonin treatment of sleep-wake cycle 
disorders in children and adolescents. Dev Med Child Neurol 1999; 41(7):491-
500. 
 153.  Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin 
deficiency and dysfunction. ScientificWorldJournal 2012; 2012:640389. 
 154.  Zisapel N. The use of melatonin for the treatment of insomnia. Biol Signals 
Recept 1999; 8(1-2):84-89. 
 155.  Hida A, Kitamura S, Mishima K. Pathophysiology and pathogenesis of circadian 
rhythm sleep disorders. J Physiol Anthropol 2012; 31(1):7. 
 156.  Rivkees SA. Rest-activity patterns in children with hypopituitarism. Pediatrics 
2003; 111(6 Pt 1):e720-e724. 
 157.  Rivkees SA, Fink C, Nelson M, Borchert M. Prevalence and risk factors for 
disrupted circadian rhythmicity in children with optic nerve hypoplasia. Br J 
Ophthalmol 2010; 94(10):1358-1362. 
 158.  Smith C. Sleep states and memory processes. Behav Brain Res 1995; 69(1-
2):137-145. 
 159.  Skene DJ, Arendt J. Circadian rhythm sleep disorders in the blind and their 
treatment with melatonin. Sleep Med 2007; 8(6):651-655. 
 160.  Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 
2002; 418(6901):935-941. 
 161.  Isobe Y, Nishino H. Signal transmission from the suprachiasmatic nucleus to the 
pineal gland via the paraventricular nucleus: analysed from arg-vasopressin 
peptide, rPer2 mRNA and AVP mRNA changes and pineal AA-NAT mRNA 
after the melatonin injection during light and dark periods. Brain Res 2004; 
1013(2):204-211. 
 162.  Arendt J, Van Someren EJ, Appleton R, Skene DJ, Akerstedt T. Clinical update: 
melatonin and sleep disorders. Clin Med 2008; 8(4):381-383. 
 163.  Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled 
children. Lancet 1998; 351(9111):1254. 
 164.  Forsling ML, Wheeler MJ, Williams AJ. The effect of melatonin administration 
on pituitary hormone secretion in man. Clin Endocrinol (Oxf) 1999; 51(5):637-
642. 
 165.  Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of 
melatonin. Sleep Med Rev 2005; 9(1):11-24. 
189 
 
 166.  Dattani MT. Growth hormone deficiency and combined pituitary hormone 
deficiency: does the genotype matter? Clinical Endocrinology 2005; 63(2):121-
130. 
 167.  Andersen B, Rosenfeld MG. POU domain factors in the neuroendocrine system: 
lessons from developmental biology provide insights into human disease. 
Endocr Rev 2001; 22(1):2-35. 
 168.  Snell GD. DWARF, A NEW MENDELIAN RECESSIVE CHARACTER OF 
THE HOUSE MOUSE. Proc Natl Acad Sci U S A 1929; 15(9):733-734. 
 169.  Dasen JS, Rosenfeld MG. Signaling and transcriptional mechanisms in pituitary 
development. Annu Rev Neurosci 2001; 24:327-355. 
 170.  Cohen LE, Radovick S. Molecular basis of combined pituitary hormone 
deficiencies. Endocr Rev 2002; 23(4):431-442. 
 171.  Dattani MT. The candidate gene approach to the diagnosis of monogenic 
disorders. Horm Res 2009; 71 Suppl 2:14-21. 
 172.  OPCS Standard Occupational Classification Volume 3. London: HMSO.: 1991. 
 173.  Cole TJ. The LMS method for constructing normalized growth standards. Eur J 
Clin Nutr 1990; 44(1):45-60. 
 174.  Edmonds CJ, Isaacs EB, Cole TJ et al. The effect of intrauterine growth on 
verbal IQ scores in childhood: a study of monozygotic twins. Pediatrics 2010; 
126(5):e1095-e1101. 
 175.  Tanner JM, Whitehouse RH, Marshall WA, Healy MJR, Coldstein H. 
Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method). 
2nd edition ed. London: Academic Press, 1983. 
 176.  Tanner JM. Growth and maturation during adolescence. Nutr Rev 1981; 
39(2):43-55. 
 177.  Mehta A, Hindmarsh PC, Dattani MT. An update on the biochemical diagnosis 
of congenital ACTH insufficiency. Clin Endocrinol (Oxf) 2005; 62(3):307-314. 
 178.  Fischl B, Salat DH, van der Kouwe AJ et al. Sequence-independent 
segmentation of magnetic resonance images. Neuroimage 2004; 23 Suppl 1:S69-
S84. 
 179.  Bondy CA, Lee WH. Patterns of insulin-like growth factor and IGF receptor 
gene expression in the brain. Functional implications. Ann N Y Acad Sci 1993; 
692:33-43. 
 180.  Caeyenberghs K, Leemans A, Geurts M et al. Brain-behavior relationships in 
young traumatic brain injury patients: DTI metrics are highly correlated with 
postural control. Hum Brain Mapp 2010; 31(7):992-1002. 
190 
 
 181.  Lindenberg R, Renga V, Zhu LL, Betzler F, Alsop D, Schlaug G. Structural 
integrity of corticospinal motor fibers predicts motor impairment in chronic 
stroke. Neurology 2010; 74(4):280-287. 
 182.  Draganski B, Bhatia KP. Brain structure in movement disorders: a neuroimaging 
perspective. Curr Opin Neurol 2010; 23(4):413-419. 
 183.  Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false 
discovery rate in behavior genetics research. Behav Brain Res 2001; 125(1-
2):279-284. 
 184.  Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage 
2000; 11(6 Pt 1):805-821. 
 185.  Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 
2007; 38(1):95-113. 
 186.  Isaacs EB, Edmonds CJ, Chong WK, Lucas A, Morley R, Gadian DG. Brain 
morphometry and IQ measurements in preterm children. Brain 2004; 127(Pt 
12):2595-2607. 
 187.  Smith SM, Jenkinson M, Woolrich MW et al. Advances in functional and 
structural MR image analysis and implementation as FSL. Neuroimage 2004; 23 
Suppl 1:S208-S219. 
 188.  Hua K, Zhang J, Wakana S et al. Tract probability maps in stereotaxic spaces: 
analyses of white matter anatomy and tract-specific quantification. Neuroimage 
2008; 39(1):336-347. 
 189.  Kushida CA, Chang A, Gadkary C, Guilleminault C, Carrillo O, Dement WC. 
Comparison of actigraphic, polysomnographic, and subjective assessment of 
sleep parameters in sleep-disordered patients. Sleep Med 2001; 2(5):389-396. 
 190.  Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The 
role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003; 
26(3):342-392. 
 191.  Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. 
Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 
86(10):4727-4730. 
 192.  Waldhauser F, Weiszenbacher G, Tatzer E et al. Alterations in nocturnal serum 
melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 
1988; 66(3):648-652. 
 193.  Achenbach T.M., Rescorla L.A. Manual for the ASEBA School-age Forms & 
Profiles. Research Center for Children, Youth, & Families, Burlington, VT, 
2001. 
 194.  Wechsler D. Wechsler Intelligence Scale for Children. [3rd edn]. 1992. London, 
Psychological Corporation.  
Ref Type: Generic 
191 
 
 195.  Henderson SE, Sugden DA. Movement Assessment Battery for Children: 
Manual. London: The Psychological Corporation, 1992. 
 196.  Geuze RH, Jongmans M, Schoemaker M, Smits-Engelsman B. Developmental 
coordination disorder. Hum Mov Sci 2001; 20(1-2):1-5. 
 197.  Korkman M, Kirk U, Kemp S. NEPSY: A developmental Neuropsycholigical 
assessment. San Antonio: The Psychological Corporation, 1998. 
 198.  Luciana M, Nelson CA. Assessment of neuropsychological function through use 
of the Cambridge Neuropsychological Testing Automated Battery: performance 
in 4- to 12-year-old children. Dev Neuropsychol 2002; 22(3):595-624. 
 199.  Wechsler D. Wechsler Intelligence Scale for Children. London: Psychological 
Corporation, 2004. 
 200.  Wechsler D. The Wechsler Preschool and Primary Scale of Intelligence. Third 
UK Edition ed. London: 2003. 
 201.  Reynell J. Manual for the Reynell-Zinkin Scales. London: NFER, 1979. 
 202.  Bacharach VR, Baumeister AA. Effects of maternal intelligence, marital status, 
income, and home environment on cognitive development of low birthweight 
infants. J Pediatr Psychol 1998; 23(3):197-205. 
 203.  Kelberman D, Rizzoti K, Avilion A et al. Mutations within Sox2/SOX2 are 
associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice 
and humans. J Clin Invest 2006; 116(9):2442-2455. 
 204.  Salvatori R, Hayashida CY, Aguiar-Oliveira MH et al. Familial dwarfism due to 
a novel mutation of the growth hormone-releasing hormone receptor gene. J 
Clin Endocrinol Metab 1999; 84(3):917-923. 
 205.  Salvatori R, Fan X, Mullis PE, Haile A, Levine MA. Decreased expression of 
the GHRH receptor gene due to a mutation in a Pit-1 binding site. Mol 
Endocrinol 2002; 16(3):450-458. 
 206.  Thomas PQ, Dattani MT, Brickman JM et al. Heterozygous HESX1 mutations 
associated with isolated congenital pituitary hypoplasia and septo-optic 
dysplasia. Hum Mol Genet 2001; 10(1):39-45. 
 207.  Turton JP, Reynaud R, Mehta A et al. Novel mutations within the POU1F1 gene 
associated with variable combined pituitary hormone deficiency. J Clin 
Endocrinol Metab 2005; 90(8):4762-4770. 
 208.  Woods KS, Cundall M, Turton J et al. Over- and underdosage of SOX3 is 
associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 
2005; 76(5):833-849. 
 209.  Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth 
factor system and its pleiotropic functions in brain. Endocr Rev 2005; 
26(7):916-943. 
192 
 
 210.  Gluckman P, Klempt N, Guan J et al. A role for IGF-1 in the rescue of CNS 
neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun 
1992; 182(2):593-599. 
 211.  Stabler B, Clopper RR, Siegel PT, Stoppani C, Compton PG, Underwood LE. 
Academic achievement and psychological adjustment in short children. The 
National Cooperative Growth Study. J Dev Behav Pediatr 1994; 15(1):1-6. 
 212.  Kadotani H, Hirano T, Masugi M et al. Motor discoordination results from 
combined gene disruption of the NMDA receptor NR2A and NR2C subunits, 
but not from single disruption of the NR2A or NR2C subunit. J Neurosci 1996; 
16(24):7859-7867. 
 213.  Kontis D, Catani M, Cuddy M et al. Diffusion tensor MRI of the corpus 
callosum and cognitive function in adults born preterm. Neuroreport 2009; 
20(4):424-428. 
 214.  Nilsson L, Sara VR, Nordberg A. Insulin-like growth factor 1 stimulates the 
release of acetylcholine from rat cortical slices. Neurosci Lett 1988; 88(2):221-
226. 
 215.  Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in 
the brain. Front Aging Neurosci 2010; 2:12. 
 216.  Kodl CT, Franc DT, Rao JP et al. Diffusion tensor imaging identifies deficits in 
white matter microstructure in subjects with type 1 diabetes that correlate with 
reduced neurocognitive function. Diabetes 2008; 57(11):3083-3089. 
 217.  Sonntag WE, Bennett C, Ingram R et al. Growth hormone and IGF-I modulate 
local cerebral glucose utilization and ATP levels in a model of adult-onset 
growth hormone deficiency. Am J Physiol Endocrinol Metab 2006; 
291(3):E604-E610. 
 218.  Fahn S. Biochemistry of the basal ganglia. Adv Neurol 1976; 14:59-89. 
 219.  Ozdinler PH, Macklis JD. IGF-I specifically enhances axon outgrowth of 
corticospinal motor neurons. Nat Neurosci 2006; 9(11):1371-1381. 
 220.  Bernal J, Nunez J. Thyroid hormones and brain development. Eur J Endocrinol 
1995; 133(4):390-398. 
 221.  Rosman NP, Malone MJ, Helfenstein M, Kraft E. The effect of thyroid 
deficiency on myelination of brain. A morphological and biochemical study. 
Neurology 1972; 22(1):99-106. 
 222.  World Health Organisation. The ICD classification of mental and behavioural 
disorders: Clinical descriptions and diagnostic guidelines. Geneva, Switzerland: 
World Health Organisation, 1992. 
 223.  Fischl B, Salat DH, Busa E et al. Whole brain segmentation: automated labeling 
of neuroanatomical structures in the human brain. Neuron 2002; 33(3):341-355. 
193 
 
 224.  Han X, Fischl B. Atlas renormalization for improved brain MR image 
segmentation across scanner platforms. IEEE Trans Med Imaging 2007; 
26(4):479-486. 
 225.  Reynell J, Zinkin PM. New procedures for developmental assessment of young 
children with severe visual handicaps. Child: Care, Health and Development 
1975; 1:61-69. 
 226.  Abdul-Rahman MF, Qiu A, Sim K. Regionally specific white matter disruptions 
of fornix and cingulum in schizophrenia. PLoS One 2011; 6(4):e18652. 
 227.  Cannistraro PA, Makris N, Howard JD et al. A diffusion tensor imaging study of 
white matter in obsessive-compulsive disorder. Depress Anxiety 2007; 
24(6):440-446. 
 228.  Fontenelle LF, Harrison BJ, Yucel M, Pujol J, Fujiwara H, Pantelis C. Is there 
evidence of brain white-matter abnormalities in obsessive-compulsive disorder?: 
a narrative review. Top Magn Reson Imaging 2009; 20(5):291-298. 
 229.  Althoff RR, Ayer LA, Rettew DC, Hudziak JJ. Assessment of dysregulated 
children using the Child Behavior Checklist: a receiver operating characteristic 
curve analysis. Psychol Assess 2010; 22(3):609-617. 
 230.  Alexander AL, Lee JE, Lazar M et al. Diffusion tensor imaging of the corpus 
callosum in Autism. Neuroimage 2007; 34(1):61-73. 
 231.  Barnea-Goraly N, Kwon H, Menon V, Eliez S, Lotspeich L, Reiss AL. White 
matter structure in autism: preliminary evidence from diffusion tensor imaging. 
Biol Psychiatry 2004; 55(3):323-326. 
 232.  Anjari M, Srinivasan L, Allsop JM et al. Diffusion tensor imaging with tract-
based spatial statistics reveals local white matter abnormalities in preterm 
infants. Neuroimage 2007; 35(3):1021-1027. 
 233.  Koester SE, O'Leary DD. Axons of early generated neurons in cingulate cortex 
pioneer the corpus callosum. J Neurosci 1994; 14(11 Pt 1):6608-6620. 
 234.  Rash BG, Richards LJ. A role for cingulate pioneering axons in the development 
of the corpus callosum. J Comp Neurol 2001; 434(2):147-157. 
 235.  Wang F, Jackowski M, Kalmar JH et al. Abnormal anterior cingulum integrity in 
bipolar disorder determined through diffusion tensor imaging. Br J Psychiatry 
2008; 193(2):126-129. 
 236.  Carper RA, Courchesne E. Inverse correlation between frontal lobe and 
cerebellum sizes in children with autism. Brain 2000; 123 ( Pt 4):836-844. 
 237.  Herbert MR, Ziegler DA, Makris N et al. Localization of white matter volume 
increase in autism and developmental language disorder. Ann Neurol 2004; 
55(4):530-540. 
194 
 
 238.  Luna B, Minshew NJ, Garver KE et al. Neocortical system abnormalities in 
autism: an fMRI study of spatial working memory. Neurology 2002; 59(6):834-
840. 
 239.  Chandana SR, Behen ME, Juhasz C et al. Significance of abnormalities in 
developmental trajectory and asymmetry of cortical serotonin synthesis in 
autism. Int J Dev Neurosci 2005; 23(2-3):171-182. 
 240.  Chugani DC, Muzik O, Behen M et al. Developmental changes in brain 
serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 
1999; 45(3):287-295. 
 241.  Yakovlev PI, Lecours A. The myelogenetic cycles of regional maturation of the 
brain. In: Minkowski A, editor. Regional development of the brain in early life. 
Blackwell: Oxford, 1967: 3-70. 
 242.  Iglowstein I, Jenni OG, Molinari L, Largo RH. Sleep duration from infancy to 
adolescence: reference values and generational trends. Pediatrics 2003; 
111(2):302-307. 
 243.  Melke J, Goubran BH, Chaste P et al. Abnormal melatonin synthesis in autism 
spectrum disorders. Mol Psychiatry 2008; 13(1):90-98. 
 244.  Arendt J, Bojkowski C, Folkard S et al. Some effects of melatonin and the 
control of its secretion in humans. Ciba Found Symp 1985; 117:266-283. 
 245.  Arendt J. Melatonin and the Mammalian Pineal Gland. London: 1994. 
 246.  Haddad NG, Eugster EA. Hypopituitarism and neurodevelopmental 
abnormalities in relation to central nervous system structural defects in children 
with optic nerve hypoplasia. J Pediatr Endocrinol Metab 2005; 18(9):853-858. 
 247.  Phillips L, Appleton RE. Systematic review of melatonin treatment in children 
with neurodevelopmental disabilities and sleep impairment. Dev Med Child 
Neurol 2004; 46(11):771-775. 
 248.  Webb EA, Mehta A, Dattani MT. Can the phenotype of septo-optic dysplasia at 
presentation be used to predict the severity of associated hormonal 
abnormalities, developmental delay, obesity, sleep and behavioural disorders? 
Horm.Res.  2009.  
Ref Type: Abstract 
 249.  Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin 
in man following oral absorption of different preparations. Br J Clin Pharmacol 
1985; 19(4):517-521. 
 250.  Stabler B, Clopper RR, Siegel PT et al. Links between growth hormone 
deficiency, adaptation and social phobia. Horm Res 1996; 45(1-2):30-33. 
 251.  Edouard T, Grunenwald S, Gennero I, Salles JP, Tauber M. Prevalence of IGF1 
deficiency in prepubertal children with isolated short stature. Eur J Endocrinol 
2009; 161(1):43-50. 
195 
 
 252.  Goddard AD, Covello R, Luoh SM et al. Mutations of the growth hormone 
receptor in children with idiopathic short stature. The Growth Hormone 
Insensitivity Study Group. N Engl J Med 1995; 333(17):1093-1098. 
 253.  van Dam PS, de Winter CF, de VR et al. Childhood-onset growth hormone 
deficiency, cognitive function and brain N-acetylaspartate. 
Psychoneuroendocrinology 2005; 30(4):357-363. 
 254.  Rivkees SA. Arrhythmicity in a child with septo-optic dysplasia and 
establishment of sleep-wake cyclicity with melatonin. J Pediatr 2001; 
139(3):463-465. 
 255.  Gringras P. When to use drugs to help sleep. Arch Dis Child 2008; 93(11):976-
981. 
 256.  Smedje H, Broman JE, Hetta J. Associations between disturbed sleep and 
behavioural difficulties in 635 children aged six to eight years: a study based on 
parents' perceptions. Eur Child Adolesc Psychiatry 2001; 10(1):1-9. 
 
 
196 
 
8.  APPENDICES 
A. Examples of Information Sheets 
The Wider Effects of Growth Hormone 
Information to answer your questions  
(Children with IGHD) 
 
You are invited to take part in a research 
study. The study will look at some of the 
genes in your body that are important for 
making you grow and for allowing you to be 
active. Before you decide to say YES or 
NO, it is important for you to know why the research is being 
done and what it will involve. Please read, or have someone to 
read for you, this fact sheet. Do not worry if you do not 
understand it straight away. Your parents have also been told 
about this, and you can ask them to help you understand. Ask 
us if there is anything that is not clear or if you would like 
more information.  
 
Introduction 
A special part of the brain makes a number of chemicals 
called hormones that help you to grow. In some children who 
do not grow well, the brain cannot make these hormones. 
These children would need to be given the hormones that are 
not there. We know that the way your body changes and 
grows depends on the genetic material (called DNA, which is 
made up of thousands of genes) that you inherit from your 
parents. Changes within genes are the reason why we are all 
very different to each other. Normally, you have two copies 
of a gene, one that comes to you from your father and one 
197 
 
that comes to you from your mother. Sometimes a change 
within a gene that you get from your parents can lead to a 
medical condition. 
 
Sometimes, when these hormones are missing, the way in 
which people behave and learn things are different.  
 
We want to understand how the medicine changes the way 
children with these missing hormones learn 
 
Why are you asking for my help? 
We want to know why you have to take medicine, and why you 
have been ill in the past. We want to look at your genetic 
material (called DNA) for changes. We want to understand 
how giving you medicine changes the way in which you learn. 
These studies will help us understand why children have these 
particular conditions and how they can be helped best. 
 
We ask all children who have a condition like yours to take 
part. 
 
What will happen to me if I take part? 
A few extra samples of blood will be taken from you after 
putting on a special cream to stop the blood test from 
hurting.   
 
We will ask you some questions about how 
you sleep. We will ask you and your mum and 
dad these questions before you start 
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taking your medicine. We will also ask your teacher about your 
school work (if you don’t mind). We will ask you to wear a 
small watch for 2 weeks to see how well you sleep. 
 
We would like to see how you learn new things, use words and 
play. All the tests that we would like to use are like games and 
are made for children so we think that you will have fun 
taking part. But, if you get tired, we will take a break or stop.  
 
Your doctors have decided that they want to take some 
special pictures of you. They are going to use a special 
machine called an MRI scanner. This machine can take 
pictures of the inside of you almost like an X-ray camera. 
When you are already in the MRI scanner, having all your 
pictures taken, we will take some extra pictures. Normally, all 
the pictures can be taken in about half an hour. If you let us 
take extra pictures, the whole scan will last about 10 minutes 
more.  
 
The doctors or nurses will tell you what is going to happen. 
You will have to lie quite still when you are being scanned. The 
machine is also rather noisy, so you will have some headphones 
on. If you want to, you can watch a video whilst you are having 
your pictures taken.  
 
Is it dangerous? 
No, all of these tests are safe. MRI scanning is very safe. We 
take pictures of children every day with the MRI scanner. 
 
What about my results? 
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The doctors looking after you will talk to you and your 
parents about the results of these tests. We hope that these 
tests will help us to look after both you and other children 
with similar conditions better now and in the future. 
 
Do I have to take part? 
No. It is up to you and your parents to decide. If you decide 
you don’t want to, then that’s fine. The doctors and nurses 
will look after you as best as they can anyway. 
 
Who will get to see this information about me? 
The doctors looking after you will be able to see your test 
results. We will look at all the results and may print the 
results in a magazine so that other people can learn what we 
have learned. Your name will be taken off, so that nobody 
knows whose results they are. 
 
Who can I speak to if I have any questions? 
You can speak to your parents who have also been given facts 
to read about this study. You can also speak to the doctors or 
nurses who look after you in the hospital.  
 
Emma Webb  
Phone: 0787 2021356  
Email: emmaalicewebb@yahoo.com 
Dr Michelle O’Reilly 
Phone: 07947 663371 
Email: m.oreilly@ich.ucl.ac.uk 
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The Wider Effects of Growth Hormone 
Information to answer your questions 
(IGHD parent Information Leaflet) 
 
Your child is being invited to take part in a research study. This 
study is being carried out by Dr Emma Webb and Dr Michelle 
O'Reilly with the assistance of Prof. Mehul Dattani, Dr Naomi 
Dale and Dr Alison Salt at Great Ormond Street Hospital. 
Before you consider being involved, we want to make sure you 
know why we are doing this research so please read the following 
information carefully and discuss it with other people if it helps. 
You can call, email or write to us if anything is not clear or if you 
have more questions. Take time to decide whether or not you 
wish to take part. Thank you for reading this.  
 
Introduction 
The pituitary 
gland in the brain 
makes a number 
of chemicals 
called hormones 
that help you 
grow and develop 
normally. In some 
children who do 
not grow well, the 
pituitary gland 
may not make growth hormone (GH) and/or other hormones. The 
gland may be very small or even absent. These children would 
need to be treated with the hormones that are missing. 
Occasionally, the small pituitary gland may be associated with 
abnormalities affecting the eyes and the brain; this is called 
septo-optic dysplasia or SOD.  
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We now know that the way your body changes and grows depends 
on the genetic material (called DNA, which is made up of 
thousands of genes) that you inherit from your parents. Changes 
within genes are the reason why we are all very different to 
each other. Normally, you have two copies of a gene, one that 
comes to you from your father and one that comes to you from 
your mother. Sometimes a change within a gene that you get 
from your parents can lead to a medical condition. So far, we 
only know some of the genes that are important for pituitary 
development. 
 
We have noticed that children who do not make enough GH are 
more likely to have abnormal behaviour and to be slow with their 
development. We know that treatment with GH makes you grow 
taller and it has been suggested that treatment may also 
improve behaviour. 
 
What is the purpose of the study? 
In this study, we aim to study the genes controlling the 
development of the brain and pituitary gland. We have recently 
found that changes in 3 genes are associated with a small 
pituitary gland and a lack of growth hormone (GH) in some of our 
patients. We now want to look at children with these conditions 
in more detail and to examine their DNA for abnormalities in 
these and other genes that are important for the normal 
development of the brain. We hope that this will help us to 
understand why children suffer from these particular 
conditions. 
 
We’re also interested in the effect of GH treatment on brain 
structure (using MRI). We hope that this research will help us 
gain better understanding of the strengths and weaknesses that 
children with GH deficiency may have and make us think of the 
ways that parents and professionals may help if specific 
difficulties arise. 
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How is the study being done? (Summary attached) 
All of the tests outlined below will be arranged around your 
routine visits to the hospital to minimise any disruption the 
study may have on your child and your family. 
 
1. Blood tests  
 
The blood test/cannula insertion will be performed by a member 
of the Paediatric Endocrinology team at Great Ormond Street 
Children’s Hospital during one of your routine visits to the 
hospital. We need to take a small blood sample (2 teaspoonfuls) 
from your child for the genetic) tests. To minimise discomfort, 
we will perform the blood test using local anaesthetic cream.  
 
Only a single sample of blood is required for the genetic study. 
If a change (mutation) is found within one of the genes that are 
important for pituitary development, then further blood samples 
may be required from your child and the rest of your family. 
However, the requirement for these samples will be discussed in 
detail with you and your family. 
 
2. Questionnaires 
 
We will ask you some questions about your child (including date 
of birth, medical problems, birth history) the first time we see 
you. This will take about half an hour. We will 
ask you to keep a diary recording your child’s 
sleep pattern for a 2week period whilst they 
wear a small comfortable watch which records 
how well they sleep before starting treatment 
with GH. 
 
3. Developmental Assessment 
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We are interested to see how your child is learning about their 
world, uses language, interacts with other people, and responds 
in social situations like story-time.  To understand this we would 
assess your child’s language, cognitive and social development 
using a selection of tests. These will be carried out by a team 
with a special interest in the development of children with and 
without visual impairment. For this we will arrange for you to 
come with your child to the Developmental Clinic on the same day 
as your endocrine clinic visit or we can arrange a home, nursery 
or school visit if this is more convenient for you. All the tests 
that we would like to use in this research are game-like and 
designed especially for children so we anticipate that most 
children will have fun taking part. However, if your child gets 
tired we will take a break or stop altogether. We will ask your 
child’s school teacher how they are doing in school (if you and 
your child are happy for us to contact them). This will provide a 
clear picture outlining the developmental progress and any 
developmental delay/behavioural problems present in your child.  
 
4. MRI Scan 
 
We also want to add 10mins extra pictures onto your child’s 
routine magnetic resonance imaging (MRI) scan to get a better 
picture of the overall brain structure and the volumes of the 
different areas of the brain that may be important in GH 
deficiency. MRI does not involve ionising radiation, unlike 
computed tomography (CT) or x-rays, and is therefore a good 
and safe imaging investigation to use in children.  
 
It is very important to keep very still throughout any MRI scan 
as otherwise, the pictures become blurred and of no use, so it is 
routine clinical practice to use sedation or general anaesthesia in 
young children during a scan. Sometimes the scans can be done in 
babies if they are asleep and wrapped so that they do not move. 
Usually however sedation or general anaesthesia is used as the 
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scanner is noisy, and the scan can last up to 40 minutes. Your 
doctor will talk to you about whether your child will be sedated 
or given general anaesthetic for his/her scan and will get 
separate consent from you for this. This is routine clinical 
practice and is not a consequence of our project. The choice 
between non-sedation, sedation, or general anaesthesia will not 
be altered whether or not your child participates in the project. 
MRI is a well established investigation at Great Ormond Street 
Hospital for Children and is performed under sedation or 
anaesthesia on several children every day. 
 
We will also collect additional images during scanning to look at 
the white matter pathways connecting different parts of the 
brain – this is known as diffusion tensor imaging or DTI.  
 
During the scan, we will need to inject a small volume of contrast 
fluid (dye) intravenously. This too is routine practice, 
independent of project participation, and is regarded as a very 
safe procedure. Our project involves taking extra pictures while 
your child has his/her MRI scan. This means that the scan will 
take 10 minutes longer than a routine scan. 
 
 
What are the risks and discomfort? 
No risk to the child can be foreseen. There is discomfort from a 
single needle prick for blood testing, but this will be minimised 
by using local anaesthetic cream. MRI uses electromagnetic 
pulses to produce images of organs and tissues. It is used 
routinely in all age groups, and there are no identified side 
effects. Compared to a normal scan, the scan time in the project 
will be longer, and we will apply more electromagnetic pulses. 
However, we will always operate within the limitations that are 
set for clinical use of MRI. If your child is sedated or under 
general anaesthetic, this will not have any effect on their level 
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of discomfort. If they are awake, then it will mean they may 
have to keep still for a little longer. 
 
What are the potential benefits? 
This study may help us to understand why your child has 
developed their problems. Additionally, we may be able to make 
the diagnosis earlier in future children who may have the 
condition, and where one child in the family already has the 
disorder, we may be able to make a diagnosis before birth in 
future pregnancies. An improved understanding of these 
conditions will help us to find the best ways of making the 
diagnosis i.e. using the best tests available so that the diagnosis 
can be made with minimal discomfort to the child. Some of these 
genes are associated with a changing (evolving) picture, with 
more hormonal abnormalities appearing with time. If that is the 
case, then we will be in a better position to anticipate these 
abnormalities once we have the genetic information and hence 
we will be able to diagnose the problem more rapidly. We hope 
that a better understanding of the role GH has on behaviour and 
brain structure will help us to guide the use of GH in children 
with these problems in the future.  
 
Who will get to see this information about my child? 
Only the researchers and a representative of the Research 
Ethics Committee will have access to the data collected during 
the study. We will tell people what we have learned in the study 
in reports and publications, but nobody will learn anything 
personal about your child, or any other child, by reading these 
reports or publications. The use of some types of personal 
information is safeguarded by the Data Protection Act 1998 
(DPA). The DPA places an obligation on those who record or use 
personal information, but also gives rights to people about whom 
information is held. If you have any questions about data 
protection, contact the Data Protection officer via the 
switchboard on 020 7405 9200 extension 5217. 
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Who has approved the study and who is funding it? 
The Child Growth Foundation is funding this study. The project 
has been approved by an independent research ethics committee 
who believe that it is of minimal risk to you. However, research 
can carry unforeseen risks and we want you to be informed of 
your rights in the unlikely event that any harm should occur as a 
result of taking part in this study. 
 
This research is covered by a compensation scheme, which may 
apply in the event of any significant harm resulting to your child 
from involvement in the study. Under this scheme, it would not 
be necessary for you to prove fault. You also have the right to 
claim damages in a court of law. This would require you to prove 
fault on the part of the Hospital/Institute and/or any 
manufacturer involved. 
 
If taking part in this study means that you have to make 
additional trips to hospital we will reimburse your travel costs. 
 
Does my child have to take part in this study? 
No. If you decide, now or at a later stage, that you do not wish 
to participate in this research project, that is entirely your 
right, and will not in any way prejudice any present or future 
treatment. 
 
Who do I speak to if problems arise? 
Please contact Dr Emma Webb or Dr Michelle O’Reilly directly 
with any problems relating to the study. If you have any 
complaints about the way in which this research project has 
been, or is being conducted, please, in the first instance, discuss 
them with the researchers. If the problems are not resolved, or 
you wish to comment in any other way, please contact the 
Principal Investigator, Professor Mehul Dattani by post at the 
Institute of Child Health, 30 Guilford Street, London WC1N 
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1EH, or if urgent, by telephone on 4059200, and the 
switchboard will put you in contact with him. 
 
Dr Emma Webb,  
Research fellow in Paediatric Endocrinology 
Clinical and Molecular Genetics Unit, Institute of Child Health, 
30 Guilford Street, London, WC1N 1EH. 
Telephone: 07872021356       
Email: emmaalicewebb@yahoo.com 
 
Dr Michelle O’Reilly, 
Research Associate, Neurosciences Unit, Institute of Child 
Health, the Wolfson Centre, Mecklenburgh Square, London 
WC1N 2AP. 
Telephone: 0794 7663371 
Email: m.oreilly@ich.ucl.ac.uk 
 
 
Thank you for your time and for considering taking part in 
this study!  
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GHD STUDY SCHEDULE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Developmental 
assessment (3 hrs): 
• Age	  appropriate	  
developmental	  
assessment	  to	  
assess	  verbal	  and	  
cognitive	  
development,	  
attention	  and	  
behaviour	  	  
• Parental	  
questionnaire	  	  
about	  behaviour	  
and	  development	  	  
Imaging (additional 
10 min): 
• Volumetric	  MRI	  
• DTI	  
	  
Questionnaire (30 min) 
• Basic	  information	  
Genetics (1 min): 
1 teaspoon blood 
sample 
Sleep assessment: 
• Actiwatch-­‐worn	  for	  2weeks	  
• 2week-­‐	  sleep	  diary	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The Wider Effects of Growth Hormone 
Information to answer your questions  
(Children with SOD) 
 
You are invited to take part in a study. 
Before you decide to say YES or NO, it 
is important for you to know why the 
study is being done and what it will 
involve. Please read, or have someone to 
read for you, this fact sheet. Do not 
worry if you do not understand it straight away. Your parents 
have also been told about this, and you can ask them to help 
you understand. Ask us if there is anything that is not clear 
or if you would like more information.  
 
What is the purpose of the study? 
A special part of the brain makes a number of chemicals 
called hormones that help you to grow. In some children who 
do not grow well, the brain cannot make these hormones. 
These children would need to be given the hormones that are 
not there.  
 
We know that the way your body changes and grows depends 
on the genetic material (called DNA, which is made up of 
thousands of genes) that you inherit from your parents. 
Changes within genes are the reason why we are all very 
different to each other.  
 
Normally, you have two copies of a gene, one that comes to 
you from your father and one that comes to you from your 
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mother. Sometimes a change within a gene that you get from 
your parents can lead to a medical condition. Sometimes, when 
these hormones are missing, the way in which people behave 
and learn things are different.  
 
We want to understand how in children that need medicine to 
help them to grow the medicine changes the way in which they 
learn.  
 
Why are we asking for your help? 
We want to know why you have to take medicine, and why you 
have been ill in the past. We want to look at your genetic 
material (called DNA) for changes. We want to understand 
how giving you medicine changes the way in which you learn, 
and changes your body shape. These studies will help us 
understand why children have these particular conditions and 
how they can be helped best. 
 
What will happen to me if I take part? 
A few extra samples of blood will be taken from you after 
special cream to stop the blood test from hurting has been 
put on.  
 
We will ask you some questions about how you sleep. We will 
ask you and your mum and dad these questions We will also 
ask your teacher about your school work (if you don’t mind). 
We will ask you to wear a small watch for 2 weeks to see how 
well you sleep. 
 
We would like to see how you learn new 
things, use words and play.  All the tests that 
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we would like to use to see how you learn are like games and 
are made for children so we think that you will have fun 
taking part. But, if you get tired, we will take a break or stop.  
 
Your doctors have decided that they want to take some 
special pictures of you. They are going to use a special 
machine called an MRI scanner. This machine can take 
pictures of the inside of you almost like an X-ray camera. 
When you are already in the MRI scanner, having all your 
pictures taken, we will take some extra pictures. Normally, all 
the pictures can be taken in about half an hour. If you let us 
take extra pictures, the whole scan will last about 10minutes 
more. 
 
Is it dangerous? 
No, all of these tests are safe. MRI scanning is very safe. We 
take pictures of children every day with the MRI scanner. 
 
What about my results? 
The doctors looking after you will talk to you and your 
parents about the results of these tests. We hope that these 
tests will help us to look after both you and other children 
with similar conditions better now and in the future. 
 
Who will get to see this information about me? 
The doctors looking after you will be able to see your test 
results. We will look at all the results and may print the 
results in a magazine so that other people 
can learn what we have learned. Your 
name will be taken off, so that nobody 
knows whose results they are. 
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Do I have to take part? 
No. It is up to you and your parents to decide. If you decide 
you don’t want to, that’s fine. The doctors and nurses will look 
after you as best as they can anyway. 
 
Who can I speak to if I have any questions? 
You can speak to your parents who have also been given some 
facts to read about this study. You can also speak to the 
doctors or nurses who look after you in the hospital.  
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The Wider Effects of Growth Hormone 
Information to answer your questions 
(SOD parent Info Leaflet) 
 
Your child is being invited to take part in a research study. This 
study is being carried out by Dr Emma Webb and Dr Michelle 
O'Reilly with the assistance of Prof. Mehul Dattani, Dr Naomi 
Dale and Dr Alison Salt at Great Ormond Street Hospital. 
Before you consider being involved, we want to make sure you 
know why we are doing this research so please read the following 
information carefully and discuss it with other people if it helps. 
You can call, email or write to us if anything is not clear or if you 
have more questions. Take time to decide whether or not you 
wish to take part. Thank you for reading this.  
 
Introduction 
The pituitary gland in the 
brain makes a number of 
chemicals called hormones 
that help you grow and 
develop normally. In some 
children who do not grow 
well, the pituitary gland 
may not make growth 
hormone (GH) and/or 
other hormones. The gland 
may be very small or even absent. These children would need to 
be treated with the hormones that are missing. Occasionally, the 
small pituitary gland may be associated with abnormalities 
affecting the eyes and the brain; this is called septo-optic 
dysplasia or SOD.  
 
We now know that the way your body changes and grows depends 
on the genetic material (called DNA, which is made up of 
thousands of genes) that you inherit from your parents. Changes 
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within genes are the reason why we are all very different to 
each other. Normally, you have two copies of a gene, one that 
comes to you from your father and one that comes to you from 
your mother. Sometimes a change within a gene that you get 
from your parents can lead to a medical condition. So far, we 
only know some of the genes that are important for pituitary 
development. 
 
We have noticed that children who do not make enough GH are 
more likely to have abnormal behaviour and to be slow with their 
development. We know that treatment with GH makes you grow 
taller and it has been suggested that treatment may also 
improve behaviour and sleep. 
 
What is the purpose of the study? 
In this study, we aim to study the genes controlling the 
development of the brain and pituitary gland. We have recently 
found that changes in 3 genes associated with a small pituitary 
gland and a lack of growth hormone (GH) in some of our patients. 
We now want to look at children with these conditions in more 
detail and to examine their DNA for abnormalities in these and 
other genes that are important for the normal development of 
the brain. We hope that this will help us to understand why 
children suffer from these particular conditions. 
 
We hope that this research will help us gain better 
understanding of the strengths and weaknesses that children 
with GH deficiency may have and make us think of the ways that 
parents and professionals may help if specific difficulties arise. 
 
How is the study being done? (Summary attached) 
All of the tests outlined below will be arranged around your 
routine visits to the hospital to minimise any disruption the 
study may have on your child and your family. 
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1. Blood tests  
The blood test/cannula insertion will be performed by a member 
of the Paediatric Endocrinology team at Great Ormond Street 
Children’s Hospital during one of your routine visits to the 
hospital. We need to take a small blood sample (2 teaspoonfuls) 
from your child for the genetic tests. To minimise discomfort, 
we will perform the blood test using local anaesthetic cream.  
 
Only a single sample of blood is required for the genetic study. 
If a change (mutation) is found within one of the genes that are 
important for pituitary development, then further blood samples 
may be required from your child and the rest of your family. 
However, the requirement for these samples will be discussed in 
detail with you and your family. 
 
All children with growth hormone deficiency routinely have 
hourly measurements of a stress hormone called cortisol for a 
24hr period. In addition to the routine measurements of 
cortisol, we will take one extra blood sample every hour (1.5ml-1 
teaspoon) to measure the hormone melatonin if your child weighs 
more than 10kg. Melatonin is very important in determining when 
we fall asleep and if it is not produced correctly children may 
have problems sleeping.  
 
2. Questionnaires 
We will ask you some questions about your child (including date 
of birth, medical problems, birth history) the first time we see 
you. This will take about half an hour. This will help us to 
understand all of the benefits of GH 
treatment. We will ask you to keep a diary 
recording your child’s sleep pattern for a 
2week period whilst they wear a small 
comfortable watch which records how well 
they sleep. 
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3. Developmental Assessment 
We are interested to see how your child is learning about their 
world, uses language, interacts with other people, and responds 
in social situations like story-time.  To understand this we would 
assess your child’s language, cognitive and social development 
using a selection of tests. These will be carried out by a team 
with a special interest in the development of children with and 
without visual impairment. For this we will arrange for you to 
come with your child to the Developmental Clinic on the same day 
as your endocrine clinic visit or we can arrange a home, nursery 
or school visit if this is more convenient for you. All the tests 
that we would like to use in this research are game-like and 
designed especially for children so we anticipate that most 
children will have fun taking part. However, if your child gets 
tired we will take a break or stop altogether. We will ask your 
child’s school teacher how they are doing in school (if you and 
your child are happy for us to contact them).This will provide a 
clear picture outlining the developmental progress and any 
developmental delay/behavioural problems present in your child.  
 
4. MRI Scan 
We also want to add 10mins extra pictures onto your child’s 
routine magnetic resonance imaging (MRI) scan to get a better 
picture of the overall brain structure and the volumes of the 
different areas of the brain that may be important in GH 
deficiency. MRI does not involve ionising radiation, unlike 
computed tomography (CT) or x-rays, and is therefore a good 
and safe imaging investigation to use in children. MRI is a well 
established investigation at Great Ormond Street Hospital for 
Children and is performed under sedation or anaesthesia on 
several children every day. 
 
It is very important to keep very still throughout any MRI scan 
as otherwise, the pictures become blurred and of no use, so it is 
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routine clinical practice to use sedation or general anaesthesia in 
young children during a scan. Sometimes the scans can be done in 
babies if they are asleep and wrapped so that they do not move. 
Usually however sedation or general anaesthesia is used as the 
scanner is noisy, and the scan can last up to 40 minutes. Your 
doctor will talk to you about whether your child will be sedated 
or given general anaesthetic for his/her scan and will get 
separate consent from you for this. This is routine clinical 
practice and is not a consequence of our project. The choice 
between non-sedation, sedation, or general anaesthesia will not 
be altered whether or not your child participates in the project.  
 
During the scan, we will need to inject a small volume of contrast 
fluid (dye) intravenously. This too is routine practice, 
independent of project participation, and is regarded as a very 
safe procedure. Our project involves taking extra pictures while 
your child has his/her MRI scan. This means that the scan will 
take 10minutes longer than a routine scan. 
 
What are the risks and discomfort? 
No risk to the child can be foreseen. There is discomfort from a 
single needle prick for blood testing, but this will be minimised 
by using local anaesthetic cream. MRI uses electromagnetic 
pulses to produce images of organs and tissues. It is used 
routinely in all age groups, and there are no identified side 
effects. Compared to a normal scan, the scan time in the project 
will be longer, and we will apply more electromagnetic pulses. 
However, we will always operate within the limitations that are 
set for clinical use of MRI. If your child is sedated or under 
general anaesthetic, this will not have any effect on their level 
of discomfort. If they are awake, then it will mean they may 
have to keep still for a little longer. 
 
 
What are the potential benefits? 
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This study may help us to understand why your child has 
developed their problems. Additionally, we may be able to make 
the diagnosis earlier in future children who may have the 
condition, and where one child in the family already has the 
disorder, we may be able to make a diagnosis before birth in 
future pregnancies. An improved understanding of these 
conditions will help us to find the best ways of making the 
diagnosis i.e. using the best tests available so that the diagnosis 
can be made with minimal discomfort to the child. Some of these 
genes are associated with a changing (evolving) picture, with 
more hormonal abnormalities appearing with time. If that is the 
case, then we will be in a better position to anticipate these 
abnormalities once we have the genetic information and hence 
we will be able to diagnose the problem more rapidly. We hope 
that a better understanding of the role GH has on behaviour and 
brain structure will help us to guide the use of GH in children 
with these problems in the future. Additionally, these studies 
will help us to understand why some children with GH deficiency 
develop sleep problems.   
 
Who will get to see this information about my child? 
Only the researchers and a representative of the Research 
Ethics Committee will have access to the data collected during 
the study. We will tell people what we have learned in the study 
in reports and publications, but nobody will learn anything 
personal about your child, or any other child, by reading these 
reports or publications. The use of some types of personal 
information is safeguarded by the Data Protection Act 1998 
(DPA). The DPA places an obligation on those who record or use 
personal information, but also gives rights to people about whom 
information is held. If you have any questions about data 
protection, contact the Data Protection officer via the 
switchboard on 020 7405 9200 extension 5217. 
 
Who has approved the study and who is funding it? 
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The Child Growth Foundation is funding this study. The project 
has been approved by an independent research ethics committee 
who believe that it is of minimal risk to you. However, research 
can carry unforeseen risks and we want you to be informed of 
your rights in the unlikely event that any harm should occur as a 
result of taking part in this study. 
 
This research is covered by a compensation scheme, which may 
apply in the event of any significant harm resulting to your child 
from involvement in the study. Under this scheme, it would not 
be necessary for you to prove fault. You also have the right to 
claim damages in a court of law. This would require you to prove 
fault on the part of the Hospital/Institute and/or any 
manufacturer involved. 
 
If taking part in this study means that you have to make 
additional trips to hospital we will reimburse your travel costs. 
 
Do I have to take part in this study? 
No. If you decide, now or at a later stage, that you do not wish 
to participate in this research project, that is entirely your 
right, and will not in any way prejudice any present or future 
treatment. 
 
Who do I speak to if problems arise? 
Please contact Dr Emma Webb or Dr Michelle O’Reilly directly 
with any problems relating to the study. If you have any 
complaints about the way in which this research project has 
been, or is being conducted, please, in the first instance, discuss 
them with the researchers. If the problems are not resolved, or 
you wish to comment in any other way, please contact the 
Principal Investigator, by post at the 
Institute of Child Health, 30 Guilford Street, London WC1N 
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1EH, or if urgent, by telephone on 0207405 9200, and the 
switchboard will put you in contact with him. 
 
  
 
 
 
       
 
 
 
 
 
 
 
 
 
Thank you for your time and for considering taking part in 
this study!  
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STUDY SCHEDULE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key:  Text in black: Routine investigation 
       Text in blue: Additional investigation
Developmental assessment 
(3hrs): 
• Age	  appropriate	  
developmental	  assessment	  to	  
assess	  verbal	  and	  cognitive	  
development,	  attention	  and	  
behaviour	  	  
• Parental	  questionnaire	  	  about	  
behaviour	  and	  development	  	  
	  
Sleep assessment: 
• Actiwatch-­‐worn	  for	  2weeks	  
• 2week-­‐	  sleep	  diary	  
• 24hr	  Cortisol,	  Melatonin,	  blood	  
sugar	  +	  	  temperature	  (hourly)	  
Imaging (extra 
10min): 
• Volumetric	  
MRI	  
Questionnaire (30min): 
• Basic	  information	  
Genetics (1min): 
1teaspoon blood 
sample 
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B. Confidential Data Sheet for GH/Development Study (page 1 to be held 
separately from main data form) 
 
 
Study Number   
 
   
    
 
Patient DNA Sample 
Number 
 
   
  
       
 
 
      
 
 D D M M Y Y 
Date of Birth       
   
 
 
 
Forename   
 
 
    
Surname 
 
   
    
Hospital Consultant 
 
   
    
Hospital Number   
 
 
    
Postcode 
 
   
    
Home phone no   
 
 
    
Mobile phone no   
 
 
    
Right/left handed     
 
 
 
1. Study Number    
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M F  
2. Sex   
 
 
Yrs Mths 
3. Age at baseline     
4. Age at 6mths into study     
5. Age at 12mths into study     
D D M M Y Y Y Y  
6. Date of 1st study visit         
   
7. First language  
 
8. Ethnicity(mark one box) 
White British  Asian 
Pakastani 
 Black African  Chinese  
White other  Asian Indian  Black 
Caribbean 
 Any other ethnic 
background 
 
Asian 
Bangladeshi 
 Asian other  Black other  Specify:  
9. Study Group (mark one box) 
                    VI                IGHD                  SOD   
                 ONH              MPHD   
   
10. Antenatal History Y N 
11. Maternal Smoking   
12. Maternal Alcohol   
13. Consanguinity   
14. Family History: 
 
 
15. Mothers Highest 
Educational level: 
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16. Mums occupation 
 
 
17. Dads Occupation: 
 
Yrs Mths  
18. Maternal Age (years) at delivery     
 
19. Delivery 
 
         
20. Gestation at birth   wks   Days 
 
 Y N 
21. IUGR   
22. Breast fed   
23. Exclusive breast feeding   
   
24. Length Breast Fed           Exclusive:  Mixed: 
    
25. Birth length   Cms 
    
26. Birth weight     Cms  
    
27. Birth head circumference    Cms  
     
 
28. Neonatal complications 
 
 
MEASUREMENTS AT PRESENTATION, 6 and 12mths  
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29. Weight (kg)   Baseline    .   Kg 
                            6mth       Kg 
                            12mth       kg 
30. Height (cm)  Baseline    Cm 
                           6mth     Cm 
                           12mth    cm 
31. Head circumference (cm)  Baseline    cm 
                                                 6mth    cm 
                                                12mth    cm 
32. Mothers height      Cm 
33. Fathers height    Cm 
34. Mid-parental height    Cm 
35. Final height    Cm 
36. Age at which diagnosed (years)   Yrs 
Y N U  
37. Spontaneuous puberty    
 
 
EYE FEATURES 
 
38. Visual Acuity right eye   
39. Visual Acuity left eye   
40. Right Optic disc   
41. Left optic disc  
42. EEG   
43. VER   
44. Other opthalmological features:   
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CHILD CARE YES NO 
45. Nanny   
46. hrs/week Hrs 
47. Nursery attendance   
48. hrs/week Hrs 
49. Child minder   
50. hrs/week Hrs 
 
ENDOCRINE FUNCTION TESTS 
   
51. Free Thyroxine     
52. Basal TSH     
53. TRH test peak TSH     
54. Basal prolactin     
55. TRH test peak prolactin     
56. Basal LH     
57.Peak LH on LHRH     
58. Basal FSH      
59. Peak FSH on LHRH     
60. Basal Cortisol     
61. Peak Cortisol     
62. Peak GH     
 
63. OGTT-baseline 
0 Insulin   0 Glucose   
30 Insulin   30 Glucose   
60 Insulin   60 Glucose   
90 Insulin   90 Glucose   
120 Insulin   120 Glucose   
150 Insulin   150 Glucose   
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180 Insulin   180 Glucose   
 
64. OGTT after 6mths on GH 
0 Insulin   0 Glucose   
30 Insulin   30 Glucose   
60 Insulin   60 Glucose   
90 Insulin   90 Glucose   
120 Insulin   120 Glucose   
150 Insulin   150 Glucose   
180 Insulin   180 Glucose   
 
65. 24hr         Cortisol                     Glucose                                 Melatonin 
0100       
0200       
0300       
0400       
0500       
0600      
0700      
0800      
0900      
1000      
1100      
1200      
1300      
1400      
1500      
1600      
 Cortisol  Glucose  Melatonin 
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1700      
1800      
1900      
2000      
2100      
2200      
2300      
2400      
66. 2nd 
profile 
 
Cortisol 
  
Glucose 
  
Melatonin 
0100       
0200       
0300       
0400       
0500       
0600      
0700      
0800      
0900      
1000      
1100      
1200      
1300      
1400      
1500      
1600      
1700      
1800      
 Cortisol  Glucose  Melatonin 
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1900      
2000      
2100      
2200      
2300      
2400      
     
67. Baseline IGF-1     
68. 6mth after onset Tx IGF-1     
69. Baseline IGFBP-3     
70. 6mth after onset Tx IGFBP-3     
71. Baseline Leptin     
72. 6mth after onset Tx Leptin     
73. Baseline Ghrelin     
74. 6mth after onset Tx Ghrelin     
75. Baseline Adiponectin     
76. 6mth after onset Tx Adiponectin     
 YES NO 
77. Diabetes Insipidus   
78. Any other endocrine results   
 
MEDICATION 
 
YES 
 
Date started 
79. Hydrocortisone    
80. Thyroxine    
81. GH   
82. Any change in GH dose   
83. DDAVP   
84. Sex steroids   
85. Zoladex   
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Medication Dose                                                   DOSE              UNITS 
86. Hydrocortisone                                       am 
                                                                      Pm 
 
 
 
87. Thyroxine    
88. GH   
89. Any change in GH dose   
90. DDAVP                                                  am 
                                                                     Pm 
  
91. Sex steroids   
92. Zoladex   
    
 93. Result of neuroimaging 
 
   
   
94.Candidate Gene to be tested  
 
95. Any genetic finding?  
 M M D D Y Y Y Y 
96. 1st developmental assessment         
97. 2nd developmental assessment         
98. 3rd developmental assessment         
 
99. Result developmental assessment 1 
A          
B          
C          
D          
E          
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100. Result developmental assessment 2 
A          
B          
C          
D          
E          
 
101. Result developmental assessment 3 
A          
B          
C          
D          
E          
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C. Consent Form 
Great Ormond Street Hospital for Children NHS Trust and Institute of Child Health 
Research Ethics Committee 
 Consent Form for PARENTS OR GUARDIANS 
 of Children Participating in Research Studies 
 
Title: A genetic analysis of children with forebrain, eye and / or pituitary defects 
 
NOTES FOR PARENTS OR GUARDIANS 
 
1. Your child has been asked to take part in a research study.  The person organising 
that study is responsible for explaining the project to you before you give consent. 
 
2. Please ask the researcher any questions you may have about this project, before you 
decide whether you wish to participate. 
 
3. If you decide, now or at any other stage, that you do not wish your child to 
participate in the research project, that is entirely your right, and if your child is a 
patient it will not in any way prejudice any present or future treatment. 
 
4. You will be given an information sheet which describes the research project.  This 
information sheet is for you to keep and refer to.  Please read it carefully. 
 
5. If you have any complaints about the way in which this research project has been or 
is being conducted, please, in the first instance, discuss them with the researcher.  If 
the problems are not resolved, or you wish to comment in any other way, please 
contact the Chairman of the Research Ethics Committee, by post via The Research 
and Development Office, Institute of Child Health, 30 Guilford Street, London 
WC1N 1EH or if urgent, by telephone on 020 7905 2620 and the committee 
administration will put you in contact with him. 
 
CONSENT 
 
I/We _____________________________, being the parent(s)/guardian(s) of 
 _____________________________ agree that the Research Project named above has 
been 
explained to me to my/our satisfaction, and I/We give permission for our child to take part 
in this study.  I/We have read both the notes written above and the Information Sheet  
provided, and understand what the research study involves. 
 
SIGNED (Parent (s)/Guardian (s) )    PRINTED    DATE 
 
------------------------------------------------  ----------------------------------  ---------------- 
SIGNED (Researcher)     PRINTED    DATE 
